UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF
1933
SUNSHINE BIOPHARMA INC.
(Exact
name of registrant as specified in its charter)
Colorado
|
|
8731
|
|
20-5566275
|
(State
of Incorporation)
|
|
(Primary
Standard Industrial
Classification
Number)
|
|
(IRS
Employer
Identification
Number)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(514) 426-6161
(Address,
including zip code, and telephone number, including area
code,
of
registrant’s principal executive offices)
Please
send copies of all communications to:
Lucosky Brookman LLP
101 Wood Avenue South, 5
th
Floor
Woodbridge, NJ 08830
Tel. No.: (732) 395-4400
Fax No.: (732) 395-4401
(Address,
including zip code, and telephone, including area
code)
Approximate
date of proposed sale to the public:
From time to time after the effective date of
this registration statement.
If any
of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. [X]
If this
Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same
offering. [ ]
If this
Form is a post-effective amendment filed pursuant to rule 462(c)
under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier
effective registration statement for the same offering.
[ ]
If this
Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier
effective registration statement for the same offering.
[ ]
Indicate
by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See definitions of “large accelerated
filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
Large
accelerated filer
|
[ ]
|
Accelerated
filer
|
[ ]
|
Non-accelerated
filer
|
[ ]
|
Smaller
reporting company
|
[X]
|
(do not
check if a smaller reporting company)
|
Emerging
Growth Company
|
[ ]
|
CALCULATION OF REGISTRATION FEE
Title of Each
Class of
securities to be
registered
|
Number of shares
of
Common Stock to
be registered (1)
|
Proposed
Maximum
Offering
Price Per
Share
(2)
|
Proposed
Maximum
Aggregate
Offering
Price
|
Amount of
Registration
Fee
(3)
|
|
|
|
|
|
Common
Stock
|
266,417,879
|
$
0.0019
|
$
460,081.24
|
$
63.02
|
(1)
In
accordance with Rule 416(a), this registration statement shall also
cover an indeterminate number of shares that may be issued and
resold resulting from stock splits, stock dividends or similar
transactions.
(2)
Based
on the reported closing price for our Common Stock on September 25,
2018 of $0.0019. The shares offered, hereunder, may be sold by the
Selling Stockholder from time to time in the open market, through
privately negotiated transactions, or a combination of these
methods at market prices prevailing at the time of sale or at
negotiated prices.
(3)
The fee
is calculated by multiplying the aggregate offering amount by
0.00012450, pursuant to Section 6(b) of the Securities Act of
1933.
The registrant hereby may amend this Registration Statement on such
date or dates as may be necessary to delay our effective date until
the registrant shall file a further amendment which specifically
states that this Registration Statement shall, thereafter, become
effective in accordance with Section 8(a) of the Securities Act of
1933, or until the Registration Statement shall become effective on
such date as the Commission, acting pursuant to Section 8(a) may
determine.
PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED OCTOBER____,
2018
The information in this Prospectus is not complete and may be
changed. These securities may not be sold until the Registration
Statement filed with the Securities and Exchange Commission is
effective. This preliminary Prospectus is not an offer to sell
these securities and is not soliciting an offer to buy these
securities in any state where the offer or sale is not
permitted.
Sunshine Biopharma Inc.
266,417,879 Common Shares
The
Selling Stockholder identified below in this Prospectus may offer
an indeterminate number of shares of its Common Stock, which will
consist of up to 266,417,879 shares of Common Stock to be sold by
GHS Investments LLC (“GHS”) pursuant to an Equity
Financing Agreement dated September 10, 2018 (the “Financing
Agreement”). If issued presently, the 266,417,879 of Common
Stock registered for resale by GHS would represent 16.8% of our
issued and outstanding shares of Common Stock as of September 20,
2018. If issued presently, the 266,417,879 of Common Stock
registered for resale by GHS would represents approximately 30% of
our public float as of the date hereof.
The
Selling Stockholder may sell all or a portion of the shares being
offered pursuant to this Prospectus at fixed prices and prevailing
market prices at the time of sale, at varying prices, or at
negotiated prices.
We will
not receive any proceeds from the sale of the shares of our Common
Stock by GHS. However, we will receive proceeds from our initial
sale of shares to GHS pursuant to the Financing Agreement. We will
sell shares to GHS at a price equal to 81% of the average of the
three lowest VWAPs of our Common Stock during the ten (10)
consecutive trading day period beginning on the date on which we
deliver a put notice to GHS (the “Market Price”). There
will be a minimum of ten (10) trading days between
purchases.
GHS is
an underwriter within the meaning of the Securities Act of 1933,
and any broker-dealers or agents that are involved in selling the
shares may be deemed to be “underwriters” within the
meaning of the Securities Act of 1933 in connection with such
sales. In such event, any commissions received by such
broker-dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act of 1933.
Our
Common Stock is traded on OTC Markets under the symbol
“SBFM”. On September 25, 2018, the reported closing
price for our Common Stock was $0.0019 per share.
Historically,
there has been a very limited market for our securities. While our
Common Stock is on the OTC Markets, there is no guarantee that an
active trading market will develop in our securities.
This offering is highly speculative and these securities involve a
high degree of risk and should be considered only by persons who
can afford the loss of their entire investment. See “Risk
Factors” contained herein. Neither the Securities and
Exchange Commission nor any state securities commission has
approved or disapproved of these securities or passed upon the
accuracy or adequacy of this Prospectus. Any representation to the
contrary is a criminal offense.
The
date of this Prospectus is October__, 2018.
Table of Contents
The
following table of contents has been designed to help you find
information contained in this Prospectus. We encourage you to read
the entire Prospectus.
Prospectus
Summary
|
1
|
Summary
Consolidated Financial Information
|
9
|
Risk
Factors
|
12
|
Cautionary
Note Regarding Forward-Looking Statements
|
23
|
Use of
Proceeds
|
24
|
Determination of Offering Price
|
24
|
Dilution
|
24
|
Selling
Stockholders
|
24
|
The
Offering
|
26
|
Plan of Distribution
|
27
|
Description of Securities to be Registered
|
28
|
Interests
of Named Experts and Counsel
|
30
|
Market
for Our Common Stock and Related Stockholder Matters
|
38
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
39
|
Directors,
Executive Officers and Key Employees
|
53
|
Executive
Compensation
|
55
|
Security
Ownership of Certain Beneficial Owners and Management
|
56
|
Index
to Consolidated Financial Statements
|
F-1
|
You may only rely on the information contained in this Prospectus
or that we have referred you to. We have not authorized any person
to give you any supplemental information or to make any
representations for us. This Prospectus does not constitute an
offer to sell or a solicitation of an offer to buy any securities
other than the Common Stock offered by this Prospectus. This
Prospectus does not constitute an offer to sell or a solicitation
of an offer to buy any Common Stock in any circumstances in which
such offer or solicitation is unlawful. Neither the delivery of
this Prospectus nor any sale made in connection with this
Prospectus shall, under any circumstances, create any implication
that there has been no change in our affairs since the date of this
Prospectus is correct as of any time after its date. You should not
rely upon any information about our company that is not contained
in this Prospectus. Information contained in this Prospectus may
become stale. You should not assume the information contained in
this Prospectus or any Prospectus supplement is accurate as of any
date other than their respective dates, regardless of the time of
delivery of this Prospectus, any Prospectus supplement or of any
sale of the shares. Our business, financial condition, results of
operations, and prospects may have changed since those dates. The
Selling Stockholder is offering to sell and seeking offers to buy
shares of our Common Stock only in jurisdictions where offers and
sales are permitted.
In this
Prospectus, “Sunshine Biopharma” the
“Company,” “we,” “us,” and
“our” refer to Sunshine Biopharma Inc., a Colorado
corporation.
PROSPECTUS SUMMARY
You
should carefully read all information in the Prospectus, including
the financial statements and their explanatory notes under the
Financial Statements prior to making an investment
decision.
This summary highlights selected information appearing elsewhere in
this Prospectus. While this summary highlights what we consider to
be important information about us, you should carefully read this
entire Prospectus before investing in our Common Stock, especially
the risks and other information we discuss under the headings
“Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operation”
and our consolidated financial statements and related notes
beginning on page F-1. Our fiscal year end is December 31 and our
fiscal years ended December 31, 2016 and 2017 are sometimes
referred to herein as fiscal years 2016 and 2017, respectively.
Some of the statements made in this Prospectus discuss future
events and developments, including our future strategy and our
ability to generate revenue, income and cash flow. These
forward-looking statements involve risks and uncertainties which
could cause actual results to differ materially from those
contemplated in these forward-looking statements. See
“Cautionary Note Regarding Forward-Looking Statements”.
Unless otherwise indicated or the context requires otherwise, the
words “we,” “us,” “our”, the
“Company” or “our Company” or
“Sunshine Biopharma” refer to Sunshine Biopharma, Inc.,
a Colorado corporation, and our each of our
subsidiaries.
History
We were incorporated in the State of Colorado on August 31, 2006
under the name “Mountain West Business Solutions, Inc.”
Until October 2009, our business was to provide management
consulting with regard to accounting, computer and general business
issues for small and home-office based companies.
In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado
corporation holding an exclusive license to a new anticancer drug
bearing the laboratory name, Adva-27a. As a result of this
transaction we changed our name to “Sunshine Biopharma, Inc.
and our officers and directors resigned their positions with us and
were replaced by Sunshine’s management at the time, including
our current CEO, Dr. Steve N. Slilaty, and our current CFO, Camille
Sebaaly each of whom remain part of our current management. Our
principal business became that of a pharmaceutical company focusing
on the development of our licensed Adva-27a anticancer compound. In
December 2015 we acquired all issued and pending patents pertaining
to our Adva-27a technology and terminated the license.
In July 2014, we formed a wholly owned Canadian subsidiary,
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for
the purposes of offering generic pharmaceutical products in Canada
and elsewhere around the world. Sunshine Canada has recently signed
licensing agreements for four (4) generic prescription drugs for
the treatment of cancer and BPH (Benign Prostatic
Hyperplasia).
In January 2018, we acquired Atlas Pharma Inc., a certified company
dedicated to chemical analysis of pharmaceutical and other
industrial samples whose operations are authorized by a Drug
Establishment License issued by Health Canada.
In March 2018, we formed NOX Pharmaceuticals, Inc., a Colorado
corporation and assigned all of our interest in our Adva-27a
anticancer compound to that company.
Our principal place of business is located at 6500 Trans-Canada
Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. Our
phone number is (514) 426-6161and our website address is
www.sunshinebiopharma.com.
Business Operations
As of
the date of this report we are operating through the following
wholly owned subsidiaries:
●
NOX
Pharmaceuticals, Inc., a recently formed Colorado company focused
on the research, development and commercialization of proprietary
drugs for the treatment of cancer including Adva-27a, a
multi-purpose anti-tumor compound targeted for the treatment of
multidrug resistant cancer;
●
Sunshine Biopharma
Canada Inc., a Canadian company, which offers generic prescription
drugs for the treatment of cancer and other acute and chronic
indications; and
●
Atlas Pharma Inc.,
a Canadian company acquired in January 2018, offering certified
chemical analysis of pharmaceutical and other industrial
samples.
Proprietary Drug Development Operations
Since inception, our proprietary drug development activities have
been focused on the development of a small molecule called Adva-27a
for the treatment of aggressive forms of cancer. A Topoisomerase II
inhibitor, Adva-27a has been shown to be effective at destroying
Multidrug Resistant Cancer cells including Pancreatic Cancer cells,
Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine
Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Sunshine Biopharma is direct owner of all
issued and pending worldwide patents pertaining to Adva-27a
including U.S. Patent Number 8,236,935.
Adva-27a is a GEM-difluorinated C-glycoside derivative of
Podophyllotoxin. Another derivative of Podophyllotoxin called
Etoposide is currently on the market and is used to treat various
types of cancer including leukemia, lymphoma, testicular cancer,
lung cancer, brain cancer, prostate cancer, bladder cancer, colon
cancer, ovarian cancer, liver cancer and several other forms of
cancer. Etoposide is one of the most widely used anticancer drugs.
Adva-27a and Etoposide are similar in that they both attack the
same target in cancer cells, namely the DNA unwinding enzyme,
Topoisomerase II. Unlike Etoposide and other anti-tumor drugs
currently in use, Adva-27a is able to destroy Multidrug Resistant
Cancer cells. Adva-27a is the only compound known today that is
capable of destroying Multidrug Resistant Cancer. In addition,
Adva-27a has been shown to have distinct and more desirable
biological and pharmacological properties compared to Etoposide. In
side-by-side studies using Multidrug Resistant Breast Cancer cells
and Etoposide as a reference, Adva-27a showed markedly improved
cell killing activity (see Figure below). Our preclinical studies
to date have shown that:
Adva-27a is effective at killing different types of Multidrug
Resistant cancer cells, including Pancreatic Cancer Cells (Panc-1),
Breast Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells
(H69AR), and Uterine Sarcoma Cells (MES-SA/Dx5).
●
Adva-27a
is unaffected by P-Glycoprotein, the enzyme responsible for making
cancer cells resistant to anti-tumor drugs.
●
Adva-27a
has excellent clearance time (half-life = 54 minutes) as indicated
by human microsomes stability studies and pharmacokinetics data in
rats.
●
Adva-27a
clearance is independent of Cytochrome P450, a mechanism that is
less likely to produce toxic intermediates.
●
Adva-27a
is an excellent inhibitor of Topoisomerase II with an IC50 of only
13.7 micromolar (this number has recently been reduce to 1.44
micromolar as a result of resolving the two isomeric forms of
Adva-27a).
●
Adva-27a
has shown excellent pharmacokinetics profile as indicated by
studies done in rats.
●
Adva-27a
does not inhibit tubulin assembly.
These and other preclinical data have been published in ANTICANCER
RESEARCH, a peer-reviewed International Journal of Cancer Research
and Treatment. The publication which is entitled “Adva-27a, a
Novel Podophyllotoxin Derivative Found to Be Effective Against
Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH
32: 4423-4432 (2012)] is available on our website at
www.sunshinebiopharma.com
.
We have been delayed in our clinical development program due to
lack of funding. Our fund raising efforts are continuing and as
soon as adequate financing is in place we will continue our
clinical development program of Adva-27a by conducting the
following next sequence of steps:
●
GMP
Manufacturing of 2 kilogram for use in IND-Enabling Studies and
Phase I Clinical Trials
●
Regulatory
Filing (Fast-Track Status Anticipated)
●
Phase
I Clinical Trials (Pancreatic Cancer Indication)
On November 14, 2014, we entered into a Manufacturing Services
Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly
referred to as “Lonza”), whereby we engaged Lonza to be
the manufacturer of our Adva-27a anticancer drug. In June 2015 we
received a sample of the pilot manufacturing run for evaluation.
Our laboratory analyses showed that, while the sample meets all of
the required chemical, physical and biological specifications, the
amount of material generated (the “Yield”) by the pilot
run was found to be significantly lower than anticipated. We are
currently working towards finding possible solutions to increase
the Yield and define a path forward. During the course of our
discussions concerning the problem of the low Yield, Lonza informed
us that they required us to pay them $687,818 prior to moving
forward with any activity pertaining to the manufacturing agreement
we have with them. We have repeatedly indicated to Lonza that a
clear path defining exactly how the extremely low Yield issue would
be addressed is imperative prior to us making any payments. As of
the date of this Registration Statement on Form S-1, neither party
has changed its position.
Adva-27a’s initial indication will be pancreatic cancer for
which there are currently little or no treatment options available.
We are planning to conduct our clinical trials at McGill
University’s Jewish General Hospital in Montreal, Canada. All
aspects of the clinical trials in Canada will employ FDA standards
at all levels. We estimate that Phase I clinical trials will take
approximately 18 months to complete.
According to the American Cancer Society, nearly 1.5 million new
cases of cancer are diagnosed in the U.S. each year. We
believe that upon successful completion of Phase I Clinical Trials
we may receive one or more offers from large pharmaceutical
companies to buyout or license our drug. However, there
are no assurances that our Phase I Trials will be successful, or if
successful, that any pharmaceutical companies will make an
acceptable offer to us. In the event we do not
consummate such a transaction, we will require significant capital
in order to conduct additional clinical trials, manufacture and
market our new drug.
Our Lead Anti-Cancer Compound, Adva-27a, in 3D
Generic Pharmaceuticals Operations
In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma
Canada Inc. (“Sunshine Canada”), signed Cross
Referencing Agreements with a major pharmaceutical company for four
prescription generic drugs for the treatment of Breast Cancer,
Prostate Cancer and Enlarged Prostate. Following this acquisition
we have been working towards commencement of marketing of these
pharmaceutical products under our own Sunshine Biopharma label.
These four generic products are as follows:
●
Anastrozole
(brand name Arimidex® by AstraZeneca) for treatment of Breast
Cancer;
●
Letrozole
(brand name Femara® by Novartis) for treatment of Breast
Cancer;
●
Bicalutamide
(brand name Casodex® by AstraZeneca) for treatment of Prostate
Cancer;
●
Finasteride
(brand name Propecia® by Merck) for treatment of BPH (Benign
Prostatic Hyperplasia)
Worldwide sales of the brand name version of these products as
reported by the respective pharmaceutical company, owner of the
registered trademark are as follows:
●
Arimidex®
$232M in 2016
●
Propecia®
$183M in 2015
Sunshine Canada is currently in the process of securing a Drug
Identification Number (“DIN”) for each of these
products from Health Canada. We are planning to use part of the
already approved Atlas Pharma Inc. space as a drug warehouse to
facilitate the process of obtaining a Drug Establishment License
(“DEL”) from Health Canada. Upon receipt of the DEL and
DIN’s, we will be able to accept orders for our own label
SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and
SBI-Finasteride. We cannot estimate the timing in our obtaining
either the DIN’s or the DEL due to variables involved that
are out of our control. The figure below shows our 30-Pill blister
pack of Anastrozole.
We currently have twenty three (23) additional Generic
Pharmaceuticals under review for in-licensing. While no assurances
can be provided that we will acquire the rights to all or any of
these drugs, we are confident we will acquire most, if not all of
these rights. We believe that a larger product portfolio will
provide us with more opportunities and a greater reach into the
marketplace. We hope to further build our generics portfolio of
“SBI” label Generic Pharmaceuticals over time. There
are no assurances this will occur.
Various publicly available sources indicate that the worldwide
sales of generic pharmaceuticals are approximately $200 billion per
year. In the United States and Canada, the sales of generic
pharmaceuticals are approximately $50 billion and $5 billion,
respectively. The generic pharmaceuticals business is fairly
competitive and there are several multinational players in the
field including Teva (Israel), Novartis - Sandoz (Switzerland),
Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi
(Germany) and Apotex (Canada). While no assurances can be provided,
with our offering of Canadian approved products we believe that we
will be able to access at least a small percentage of the generic
pharmaceuticals marketplace.
As part of a subscription agreement entered into in 2016, we have
an obligation to pay a royalty of 5% of net sales on one of our
generic products (Anastrozole) for a period of three (3) years from
the date of the first sale of that product. As of the date of this
Registration Statement on Form S-1 we have not yet commenced
marketing efforts and no sales or royalty payments have been made.
On May 28, 2018 we issued 1,000,000 shares of our Common Stock
valued at $5,900 in exchange for cancellation of this royalty
obligation.
While no assurances can be provided and subject to the availability
of adequate financing, of which there is no assurance, we
anticipate that profits from the sales of Generic Products will be
used to finance our proprietary drug development program, including
Adva-27a, our flagship anticancer compound. In addition to
near-term revenue generation, building the generics business
infrastructure and securing the proper permits will render us
appropriately positioned for the marketing and distribution of our
proprietary Adva-27a drug candidate, provided that Adva-27a is
approved for such marketing and distribution, of which there can be
no assurance.
Analytical Chemistry Services Operations
On January 1, 2018, we entered into an agreement (the “Atlas
Agreement”) to acquire Atlas Pharma Inc.
(“Atlas”). The purchase price was $848,000 Canadian
($684,697 US). Payment of the purchase price was comprised of (i) a
cash payment of $100,500 Canadian ($80,289 US), (ii) the issuance
of 20,000,000 shares of our Common Stock valued at $246,000, and
(iii) a promissory note in the principal amount of $450,000
Canadian ($358,407 US), with interest payable at the rate of 3% per
annum. We are required to make payments of $10,000 Canadian
(approximately $8,000 US) per calendar quarter, due and payable on
or before the end of each such calendar quarter through December
31, 2023.
Atlas is a certified company dedicated to chemical analysis of
pharmaceutical and other industrial samples. Atlas has 9 full-time
employees and generated revenues of approximately $500,000 Canadian
(approximately $400,000 US) in 2017. Housed in a 5,250 square foot
facility, Atlas’s operations are authorized by a Drug
Establishment License (DEL) issued by Health Canada and are fully
compliant with the requirements of Good Manufacturing Practices
(GMP). Atlas is also registered with the FDA.
Atlas is the owner of a relatively large portfolio of analytical
chemistry methodology and Standard Operating Procedure. This
intellectual property is protected as company secrets and
controlled through employee and management confidentiality
agreements.
On June 18, 2018, we purchased laboratory equipment at a total cost
of $235,870 Canadian (approximately $181,580 US) for Microbiology
Testing as part of our plan to expand the operations services
offering of Atlas. Presently, Atlas offers Analytical Chemistry
Testing and intends to offer Microbiology Testing
soon.
Government Regulations
All of our business operations, including the Generic
Pharmaceutical Operations, the Proprietary Drug Development
Operations, and our newly acquired Analytical Chemistry Services
Operations are subject to extensive and frequently changing
federal, state, provincial and local laws and
regulations.
In the U.S, the Federal Government agency responsible for
regulating drugs is the U.S. Food and Drug Administration
(“FDA”). The Canadian counterpart to the FDA is the
Health Products and Food Branch (“HPFB”) of Health
Canada. Both the FDA and HPFB have similar requirements for a drug
to be approved for marketing. In addition, the quality standards
for brand name drugs and generic drugs are the same. The
ingredients, manufacturing processes and facilities for all drugs
must meet the guidelines for Good Manufacturing Practices
(“GMP”). Moreover, all drug manufacturers must perform
a series of tests, both during and after production, to show that
every drug batch made meets the regulatory agency’s
requirements for that product.
In
connection with our development of the new chemical entity,
Adva-27a, we will be subject to significant regulations in the U.S.
in order to obtain the approval of the FDA to offer our product on
the market. The approximate procedure for obtaining FDA approval
involves an initial filing of an IND application following which
the FDA would review the application and if all the data are in
order and acceptable would give the go ahead for the drug sponsor
to proceed with Phase I clinical (human) trials. Following
completion of Phase I, the results are filed with the FDA and a
request is made to proceed to Phase II. Similarly, following
completion of Phase II the data are filed with the FDA and a
request is made to proceed to Phase III. Following completion of
Phase III, a request is made for marketing approval. Depending on
various issues and considerations, the FDA could provide limited
marketing approval on a humanitarian basis if the drug treats
terminally ill patients with limited treatment options available.
As of the date of this Registration Statement on Form S-1 we have
not made any filings with the FDA or other regulatory bodies in
other jurisdictions. We have however had extensive discussions with
clinicians at the McGill University’s Jewish General Hospital
in Montreal where we plan to undertake our Phase I study for
pancreatic cancer and multidrug resistant breast cancer they
believe that Health Canada is likely to grant us a so-called
fast-track process on the basis of the terminal nature of the
cancer types which we will be treating. There are no assurances
this will occur.
Employees
As of the date of this Registration Statement on Form S-1 we have a
total of twelve (12) employees. In addition to our management team
which is comprised of our three (3) officers and directors, our new
wholly owned subsidiary acquired on January 1, 2018, Atlas Pharma
Inc., has 9 full-time employees. We anticipate that if we receive
financing we will need additional employees in both our generic
pharmaceutical and proprietary drug development operations
including accounting, regulatory affairs, marketing, sales and
laboratory personnel.
Competition
In the area of proprietary anticancer drug development, we will be
competing with large publicly and privately held companies engaged
in developing new cancer therapies. There are numerous other
entities engaged in this business that have greater resources, both
financial and otherwise, than the resources presently available to
us. Nearly all major pharmaceutical companies including
Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name
just a few, have on-going anti-cancer drug development programs and
some of the drug they may develop could be in direct competition
with our drug. Also, a number of small companies are
also working in the area of cancer and could develop drugs that may
be in competition with ours. However, none of these
competitor companies can use molecules similar to ours as they
would be infringing our patents.
The generic pharmaceuticals business is fairly competitive and
there are many players in the field including several
multinationals such as Teva (Israel), Novartis - Sandoz
(Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France),
Fresenius Kabi (Germany) and Apotex (Canada)with annual sales in
the range of approximately $2 billion to over $10. With our
offering of Canadian approved generic products, we believe that we
will be able to access at least a small percentage of the generic
pharmaceuticals market.
Intellectual Property
Effective
October 8, 2015, we executed a Patent Purchase Agreement (the
“October Purchase Agreement”), with Advanomics, a
related party, pursuant to which we acquired all of the right,
title and interest in and to U.S. Patent Number 8,236,935 (the
“US Patent”) for our anticancer compound, Adva-27a. On
December 28, 2015, we executed a second Patent Purchase Agreement
(the “December Purchase Agreement”), with Advanomics,
pursuant to which we acquired all of the right, title and interest
in and to all of the remaining worldwide rights covered by issued
and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029
(the “Worldwide Patents”) for our anticancer compound,
Adva-27a.
Effective
December 28, 2015, we entered into amendments (the
“Amendments”) of these Purchase Agreements pursuant to
which the total purchase price was reduced from $17,142,499 to
$618,810, the book value of this intellectual property on the
financial statements of Advanomics. Further, the Amendments
provided for automatic conversion of the promissory notes
representing the new purchase price into an aggregate of
321,305,415 shares of our Common Stock once we increase our
authorized capital such that these shares can be issued. In July
2016 we increased our authorized capital and issued the 321,305,415
Common shares to Advanomics thereby completing all aspects of the
patent purchase arrangements and securing direct ownership of all
worldwide patents and rights pertaining to Adva-27a.
In
addition, in 2016 we signed Cross Referencing Agreements with a
major pharmaceutical company for four (4) prescription generic
drugs for the treatment of Breast Cancer, Prostate Cancer and
Enlarged Prostate. These agreements give us the right to register
the four (4) generic products, Anastrozole, Letrozole, Bicalutamide
and Finasteride in Canada under our own label and obtain a DIN for
each in order to be able to place them on the market.
Our new
wholly owned subsidiary, Atlas Pharma Inc., which we acquired on
January 1, 2018 holds a Drug Establishment License from Health
Canada and is registered with the FDA. Atlas Pharma Inc. is the
owner of a relatively large portfolio of analytical chemistry
methodology and Standard Operating Procedure. This intellectual
property is protected as company secrets and controlled through
employee and management confidentiality
agreements.
Summary of the Offering
Shares
Currently Outstanding
(1)
:
|
|
1,585,628,494
|
|
|
|
Shares
Being Offered:
|
|
266,417,879
|
|
|
|
Shares
to be Outstanding After the Offering
(1)
|
|
1,852,046,373
|
|
|
|
Offering
Price per Share:
|
|
The
Selling Stockholder may sell all or a portion of the shares being
offered pursuant to this Prospectus at fixed prices and prevailing
market prices at the time of sale, at varying prices or at
negotiated prices.
|
|
|
|
Use of
Proceeds:
|
|
We will
not receive any proceeds from the sale of the shares of our Common
Stock by the Selling Stockholder. However, we will receive proceeds
from our initial sale of shares to GHS, pursuant to the Financing
Agreement. The proceeds from the initial sale of shares will be
used for the purpose of working capital and for potential
acquisitions.
|
|
|
|
Trading
Symbol:
|
|
SBFM
|
|
|
|
Risk
Factors:
|
|
See
“Risk Factors” contained herein and the other
information in this Prospectus for a discussion of the factors you
should consider before deciding to invest in shares of our Common
Stock.
|
(1)
The
number of shares of our Common Stock outstanding prior to and to be
outstanding immediately after this offering, as set forth in the
table above, is based on 1,585,628,494 shares outstanding as of
September 20, 2018, and 266,417,879 shares of Common Stock issuable
in this offering.
SUMMARY CONSOLIDATED
FINANCIAL INFORMATION
The following summary consolidated statements of operations data
for the fiscal years ended December 31, 2017 and 2016 have been
derived from our audited consolidated financial statements included
elsewhere in this Prospectus. Additionally, the six months ended
June 30, 2018 and 2017 have been derived from our unaudited
consolidated financial statements included elsewhere in this
Prospectus. The summary consolidated balance sheet data as of June
30, 2018 are derived from our consolidated financial statements
that are included elsewhere in this Prospectus. The historical
financial data presented below is not necessarily indicative of our
financial results in future periods, and the results for the six
months ended June 30, 2018 is not necessarily indicative of our
operating results to be expected for the full fiscal year ending
December 31, 2018 or any other period. You should read the summary
consolidated financial data in conjunction with those financial
statements and the accompanying notes and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations.” Our consolidated financial statements are
prepared and presented in accordance with United States generally
accepted accounting principles, or U.S. GAAP. Our consolidated
financial statements have been prepared on a basis consistent with
our audited financial statements and include all adjustments,
consisting of normal and recurring adjustments that we consider
necessary for a fair presentation of the financial position and
results of operations as of and for such periods.
SUNDHINE
BIOPHARMA INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
|
|
|
|
|
|
3 Months Ended
June 30, 2018
|
3 Months Ended
June 30, 2017
|
6 Months ended
June 30, 2018
|
6 Months Ended
June 30, 2017
|
|
|
|
|
|
Revenue:
|
$
107,250
|
$
-
|
$
198,418
|
$
-
|
Cost of
Revenue
|
91,631
|
-
|
190,913
|
-
|
|
|
|
|
|
Gross
Profit
|
15,619
|
-
|
7,505
|
-
|
|
|
|
|
|
General &
Administrative Expenses
|
|
|
|
|
Accounting
|
61,939
|
48,415
|
89,939
|
64,015
|
Consulting
|
23,682
|
33,930
|
27,800
|
59,867
|
Legal
|
31,600
|
27,920
|
59,085
|
42,824
|
Office
|
20,068
|
13,032
|
39,116
|
22,098
|
Officer &
Director remuneration
|
446,644
|
348,415
|
524,431
|
391,380
|
Rent
|
2,035
|
|
3,572
|
|
Depreciation
|
602
|
506
|
1,210
|
1,024
|
|
|
|
|
|
Total G &
A
|
586,570
|
472,218
|
745,153
|
581,208
|
|
|
|
|
|
(Loss) from
Operations
|
(570,951
)
|
(472,218
)
|
(737,648
)
|
(581,208
)
|
|
|
|
|
|
Other Income
(Expense):
|
|
|
|
|
Foreign Exchange
Gain (Loss)
|
10,016
|
(3,628
)
|
24,884
|
(4,267
)
|
Interest
Expense
|
(28,375
)
|
(9,598
)
|
(103,842
)
|
(18,742
)
|
Loss on Debt
Conversions
|
(54,998
)
|
-
|
(93,338
)
|
(76,929
)
|
|
|
|
|
|
Total Other
(Expense)
|
(73,357
)
|
(13,226
)
|
(172,296
)
|
(99,938
)
|
|
|
|
|
|
Net
Income (Loss)
|
$
(644,308
)
|
$
(485,444
)
|
$
(909,944
)
|
$
(681,146
)
|
|
|
|
|
|
Basic Income (Loss)
per Common Share
|
$
0.00
|
$
0.00
|
$
0.00
|
$
0.00
|
|
|
|
|
|
Weighted Average
Common Shares Outstanding
|
1,000,371,607
|
857,473,771
|
971,151,423
|
811,800,080
|
|
|
|
|
|
Net Income
(Loss)
|
$
(644,308
)
|
$
(485,444
)
|
$
(909,944
)
|
$
(681,146
)
|
Other Comprehensive
Income:
|
|
|
|
|
Gain (Loss) from
Foreign Exchange Translation
|
(4,056
)
|
2,680
|
(5,786
)
|
3,795
|
Comprehensive
(Loss)
|
(648,364
)
|
(482,764
)
|
(915,730
)
|
(677,351
)
|
|
|
|
|
|
Basic (Loss) per
Common Share
|
$
0.00
|
$
0.00
|
$
0.00
|
$
0.00
|
|
|
|
|
|
Weighted Average
Common Shares Outstanding
|
1,000,371,607
|
857,473,771
|
971,151,423
|
811,800,080
|
See
Accompanying Notes To These Financial Statements.
SUNSHINE
BIOPHARMA INC. AND SUBSIDIARIES
CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|
December
31,
2017
(audited)
|
December
31,
2016
(audited)
|
Revenue:
|
$
-
|
$
-
|
|
|
|
General &
Administrative Expenses
|
|
|
|
|
|
Accounting
|
81,643
|
70,413
|
Legal
|
75,908
|
57,955
|
Consulting
|
127,013
|
207,401
|
Office
|
45,726
|
45,215
|
Licenses
|
-
|
19,203
|
Officer &
Director remuneration
|
520,271
|
499,397
|
Research &
Development
|
-
|
32,793
|
Amortization &
Depreciation
|
6,629
|
60,731
|
|
|
|
Total G &
A
|
857,190
|
993,108
|
|
|
|
(Loss) from
Operations
|
(857,190
)
|
(993,108
)
|
|
|
|
Other Income
(Expense):
|
|
|
Interest
Expense
|
(104,829
)
|
(34,732
)
|
(Loss) on
Conversion of Notes Payable
|
(76,929
)
|
(1,945,898
)
|
(Loss) on
Impairment of Patents
|
-
|
(556,120
)
|
Litigation
Settlement Proceeds
|
-
|
25,000
|
(Loss) from Foreign
Exchange Transactions
|
(1,288
)
|
-
|
Gain on Interest
Forgiveness
|
-
|
381
|
Debt
Release
|
-
|
7,790
|
|
|
|
Total Other
(Expense)
|
(183,046
)
|
(2,503,579
)
|
|
|
|
Net
(Loss)
|
$
(1,040,236
)
|
$
(3,496,687
)
|
|
|
|
Basic (Loss) per
Common Share
|
$
0.00
|
$
(0.01
)
|
|
|
|
Weighted Average
Common Shares Outstanding
|
872,685,608
|
424,874,458
|
|
|
|
Net Income
(Loss)
|
$
(1,040,236
)
|
$
(3,496,687
)
|
Other Comprehensive
Income:
|
|
|
Unrealized Foreign
Currency Gain (Loss)
|
110
|
(346
)
|
Comprehensive
(Loss)
|
(1,040,126
)
|
(3,497,033
)
|
|
|
|
Basic (Loss) per
Common Share
|
(0.00
)
|
(0.01
)
|
|
|
|
Weighted Average
Common Shares Outstanding
|
872,685,608
|
424,874,458
|
See
Accompanying Notes To These Financial Statements.
RISK FACTORS
This investment has a high degree of risk. Before you invest you
should carefully consider the risks and uncertainties described
below and the other information in this Prospectus. If any of the
following risks actually occur, our business, operating results and
financial condition could be harmed and the value of our stock
could go down. This means you could lose all or a part of your
investment.
Special Information Regarding Forward-Looking
Statements
Some of
the statements in this Prospectus are “forward-looking
statements.” These forward-looking statements involve certain
known and unknown risks, uncertainties and other factors which may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by these forward-looking
statements. These factors include, among others, the factors set
forth herein under “Risk Factors.” The words
“believe,” “expect,”
“anticipate,” “intend,” “plan,”
and similar expressions identify forward-looking statements. We
caution you not to place undue reliance on these forward-looking
statements. We undertake no obligation to update and revise any
forward-looking statements or to publicly announce the result of
any revisions to any of the forward-looking statements in this
document to reflect any future or developments. However, the
Private Securities Litigation Reform Act of 1995 is not available
to us as a non-reporting issuer. Further, Section 27A(b)(2)(D) of
the Securities Act and Section 21E(b)(2)(D) of the Securities
Exchange Act expressly state that the safe harbor for forward
looking statements does not apply to statements made in connection
with an initial public offering.
Risks Related to our Operations
We may not be able to continue as a going concern or fund our
existing capital needs.
Our independent registered public accounting firm included an
explanatory paragraph in their report included herein on our
financial statements related to the uncertainty in our ability to
continue as a going concern. The paragraph stated that
we do not have sufficient cash on-hand or other funding available
to meet our obligations and sustain our operations, which raises
substantial doubt about our ability to continue as a going
concern. Our cash and cash equivalents were sufficient
to fund our existing development commitments, indebtedness and
general operating expenses through December 31, 2017; however, we
will not be generating any product-based revenues or realizing cash
flows from operations in the near term, if at all, and may not have
sufficient cash or other funding available to complete our
anticipated business activities during 2018.
We have incurred losses in the past and expect to incur greater
losses until we implement our business plan.
We are a development stage company and we have not yet begun
generating revenues from product sales and we do not expect to
begin generating significant revenues until the clinical trials for
our sole product candidate (Adva-27a) is completed and is
successful. Further, there can be no assurance that the
results obtained from laboratory or research studies will be
replicated in human studies or that such human studies will not
identify undesirable side effects. There can be no assurance
that any of our therapeutic products will meet applicable health
regulatory standards, obtain required regulatory approvals or
clearances, be produced in commercial quantities at reasonable
costs, be successfully marketed or be profitable enough that we
will recoup the investment made in such product
candidates.
We are a development stage company and may never attain product
sales.
We have not received approval for any of our product candidates
from the FDA. Any compounds that we discover or
in-license will require extensive and costly development,
preclinical testing and/or clinical trials prior to seeking
regulatory approval for commercial sales. Our most
advanced and only product candidate, Adva-27a, may never be
approved for commercial sale. The time required to
attain product sales and profitability is lengthy and highly
uncertain, and we cannot assure you that we will be able to achieve
product sales.
We expect our net operating losses to continue for at least several
years, and we are unable to predict the extent of future losses or
when we will become profitable, if ever. We have
incurred significant net losses since our formation in
2009. We have incurred an accumulated deficit of
$13,618,190 as of December 31, 2017 and $14,528,134 as of June 30,
2018. Our operating losses are due in large part to the
significant research and development costs required to identify,
validate and license potential product candidates, conduct
preclinical studies and conduct clinical trials of our more
advanced product candidates. To date, we have not
generated any revenues from product sales and we do not anticipate
generating any sales revenues in the near term, if
ever. We expect to increase our operating expenses over
the next several years as we plan to:
● Prepare and carry out for the development of
Adva-27a;
● Expand our research and development
activities;
● Increase our required corporate infrastructure and
overhead.
As a result, we expect to continue to incur significant and
increasing operating losses for the foreseeable
future. Because of the numerous risks and uncertainties
associated with our research and product development efforts, we
are unable to predict the extent of any future losses or when we
will become profitable, if ever. Even if we do achieve
profitability, we may not be able to sustain or increase
profitability on an ongoing basis.
We have not conducted any significant business operations yet and
have been unprofitable to date.
There is no prior operating history by which to evaluate the
likelihood of our success or our contribution to our overall
profitability. We may never complete clinical trials of
our product and commence significant operations or, if we do
complete these clinical trials there are no assurances that the
results will be positive.
We may require additional funding to satisfy our future capital
needs, and future financing strategies may adversely affect holders
of our Common Stock.
Even after we complete our financing with GHS our operations may
require significant additional funding in large part due to our
research and development expenses, future preclinical and clinical
testing costs, and the absence of any meaningful revenues in the
near future. We do not know whether additional financing will be
available to us on favorable terms or at all. If we
cannot raise additional funds, we may be required to reduce our
capital expenditures, scale back product development programs,
reduce our workforce and license to others products or technologies
that we may otherwise be able to commercialize.
To the extent we raise additional capital by issuing equity
securities our stockholders could experience substantial
dilution. Any additional equity securities we issue or
issuances of debt we may enter into or undertake may have rights,
preferences or privileges senior to those of existing holders of
stock. To the extent that we raise additional funds
through collaboration and licensing arrangements, we may be
required to relinquish some rights to our technologies or product
candidates, or grant licenses on terms that are not favorable to
us.
We have not recorded any revenues from the sale of therapeutic
products, have accumulated significant losses since inception and
expect to continue to incur losses in the future.
There can be no assurance that we will ever be able to achieve or
sustain sufficient sales or other revenue growth in order to
achieve profitability or positive cash flow. To become
profitable we, either alone or with one or more partners, must
develop, manufacture and successfully market therapeutic product
candidates. There can be no assurance that we will be
successful in achieving the sales levels required to achieve
profitability. In addition, lower than anticipated
revenues may negatively impact our cash flows, which could
accelerate the need for additional capital.
The FDA may change its approval policies or requirements, or apply
interpretations to its policies or requirements, in a manner that
could delay or prevent commercialization of Adva-27a.
Regulatory requirements may change in a manner that requires us to
conduct additional clinical trials, which may delay or prevent
commercialization of our only drug candidate,
Adva-27a. We cannot provide any assurance that the FDA
will not require us to repeat existing studies or conduct new or
unforeseen experiments in order to demonstrate the safety and
efficacy of Adva-27a before considering the approval of Adva-27a
for the treatment of cancer indications. Further, FDA
Advisory Panel meetings discussing such drug approvals may result
in heightened scrutiny of Adva-27a for the treatment of pancreatic
cancer, breast cancer or other cancer types.
Our business would
be materially harmed if we fail to obtain FDA approval
for
Adva-27a
.
We anticipate that our ability to generate any significant product
revenues in the near future will depend solely on the successful
development and commercialization of Adva-27a. The FDA
may not approve in a timely manner, or at all, Adva-27a drug
candidate. If we are unable to submit an NDA for
Adva-27a or other product candidates, we will be unable to
commercialize any products in the United States and our business
will be materially harmed. The FDA can and does reject
NDAs, and often requires additional clinical trials, even when
product candidates performed well or achieved favorable results in
large-scale Phase III clinical trials. The FDA imposes
substantial requirements on the introduction of pharmaceutical
products through lengthy and detailed laboratory and clinical
testing procedures, sampling activities and other costly and
time-consuming procedures. Satisfaction of these
requirements typically takes several years and may vary
substantially based upon the type and complexity of the
pharmaceutical product. Our product candidates are novel
compounds or new chemical entities, which may further increase the
period of time required for satisfactory testing
procedures.
Data obtained from preclinical and clinical activities are
susceptible to varying interpretations, which could delay, limit or
prevent regulatory approval. In addition, delays or
rejections may be encountered based on changes in, or additions to,
regulatory policies for drug approval during the period of product
development and regulatory review. The effect of
government regulation may be to delay or prevent the commencement
of clinical trials or marketing of our product candidates for a
considerable period of time, to impose costly procedures upon our
activities and to provide an advantage to our competitors that have
greater financial resources or are more experienced in regulatory
affairs. The FDA may not approve our product candidates
for clinical trials or marketing on a timely basis or at
all. Delays in obtaining or failure to obtain such
approvals would adversely affect the marketing of our product
candidates and our liquidity and capital resources.
Drug products and their manufacturers are subject to continual
regulatory review after the product receives FDA
approval. Later discovery of previously unknown problems
with a product or manufacturer may result in additional clinical
testing requirements or restrictions on such product or
manufacturer, including withdrawal of the product from the
market. Failure to comply with applicable regulatory
requirements can, among other things, result in fines, injunctions
and civil penalties, suspensions or withdrawals of regulatory
approvals, product recalls, operating restrictions or shutdown and
criminal prosecution. We may lack sufficient resources
and expertise to address these and other regulatory issues as they
arise.
We may be sued or become a party to litigation, which could require
significant management time and attention and result in significant
legal expenses and may result in an unfavorable outcome which could
have a material adverse effect on our business, financial
condition, results of operations and cash flows.
We may be forced to incur costs and expenses in connection with
defending ourselves with respect to such litigation and the payment
of any settlement or judgment in connection therewith if there is
an unfavorable outcome. The expense of defending
litigation may be significant. The amount of time to
resolve lawsuits is unpredictable and defending ourselves may
divert management’s attention from the day-to-day operations
of our business, which could adversely affect our business, results
of operations and cash flows. In addition, an
unfavorable outcome in any such litigation could have a material
adverse effect on our business, results of operations and cash
flows.
Holders of our Common Stock may suffer significant dilution in the
future.
In order to fully implement our business plan we will require
additional capital, either debt or equity, or both. As a
result, we expect to raise additional equity capital by selling
shares of our Common Stock or other securities in the future to
raise the funds necessary to allow us to implement our business
plan. If we do so, investors will suffer significant
dilution.
Our management and principal shareholders have the ability to
significantly influence or control matters requiring a shareholder
vote and other shareholders may not have the ability to influence
corporate transactions.
Currently, Dr. Steve N. Slilaty owns or controls, either directly
or indirectly, approximately 39.9% of our outstanding voting
securities. This percentage includes the votes available
through the 500,000 shares of Series B Preferred Stock owned by Dr.
Slilaty whereby each share of Series B Preferred Stock is entitled
to 1,000 votes. As a result, he essentially has the ability to
determine the outcome on all matters requiring approval of our
shareholders, including the election of directors and approval of
significant corporate transactions.
If we are unable to attract and retain qualified scientific,
technical and key management personnel, or if our key executive,
Dr. Steve N. Slilaty, discontinues his employment with us, it may
delay our research and development efforts.
We rely on the services of Dr. Slilaty for strategic and
operational management, as well as for scientific and/or medical
expertise in the development of our products. The loss
of Dr. Slilaty would result in a significant negative impact on our
ability to implement our business plan. We have not
entered into an employment agreement with any member of our
management, including Dr. Slilaty. In addition, we do
not maintain “key person” life insurance covering Dr.
Slilaty or any other executive officer. The loss of Dr.
Slilaty will also significantly delay or prevent the achievement of
our business objectives.
Our business will expose us to potential product liability risks
and there can be no assurance that we will be able to acquire and
maintain sufficient insurance to provide adequate coverage against
potential liabilities.
Our business will expose us to potential product liability risks
that are inherent in the testing, manufacturing and marketing of
pharmaceutical products. The use of our product
candidates in clinical trials also exposes us to the possibility of
product liability claims and possible adverse
publicity. These risks will increase to the extent our
product candidates receive regulatory approval and are
commercialized. We do not currently have any product
liability insurance, although we plan to obtain product liability
insurance in connection with future clinical trials of our product
candidates. There can be no assurance that we will be
able to obtain or maintain any such insurance on acceptable
terms. Moreover, our product liability insurance may not
provide adequate coverage against potential
liabilities. On occasion, juries have awarded large
judgments in class action lawsuits based on drugs that had
unanticipated side effects. A successful product
liability claim or series of claims brought against us would
decrease our cash reserves and could cause our stock price to fall
significantly.
We face regulation and risks related to hazardous materials and
environmental laws, violations of which may subject us to claims
for damages or fines that could materially affect our business,
cash flows, financial condition and results of
operations.
Our research and development activities involve the use of
controlled and/or hazardous materials and chemicals. The
risk of accidental contamination or injury from these materials
cannot be completely eliminated. In the event of an
accident, we could be held liable for any damages or fines that
result, and the liability could have a material adverse effect on
our business, financial condition and results of
operations. We are also subject to federal, state and
local laws and regulations governing the use, manufacture, storage,
handling and disposal of hazardous materials and waste
products. If we fail to comply with these laws and
regulations or with the conditions attached to our operating
licenses, the licenses could be revoked, and we could be subjected
to criminal sanctions and substantial liability or be required to
suspend or modify our operations. In addition, we may
have to incur significant costs to comply with future environmental
laws and regulations. We do not currently have a
pollution and remediation insurance policy.
Third party manufacturers may not be able to manufacture our
product candidates, which would prevent us from commercializing our
product candidates.
If any of our product candidates is approved by the FDA or other
regulatory agencies for commercial sale, we will need third parties
to manufacture the product in larger quantities. If we
are able to reach an agreement with any collaborator or third party
manufacturer in the future, of which there can be no assurance due
to factors beyond our control, these collaborators and/or third
party manufacturers may not be able to increase their manufacturing
capacity for any of our product candidates in a timely or economic
manner, or at all. Significant scale-up of manufacturing
may require additional validation studies, which the FDA must
review and approve. If we are unable to increase the
manufacturing capacity for a product candidate successfully, the
regulatory approval or commercial launch of that product candidate
may be delayed or there may be a shortage in the supply of the
product candidate. Our product candidates require
precise, high-quality manufacturing. The failure of
collaborators or third party manufacturers to achieve and maintain
these high manufacturing standards, including the incidence of
manufacturing errors, could result in patient injury or death,
product recalls or withdrawals, delays or failures in product
testing or delivery, cost overruns or other problems that could
seriously harm our business.
If we are unable to establish sales and marketing capabilities or
enter into agreements with third parties to sell and market any
products we may develop, we may be unable to generate
revenues.
We do not currently have product sales and marketing
capabilities. If we receive regulatory approval to
commence commercial sales of any of our product candidates, we will
have to establish a sales and marketing organization with
appropriate technical expertise and distribution capabilities or
make arrangements with third parties to perform these services in
other jurisdictions. If we receive approval to
commercialize Adva-27a for the treatment of breast cancer
indication, we intend to engage additional pharmaceutical or health
care companies with existing distribution systems and direct sales
organizations to assist us in North America and
abroad. We may not be able to negotiate favorable
distribution partnering arrangements, if at all. To the
extent we enter into co-promotion or other licensing arrangements,
any revenues we receive will depend on the efforts of third parties
and will not be under our control. If we are unable to establish
adequate sales, marketing and distribution capabilities, whether
independently or with third parties, our ability to generate
product revenues, and become profitable, would be severely
limited.
Our ability to generate any significant revenues in the near-term
is dependent entirely on the successful commercialization and
market acceptance of Adva-27a. Factors that may inhibit
our efforts to commercialize Adva-27a or other product candidates
without strategic partners or licensees include:
●
difficulty
recruiting and retaining adequate numbers of effective sales and
marketing personnel;
●
the
inability of sales personnel to obtain access to, or persuade
adequate numbers of, physicians to prescribe our
products;
●
the
lack of complementary products to be offered by sales personnel,
which may put us at a competitive disadvantage against companies
with broader product lines; and
●
unforeseen
costs associated with creating an independent sales and marketing
organization.
Even if we successfully develop and obtain approval for Adva-27a,
our business will not be profitable if this product does not
achieve and maintain market acceptance.
Even if our product candidate, Adva-27a, is approved for commercial
sale by the FDA or other regulatory authorities, the degree of
market acceptance of our approved product candidate by physicians,
healthcare professionals, patients and third-party payors, and our
resulting profitability and growth, will depend on a number of
factors, including:
●
our ability to
provide acceptable evidence of safety and efficacy;
●
relative
convenience and ease of administration;
●
the prevalence and
severity of any adverse side effects;
●
the availability of
alternative treatments;
●
the details of FDA
labeling requirements, including the scope of approved indications
and any safety warnings;
●
pricing and cost
effectiveness;
●
the effectiveness
of our or our collaborators' sales and marketing
strategy;
●
our ability to
obtain sufficient third-party insurance coverage or reimbursement;
and
●
our ability to have
the product listed on insurance company formularies.
If our product candidate achieves market acceptance, we may not be
able to maintain that market acceptance over time if new products
or technologies are introduced that are received more favorably or
are more cost effective. Complications may also arise,
such as development of new know-how or new medical or therapeutic
capabilities by other parties that render our product
obsolete.
Because the results of preclinical studies for our preclinical
product candidate are not necessarily predictive of future results,
our product candidate may not have favorable results in later
clinical trials or ultimately receive regulatory
approval.
Our product candidate has not been tested in clinical
trials. Positive results from preclinical studies are no
assurance that later clinical trials will
succeed. Preclinical studies are not designed to
establish the clinical efficacy of our preclinical product
candidate. We will be required to demonstrate through
clinical trials that our product candidate is safe and effective
for use before we can seek regulatory approvals for commercial
sale. There is typically an extremely high rate of
failure as product candidates proceed through clinical
trials. If our product candidate fails to demonstrate
sufficient safety and efficacy in any clinical trial, we would
experience potentially significant delays in, or be required to
abandon, development of that product candidate. This
would adversely affect our ability to generate revenues and may
damage our reputation in the industry and in the investment
community.
The future clinical testing of our product candidates could be
delayed, resulting in increased costs to us and a delay in our
ability to generate revenues.
Our product candidate will require additional preclinical testing
and extensive clinical trials prior to submitting a regulatory
application for commercial sales. We do not know whether
clinical trials will begin on time, if at all. Delays in
the commencement of clinical testing could significantly increase
our product development costs and delay product
commercialization. In addition, many of the factors that
may cause, or lead to, a delay in the commencement of clinical
trials may also ultimately lead to denial of regulatory approval of
a product candidate. Each of these results would
adversely affect our ability to generate revenues.
The commencement of clinical trials can be delayed for a
variety of reasons, including delays in:
|
●
|
demonstrating
sufficient safety to obtain regulatory approval to commence a
clinical trial;
|
|
●
|
reaching
agreement on acceptable terms with prospective research
organizations and trial sites;
|
|
●
|
manufacturing
sufficient quantities of a product candidate;
|
|
●
|
obtaining
institutional review board approvals to conduct clinical trials at
prospective sites; and
|
|
●
|
procuring
adequate financing to fund the work.
|
In addition, the commencement of clinical trials may be delayed due
to insufficient patient enrollment, which is a function of many
factors, including the size of the patient population, the nature
of the protocol, the proximity of patients to clinical sites, the
availability of effective treatments for the relevant disease, and
the eligibility criteria for the clinical trial. If we
are unable to enroll a sufficient number of evaluable patients, the
clinical trials for our product candidate could be delayed until
sufficient numbers are achieved.
We will face significant competition from other biotechnology and
pharmaceutical companies, and our operating results will suffer if
we fail to compete effectively.
We are a development stage company with only three (3) employees
involved in our drug development program. Most of our
competitors, such as Bristol-Myers Squibb, Pfizer, TEVA, Amgen, and
others, are large pharmaceutical companies with substantially
greater financial, technical and human resources than we
have. The biotechnology and pharmaceutical industries
are intensely competitive and subject to rapid and significant
technological change. The drug that we are attempting to
develop will compete with existing therapies if we receive
marketing approval. Because of their significant
resources, our competitors may be able to use discovery
technologies and techniques, or partnerships with collaborators, in
order to develop competing products that are more effective or less
costly than the product candidate we are
developing. This may render our technology or product
candidate obsolete and noncompetitive. Academic
institutions, government agencies, and other public and private
research organizations may seek patent protection with respect to
potentially competitive products or technologies and may establish
exclusive collaborative or licensing relationships with our
competitors.
As a company, we do not have any experience in conducting clinical
trials. Our competitors may succeed in obtaining FDA or
other regulatory approvals for product candidates more rapidly than
us. Companies that complete clinical trials, obtain
required regulatory agency approvals and commence commercial sale
of their drugs before we do may achieve a significant competitive
advantage, including certain FDA marketing exclusivity rights that
would delay or prevent our ability to market certain
products. Any approved drugs resulting from our research
and development efforts, or from our joint efforts with our
existing or future collaborative partners, might not be able to
compete successfully with our competitors' existing or future
products.
Because our product candidate and our development and collaboration
efforts depend on our intellectual property rights, adverse events
affecting our intellectual property rights will harm our ability to
commercialize products.
Our success will depend to a large degree on our own and our
licensors' ability to obtain and defend patents for each party's
respective technologies and the compounds and other products, if
any, resulting from the application of such
technologies. The patent positions of pharmaceutical and
biotechnology companies can be highly uncertain and involve complex
legal and technical questions. No consistent policy
regarding the breadth of claims allowed in biotechnology patents
has emerged to date. Accordingly, we cannot predict the
breadth of claims that will be allowed or maintained, after
challenge, in our or other companies' patents.
The degree of future protection for our proprietary rights is
uncertain, and we cannot ensure that:
|
●
|
we were
the first to make the inventions covered by each of our pending
patent applications;
|
|
●
|
we were
the first to file patent applications for these
inventions;
|
|
●
|
others
will not independently develop similar or alternative technologies
or duplicate any of our technologies;
|
|
●
|
any
patents issued to us or our collaborators will provide a basis for
commercially viable products, will provide us with any competitive
advantages or will not be challenged by third parties;
|
|
●
|
our
pending patent applications will result in issued
patents;
|
|
●
|
we will
develop additional proprietary technologies that are patentable;
or
|
|
●
|
the
patents of others will not have a negative effect on our ability to
do business.
|
|
●
|
our
issued patents will have sufficient useful life remaining for
commercial viability of our product candidate
|
If we cannot maintain the confidentiality of our technology and
other confidential information in connection with our
collaborations, then our ability to receive patent protection or
protect our proprietary information will be impaired. In
addition, some of the technology we have developed or licensed
relies on inventions developed using U.S. and other
governments’ resources. Under applicable law, the
U.S. government has the right to require us to grant a
nonexclusive, partially exclusive or exclusive license for such
technology to a responsible applicant or applicants, upon terms
that are reasonable under the circumstances, if the government
determines that such action is necessary.
Confidentiality agreements with employees and others may not
adequately prevent disclosure of trade secrets and other
proprietary information and may not adequately protect our
intellectual property.
We rely on trade secrets to protect our technology, particularly
when we do not believe patent protection is appropriate or
obtainable. However, trade secrets are difficult to
protect. In order to protect our proprietary technology
and processes, we rely in part on confidentiality and intellectual
property assignment agreements with our employees, consultants,
outside scientific collaborators and sponsored researchers and
other advisors. These agreements may not effectively
prevent disclosure of confidential information nor result in the
effective assignment to us of intellectual property, and may not
provide an adequate remedy in the event of unauthorized disclosure
of confidential information or other breaches of the
agreements. In addition, others may independently
discover our trade secrets and proprietary information, and in such
case we could not assert any trade secret rights against such
party. Enforcing a claim that a party illegally obtained
and is using our trade secrets is difficult, expensive and time
consuming, and the outcome is unpredictable. In
addition, courts outside the United States may be less willing to
protect trade secrets. Costly and time-consuming
litigation could be necessary to seek to enforce and determine the
scope of our proprietary rights, and failure to obtain or maintain
trade secret protection could adversely affect our competitive
business position.
The implementation of our business plan will result in a period of
rapid growth that will impose a significant burden on our current
administrative and operational resources.
Our ability to effectively manage our growth will require us to
substantially expand the capabilities of our administrative and
operational resources by attracting, training, managing and
retaining additional qualified personnel, including additional
members of management, technicians and others. To
successfully develop our products we will need to manage operating,
producing, marketing and selling our products. There can
be no assurances that we will be able to do so. Our
failure to successfully manage our growth will have a negative
impact on our anticipated results of operations.
The requirements of being a public company may strain our
resources, divert management’s attention and affect our
ability to attract and retain executive management and qualified
board members.
As a public company, we are subject to the reporting requirements
of the Securities Exchange Act of 1934, as amended, or the Exchange
Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, and other
applicable securities rules and regulations. Compliance with these
rules and regulations increases our legal and financial compliance
costs, make some activities more difficult, time-consuming or
costly and increase demand on our systems and resources,
particularly after we are no longer an “emerging growth
company,” as defined in the Jumpstart our Business Startups
Act, or the JOBS Act. The Exchange Act requires, among
other things, that we file annual, quarterly and current reports
with respect to our business and operating results. The
Sarbanes-Oxley Act requires, among other things, that we maintain
effective disclosure controls and procedures and internal control
over financial reporting. In order to maintain and, if required,
improve our disclosure controls and procedures and internal control
over financial reporting to meet this standard, significant
resources and management oversight may be required. As a
result, management’s attention may be diverted from other
business concerns which could adversely affect our business and
operating results. We may need to hire more employees in
the future or engage outside consultants which will increase our
costs and expenses.
In addition, changing laws, regulations and standards relating to
corporate governance and public disclosure are creating uncertainty
for public companies, increasing legal and financial compliance
costs and making some activities more time
consuming. These laws, regulations and standards are
subject to varying interpretations, in many cases due to their lack
of specificity, and, as a result, their application in practice may
evolve over time as new guidance is provided by regulatory and
governing bodies. This could result in continuing
uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance
practices. We intend to invest resources to comply with
evolving laws, regulations and standards, and this investment may
result in increased general and administrative expenses and a
diversion of management’s time and attention from
revenue-generating activities to compliance
activities. If our efforts to comply with new laws,
regulations and standards differ from the activities intended by
regulatory or governing bodies due to ambiguities related to their
application and practice, regulatory authorities may initiate legal
proceedings against us and our business may be adversely
affected.
However, for as long as we remain an “emerging growth
company,” we may take advantage of certain exemptions from
various reporting requirements that are applicable to public
companies that are not “emerging growth companies”
including, but not limited to, not being required to comply with
the auditor attestation requirements of Section 404, reduced
disclosure obligations regarding executive compensation in our
periodic reports and proxy statements, and exemptions from the
requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute
payments not previously approved. We may take advantage
of these reporting exemptions until we are no longer an
“emerging growth company.”
We would cease to be an “emerging growth company” upon
the earliest of: (i) the first fiscal year following the fifth
anniversary of our becoming a reporting company, (ii) the first
fiscal year after our annual gross revenues are $1.0 billion or
more, (iii) the date on which we have, during the previous
three-year period, issued more than $1.0 billion in non-convertible
debt securities, or (iv) as of the end of any fiscal year in which
the market value of our Common Stock held by non-affiliates
exceeded $700 million as of the end of the second quarter of that
fiscal year.
We also expect that being a public company and these new rules and
regulations will make it more expensive for us to obtain director
and officer liability insurance, and we may be required to accept
reduced coverage or incur substantially higher costs to obtain
coverage. These factors could also make it more
difficult for us to attract and retain qualified members of our
Board of Directors, particularly to serve on our audit committee
and compensation committee, and qualified executive
officers.
As a result of disclosure of information in this Prospectus and in
future filings required of a public company, our business and
financial condition will become more visible, which we believe may
result in threatened or actual litigation, including by competitors
and other third parties. If such claims are successful,
our business and operating results could be adversely affected, and
even if the claims do not result in litigation or are resolved in
our favor, these claims, and the time and resources necessary to
resolve them, could divert the resources of our management and
adversely affect our business and operating results.
Risks Related to our Common Stock
There is a limited trading market for our securities and there can
be no assurance that such a market will develop in the
future.
There is no assurance that a market will develop in the future or,
if developed, that it will continue. In the absence of a
public trading market, an investor may be unable to liquidate his
investment in our Company.
Our stock will be considered a “penny stock” so long as
it trades below $5.00 per share. This can adversely
affect its liquidity.
Our Common Stock is currently considered a “penny
stock” and will continue to be considered a penny stock so
long as it trades below $5.00 per share and as such, trading in our
Common Stock will be subject to the requirements of Rule 15g-9
under the Securities Exchange Act of 1934. Under this
rule, broker/dealers who recommend low-priced securities to persons
other than established customers and accredited investors must
satisfy special sales practice requirements. The
broker/dealer must make an individualized written suitability
determination for the purchaser and receive the purchaser’s
written consent prior to the transaction.
SEC regulations also require additional disclosure in connection
with any trades involving a “penny stock,” including
the delivery, prior to any penny stock transaction, of a disclosure
schedule explaining the penny stock market and its associated
risks. In addition, broker-dealers must disclose
commissions payable to both the broker-dealer and the registered
representative and current quotations for the securities they
offer. The additional burdens imposed upon
broker-dealers by such requirements may discourage broker-dealers
from recommending transactions in our securities, which could
severely limit the liquidity of our securities and consequently
adversely affect the market price for our securities. In
addition, few broker or dealers are likely to undertake these
compliance activities. Other risks associated with trading in penny
stocks could also be price fluctuations and the lack of a liquid
market.
We do not
anticipate payment of dividends, and investors will be wholly
dependent upon the market for the Common Stock to realize economic
benefit from their investment
.
As holders of our Common Stock, you will only be entitled to
receive those dividends that are declared by our Board of Directors
out of retained earnings. We do not expect to have
retained earnings available for declaration of dividends in the
foreseeable future. There is no assurance that such
retained earnings will ever materialize to permit payment of
dividends to you. Our Board of Directors will determine
future dividend policy based upon our results of operations,
financial condition, capital requirements, reserve needs and other
circumstances.
Any adverse effect on the market price of our Common Stock could
make it difficult for us to raise additional capital through sales
of equity securities at a time and at a price that we deem
appropriate.
Sales of substantial amounts of our Common Stock, or in
anticipation that such sales could occur, may materially and
adversely affect prevailing market prices for our Common
Stock.
The market price of our Common Stock may fluctuate significantly in
the future.
The market price of our Common Stock may fluctuate in response to
one or more of the following factors, many of which are beyond our
control:
|
●
|
competitive
pricing pressures;
|
|
●
|
our
ability to produce and sell our products on a cost-effective and
timely basis;
|
|
●
|
our
inability to obtain working capital financing;
|
|
●
|
the
introduction and announcement of one or more new alternatives to
our products by our competitors;
|
|
●
|
changing
conditions in the market;
|
|
●
|
changes
in market valuations of similar companies;
|
|
●
|
stock
market price and volume fluctuations generally;
|
|
●
|
regulatory
developments;
|
|
●
|
fluctuations
in our quarterly or annual operating results;
|
|
●
|
additions
or departures of key personnel; and
|
|
●
|
future
sales of our Common Stock or other securities.
|
The price at which you purchase shares of our Common Stock may not
be indicative of the price that will prevail in the trading
market. You may be unable to sell your shares of Common
Stock at or above your purchase price, which may result in
substantial losses to you and which may include the complete loss
of your investment. In the past, securities class action litigation
has often been brought against a company following periods of stock
price volatility. We may be the target of similar
litigation in the future. Securities litigation could
result in substantial costs and divert management’s attention
and our resources away from our business. Any of the
risks described above could adversely affect our sales and
profitability and also the price of our Common Stock.
Risks Related to the Offering
Our existing stockholders may experience significant dilution from
the sale of our Common Stock pursuant to the GHS Financing
Agreement.
The
sale of our Common Stock to GHS Investments LLC in accordance with
the GHS Financing Agreement may have a dilutive impact on our
shareholders. As a result, the market price of our Common Stock
could decline. In addition, the lower our stock price is at the
time we exercise our put options, the more shares of our Common
Stock we will have to issue to GHS in order to exercise a put under
the Financing Agreement. If our stock price decreases, then our
existing shareholders would experience greater dilution for any
given dollar amount raised through the offering.
The
perceived risk of dilution may cause our stockholders to sell their
shares, which may cause a decline in the price of our Common Stock.
Moreover, the perceived risk of dilution and the resulting downward
pressure on our stock price could encourage investors to engage in
short sales of our Common Stock. By increasing the number of shares
offered for sale, material amounts of short selling could further
contribute to progressive price declines in our Common
Stock.
The issuance of shares pursuant to the GHS Financing Agreement may
have a significant dilutive effect.
Depending
on the number of shares we issue pursuant to the GHS Financing
Agreement, it could have a significant dilutive effect upon our
existing shareholders. Although the number of shares that we may
issue pursuant to the Financing Agreement will vary based on our
stock price (the higher our stock price, the less shares we have to
issue), there may be a potential dilutive effect to our
shareholders, based on different potential future stock prices, if
the full amount of the Financing Agreement is realized. Dilution is
based upon Common Stock put to GHS and the stock price discounted
to GHS’s purchase price of 81% of the average of the three
lowest VWAPs of our Common Stock during the pricing
period.
GHS Investments LLC will pay less than the then-prevailing market
price of our Common Stock which could cause the price of our Common
Stock to decline.
Our
Common Stock to be issued under the GHS Financing Agreement will be
purchased at a nineteen percent (19%) discount, or eighty one
percent (81%) of the average of the three lowest VWAPs of our
Common Stock during the ten (10) consecutive trading days
immediately preceding the Purchase Date (as defined in the GHS
Financing Agreement).
GHS has
a financial incentive to sell our shares immediately upon receiving
them to realize the profit between the discounted price and the
market price. If GHS sells our shares, the price of our Common
Stock may decrease. If our stock price decreases, GHS may have
further incentive to sell such shares. Accordingly, the discounted
sales price in the Financing Agreement may cause the price of our
Common Stock to decline.
We may not have access to the full amount under the GHS Financing
Agreement.
The
average of the three lowest volume weighted average prices for the
Company’s Common Stock during the ten (10) consecutive
trading day period immediately preceding September 20, 2018 was
approximately $0.00148. At that price we would be able to sell
shares to GHS under the Financing Agreement at the discounted price
of $0.0011988. At that discounted price, the 266,417,879 shares
would only represent $319,382 which is far below the full amount of
the Financing Agreement.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This
Prospectus contains forward-looking statements. Forward-looking
statements give our current expectations or forecasts of future
events. You can identify these statements by the fact that they do
not relate strictly to historical or current facts. Forward-looking
statements involve risks and uncertainties and include statements
regarding, among other things, our projected revenue growth and
profitability, our growth strategies and opportunity, anticipated
trends in our market and our anticipated needs for working capital.
They are generally identifiable by use of the words
“may,” “will,” “should,”
“anticipate,” “estimate,”
“plans,” “potential,”
“projects,” “continuing,”
“ongoing,” “expects,” “management
believes,” “we believe,” “we intend”
or the negative of these words or other variations on these words
or comparable terminology. These statements may be found under the
sections entitled “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” and
“Business,” as well as in this Prospectus generally. In
particular, these include statements relating to future actions,
prospective products, market acceptance, future performance or
results of current and anticipated products, sales efforts,
expenses, and the outcome of contingencies such as legal
proceedings and financial results.
Examples
of forward-looking statements in this Prospectus include, but are
not limited to, our expectations regarding our business strategy,
business prospects, operating results, operating expenses, working
capital, liquidity and capital expenditure requirements. Important
assumptions relating to the forward-looking statements include,
among others, assumptions regarding demand for our products, the
cost, terms and availability of components, pricing levels, the
timing and cost of capital expenditures, competitive conditions and
general economic conditions. These statements are based on our
management’s expectations, beliefs and assumptions concerning
future events affecting us, which in turn are based on currently
available information. These assumptions could prove inaccurate.
Although we believe that the estimates and projections reflected in
the forward-looking statements are reasonable, our expectations may
prove to be incorrect.
Important
factors that could cause actual results to differ materially from
the results and events anticipated or implied by such
forward-looking statements include, but are not limited
to:
|
●
|
changes
in the market acceptance of our products;
|
|
|
|
|
●
|
increased
levels of competition;
|
|
|
|
|
●
|
changes
in political, economic or regulatory conditions generally and in
the markets in which we operate;
|
|
|
|
|
●
|
our
ability to retain and attract senior management and other key
employees;
|
|
|
|
|
●
|
our
ability to quickly and effectively respond to new technological
developments;
|
|
|
|
|
●
|
our
ability to protect our trade secrets or other proprietary rights,
operate without infringing upon the proprietary rights of others
and prevent others from infringing on the proprietary rights of the
Company; and
|
|
|
|
|
●
|
other
risks, including those described in the “Risk Factors”
discussion of this Prospectus.
|
We
operate in a very competitive and rapidly changing environment. New
risks emerge from time to time. It is not possible for us to
predict all of those risks, nor can we assess the impact of all of
those risks on our business or the extent to which any factor may
cause actual results to differ materially from those contained in
any forward-looking statement. The forward-looking statements in
this Prospectus are based on assumptions management believes are
reasonable. However, due to the uncertainties associated with
forward-looking statements, you should not place undue reliance on
any forward-looking statements. Further, forward-looking statements
speak only as of the date they are made, and unless required by
law, we expressly disclaim any obligation or undertaking to
publicly update any of them in light of new information, future
events, or otherwise.
USE OF PROCEEDS
The
Company will use the proceeds from the sale of the Shares for
general corporate and working capital purposes and acquisitions of
assets, businesses or operations or for other purposes that the
Board of Directors, in good faith deems to be in the best interest
of the Company.
DETERMINATION OF OFFERING PRICE
We have
not set an offering price for the shares registered hereunder, as
the only shares being registered are those sold pursuant to the GHS
Financing Agreement. GHS may sell all or a portion of the shares
being offered pursuant to this Prospectus at fixed prices and
prevailing market prices at the time of sale, at varying prices or
at negotiated prices.
DILUTION
Not
applicable. The shares registered under this Registration Statement
are not being offered for purchase. The shares are being registered
on behalf of our selling stockholders pursuant to the GHS Financing
Agreement.
SELLING STOCKHOLDERS
The
Selling Stockholder identified in this Prospectus may offer and
sell up to 266,417,879 shares of our Common Stock, which consists
of shares of Common Stock to be sold by GHS pursuant to the
Financing Agreement. If issued presently, the shares of Common
Stock registered for resale by GHS would represent approximately
16.8% of our issued and outstanding shares of Common Stock as of
September 20, 2018.
We may
require the Selling Stockholder to suspend the sales of the shares
of our Common Stock being offered pursuant to this Prospectus upon
the occurrence of any event that makes any statement in this
Prospectus or the related Registration Statement untrue in any
material respect or that requires the changing of statements in
those documents in order to make statements in those documents not
misleading.
The
Selling Stockholder identified in the table below may from time to
time offer and sell under this Prospectus any or all of the shares
of Common Stock described under the column “Shares of Common
Stock Being Offered” in the table below.
GHS
will be deemed to be an underwriter within the meaning of the
Securities Act. Any profits realized by such Selling Stockholder
may be deemed to be underwriting commissions.
Information
concerning the Selling Stockholder may change from time to time
and, if necessary, we will amend or supplement this Prospectus
accordingly. We cannot give an estimate as to the number of shares
of Common Stock that will actually be held by the Selling
Stockholder upon termination of this offering, because the Selling
Stockholder may offer some or all of the Common Stock under the
offering contemplated by this Prospectus or acquire additional
shares of Common Stock. The total number of shares that may be
sold, hereunder, will not exceed the number of shares offered,
hereby. Please read the section entitled “PLAN OF
DISTRIBUTION” in this Prospectus.
The
manner in which the Selling Stockholder acquired or will acquire
shares of our Common Stock is discussed below under “THE
OFFERING.”
The
following table sets forth the name of each Selling Stockholder,
the number of shares of our Common Stock beneficially owned by such
stockholder before this offering, the number of shares to be
offered for such stockholder’s account and the number and (if
one percent or more) the percentage of the class to be beneficially
owned by such stockholder after completion of the offering. The
number of shares owned are those beneficially owned, as determined
under the rules of the SEC, and such information is not necessarily
indicative of beneficial ownership for any other purpose. Under
such rules, beneficial ownership includes any shares of our Common
Stock as to which a person has sole or shared voting power or
investment power and any shares of Common Stock which the person
has the right to acquire within 60 days, through the exercise of
any option, warrant or right, through conversion of any security or
pursuant to the automatic termination of a power of attorney or
revocation of a trust, discretionary account or similar
arrangement, and such shares are deemed to be beneficially owned
and outstanding for computing the share ownership and percentage of
the person holding such options, warrants or other rights, but are
not deemed outstanding for computing the percentage of any other
person. Beneficial ownership percentages are calculated based on
1,585,628,494 shares of our Common Stock outstanding as of
September 20, 2018.
Unless
otherwise set forth below, (a) the persons and entities named in
the table have sole voting and sole investment power with respect
to the shares set forth opposite the Selling Stockholder’s
name, subject to community property laws, where applicable, and (b)
no Selling Stockholder had any position, office or other material
relationship within the past three years, with us or with any of
our predecessors or affiliates. The number of shares of Common
Stock shown as beneficially owned before the offering is based on
information furnished to us or otherwise based on information
available to us at the timing of the filing of the Registration
Statement of which this Prospectus forms a part.
|
|
Shares
Owned
by
the
Selling
Stockholders
|
|
Number of Shares
to be Owned by Selling Stockholder After the Offering and Percent
of Total Issued and Outstanding Shares
|
|
Name of Selling Stockholder
|
|
|
|
|
|
GHS Investments LLC
(3)
|
|
0
|
266,417,879
(4)
|
0
|
0
%
|
Notes:
(1)
Beneficial ownership is determined in accordance with Securities
and Exchange Commission rules and generally includes voting or
investment power with respect to shares of Common Stock. Shares of
Common Stock subject to options, warrants and convertible
debentures currently exercisable or convertible, or exercisable or
convertible within 60 days, are counted as outstanding. The actual
number of shares of Common Stock issuable upon the conversion of
the convertible debentures is subject to adjustment depending on,
among other factors, the future market price of our Common Stock,
and could be materially less or more than the number estimated in
the table.
(2)
Because the Selling Stockholder may offer and sell all or only some
portion of the 266,417,879 shares of our Common Stock being offered
pursuant to this Prospectus and may acquire additional shares of
our Common Stock in the future, we can only estimate the number and
percentage of shares of our Common Stock that any of the Selling
Stockholder will hold upon termination of the
offering.
(3)
Mark Grober exercises voting and dispositive power with respect to
the shares of our Common Stock that are beneficially owned by GHS
Investments LLC.
(4)
Consists of up to 266,417,879 shares of Common Stock to be sold by
GHS pursuant to the Financing Agreement.
THE OFFERING
On
September 10, 2018, we entered into an Equity Financing Agreement
(the “Financing Agreement”) with GHS Investments LLC
(“GHS”). Although we are not mandated to sell shares
under the Financing Agreement, the Financing Agreement gives us the
option to sell to GHS, up to $10,000,000 worth of our Common Stock
over the period ending thirty six (36) months after the date this
Registration Statement is deemed effective. The $10,000,000 was
stated as the total amount of available funding in the Financing
Agreement because this was the maximum amount that GHS agreed to
offer us in funding. In connection with the Financing Agreement,
the Company executed a promissory note dated September 10, 2018, in
the principal amount of $20,000 (the “Note”) as payment
of the commitment fee for the Financing Agreement. The Note
bears interest at the rate of 8% per annum and has a maturity date
of June 30, 2019. There is no assurance the market price of our
Common Stock will increase in the future. The number of common
shares that remain issuable may not be sufficient, dependent upon
the share price, to allow us to access the full amount contemplated
under the Financing Agreement. If the bid/ask spread remains the
same we will not be able to place a put for the full commitment
under the Financing Agreement. Based on the average of the three
lowest VWAP’s of our Common Stock during the ten (10)
consecutive trading day period preceding the filing date of this
Registration Statement was approximately $0.00148, the Registration
Statement covers the offer and possible sale of $319,382 worth of
our shares.
The
purchase price of the Common Stock will be set at eighty one
percent (81%) of the average of the three lowest VWAPs of the
Company’s Common Stock during the ten (10) consecutive
trading day period immediately preceding the date on which the
Company delivers a put notice to GHS. In addition, there is a
maximum ownership limit for GHS of 9.99% of the issued and
outstanding Common Stock of the Company.
GHS is
not permitted to engage in short sales involving our Common Stock
during the term of the commitment period. In accordance with
Regulation SHO, however, sales of our Common Stock by GHS after
delivery of a put notice of such number of shares reasonably
expected to be purchased by GHS under a put will not be deemed a
short sale.
In
addition, we must deliver the other required documents, instruments
and writings required. GHS is not required to purchase the put
shares unless:
●
Our Registration
Statement with respect to the resale of the shares of Common Stock
delivered in connection with the applicable put shall have been
declared effective;
●
We shall have
obtained all material permits and qualifications required by any
applicable state for the offer and sale of the registrable
securities; and
●
We shall have filed
all requisite reports, notices, and other documents with the SEC in
a timely manner.
As we
issue puts under the Financing Agreement, shares of our Common
Stock will be sold into the market by GHS. The sale of these shares
could cause our stock price to decline. In turn, if our stock price
declines and we issue more puts, more shares will come into the
market, which could cause a further drop in our stock price. You
should be aware that there is an inverse relationship between the
market price of our Common Stock and the number of shares to be
issued under the Financing Agreement. If our stock price declines,
we will be required to issue a greater number of shares. We have no
obligation to utilize any or the full amount available under the
Financing Agreement.
Neither
the Financing Agreement nor any of our rights or GHS’s rights
thereunder may be assigned to any other person.
PLAN OF DISTRIBUTION
The
Selling Stockholder named above and any of its pledgees and
successors-in-interest may, from time to time, sell any or all of
their shares of Common Stock on OTC Markets or any other stock
exchange, market or trading facility on which the shares of our
Common Stock are traded or in private transactions. These sales may
be at fixed prices and prevailing market prices at the time of
sale, at varying prices or at negotiated prices. The Selling
Stockholder may use any one or more of the following methods when
selling shares:
●
ordinary brokerage
transactions and transactions in which the broker-dealer solicits
purchasers;
●
block trades in
which the broker-dealer will attempt to sell the shares as agent
but may position and resell a portion of the block as principal to
facilitate the transaction;
●
purchases by a
broker-dealer as principal and resale by the broker-dealer for its
account;
●
privately
negotiated transactions;
●
broker-dealers may
agree with the Selling Stockholder to sell a specified number of
such shares at a stipulated price per share; or
●
a combination of
any such methods of sale.
Broker-dealers
engaged by the Selling Stockholder may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholder (or, if any
broker-dealer acts as agent for the purchaser of shares, from the
purchaser) in amounts to be negotiated, but, except as set forth in
a supplement to this Prospectus, in the case of an agency
transaction not in excess of a customary brokerage commission in
compliance with FINRA Rule 2440; and in the case of a principal
transaction a markup or markdown in compliance with FINRA
IM-2440.
GHS is
an underwriter within the meaning of the Securities Act of 1933 and
any broker-dealers or agents that are involved in selling the
shares may be deemed to be “underwriters” within the
meaning of the Securities Act of 1933 in connection with such
sales. In such event, any commissions received by such
broker-dealers or agents and any profit on the resale of the shares
purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act of 1933. GHS has informed us
that it does not have any written or oral agreement or
understanding, directly or indirectly, with any person to
distribute the Common Stock of our company. Pursuant to a
requirement by FINRA, the maximum commission or discount to be
received by any FINRA member or independent broker-dealer may not
be greater than 8% of the gross proceeds received by us for the
sale of any securities being registered pursuant to Rule 415
promulgated under the Securities Act of 1933.
Discounts,
concessions, commissions and similar selling expenses, if any,
attributable to the sale of shares will be borne by the Selling
Stockholder. The Selling Stockholder may agree to indemnify any
agent, dealer, or broker-dealer that participates in transactions
involving sales of the shares if liabilities are imposed on that
person under the Securities Act of 1933.
We are
required to pay certain fees and expenses incurred by us incident
to the registration of the shares covered by this Prospectus. We
have agreed to indemnify the Selling Stockholder against certain
losses, claims, damages and liabilities, including liabilities
under the Securities Act of 1933. We will not receive any proceeds
from the resale of any of the shares of our Common Stock by the
Selling Stockholder. We may, however, receive proceeds from the
sale of our Common Stock under the Financing Agreement with GHS.
Neither the Financing Agreement with GHS nor any rights of the
parties under the Financing Agreement with GHS may be assigned or
delegated to any other person.
Pursuant
to the terms of the Financing Agreement, we have agreed with GHS to
keep this Prospectus effective until GHS has sold all of the common
shares purchased by it under the Financing Agreement.
The
resale shares will be sold only through registered or licensed
brokers or dealers if required under applicable state securities
laws. In addition, in certain states, the resale shares may not be
sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or
qualification requirement is available and is complied
with.
Under
applicable rules and regulations under the Securities Exchange Act
of 1934, any person engaged in the distribution of the resale
shares may not simultaneously engage in market making activities
with respect to the Common Stock for the applicable restricted
period, as defined in Regulation M, prior to the commencement of
the distribution. In addition, the Selling Stockholder will be
subject to applicable provisions of the Securities Exchange Act of
1934 and the rules and regulations thereunder, including Regulation
M, which may limit the timing of purchases and sales of shares of
the Common Stock by the Selling Stockholder or any other person. We
will make copies of this Prospectus available to the Selling
Stockholder.
DESCRIPTION OF SECURITIES TO BE REGISTERED
Capital Stock
The
Company’s authorized capital is comprised of 3,000,000,000
shares of $0.001 par value Common Stock and 30,000,000 shares of
$0.10 par value Preferred Stock, to have such rights and
preferences as the Directors of the Company have or may assign from
time to time. Out of the authorized Preferred Stock, the Board has
designated 850,000 shares as Series “A” Preferred Stock
(“Series A”) and 500,000 shares as Series B Preferred
Stock (“Series B”). The Company currently has
1,585,628,494 shares of Common Stock, 0 shares of Series A
Preferred Stock and 500,000 shares of Series B Preferred Stock
issued and outstanding. The 500,000 shares of Series B Preferred
Stock are held by Dr. Steve N. Slilaty, the CEO of the Company. The
Series B Preferred Stock are non-convertible, non-redeemable and
non-contractible. They give the holder the right to 1,000 votes per
share and may vote together with the Common Stock.
Each
share of Common Stock shall have one (1) vote per share. Our Common
Stock does not provide a preemptive, subscription or conversion
rights and there are no redemption or sinking fund provisions or
rights. Our Common Stock holders are not entitled to cumulative
voting for election of Board of Directors.
Dividends
We have
not paid any dividends on our Common Stock or Preferred Stock since
our inception and do not intend to pay any dividends in the
foreseeable future.
The
declaration of any future cash dividends is at the discretion of
our board of directors and depends upon our earnings, if any, our
capital requirements and financial position, our general economic
conditions, and other pertinent conditions. It is our present
intention not to pay any cash dividends in the foreseeable future,
but rather to reinvest earnings, if any, in our business
operations.
Warrants
As of
the date hereof, there are no outstanding warrants of any kind
issued and outstanding.
Options
As of
the date hereof, there are no outstanding options of any kind
issued and outstanding. .
Securities Authorized for Issuance Under Equity Compensation
Plans
We have
not adopted any stock option or other employee plans as of the date
of this Registration Statement on Form S-1. We may adopt such plans
in the future.
Anti-Takeover Effects of Various Provisions of Colorado
Law
Provisions
of the Colorado Revised Statutes, our articles of incorporation, as
amended, and our bylaws could make it more difficult to acquire us
by means of a tender offer, a proxy contest or otherwise, or to
remove incumbent officers and directors. These provisions,
summarized below, would be expected to discourage certain types of
takeover practices and takeover bids our Board may consider
inadequate and to encourage persons seeking to acquire control of
us to first negotiate with us. We believe that the benefits of
increased protection of our ability to negotiate with the proponent
of an unfriendly or unsolicited proposal to acquire or restructure
us will outweigh the disadvantages of discouraging takeover or
acquisition proposals because, among other things, negotiation of
these proposals could result in an improvement of their
terms.
Blank Check Preferred Stock
Our
articles of incorporation permit our Board to issue Preferred Stock
with voting, conversion and exchange rights that could negatively
affect the voting power or other rights of our Common Stockholders.
The issuance of our Preferred Stock could delay or prevent a change
of control of our Company.
Limitations on Liability and Indemnification of Officers and
Directors
The
Colorado Revised Statutes and the Colorado Business Corporation Act
(the “CBCA”) limits or eliminates the personal
liability of directors to corporations and their stockholders for
monetary damages for breaches of directors’ fiduciary duties
as directors.
Section
7-109-102(1) of the Colorado Business Corporation Act (the
“CBCA”) permits indemnification of a director of a
Colorado corporation, in the case of a third party action, if the
director (a) conducted himself or herself in good faith, (b)
reasonably believed that (i) in the case of conduct in his or her
official capacity, his or her conduct was in the
corporation’s best interest, or (ii) in all other cases, his
or her conduct was not opposed to the corporation’s best
interest, and (c) in the case of any criminal proceeding, had no
reasonable cause to believe that his conduct was unlawful. Section
7-109-103 further provides for mandatory indemnification of
directors and officers who are successful on the merits or
otherwise in litigation.
Section
7-109-102(4) of the CBCA limits the indemnification that a
corporation may provide to its directors in two key respects. A
corporation may not indemnify a director in a derivative action in
which the director is held liable to the corporation, or in any
proceeding in which the director is held liable on the basis of his
improper receipt of a personal benefit. Sections 7-109-104 of the
CBCA permits a corporation to advance expenses to a director, and
Section 7-109-107(1)(c) of the CBCA permits a corporation to
indemnify and advance litigation expenses to officers, employees
and agents who are not directors to a greater extent than directors
if consistent with law and provided for by the bylaws, a resolution
of directors or shareholders, or a contract between the corporation
and the officer, employee or agent.
Authorized but Unissued Shares
Our
authorized but unissued shares of Common Stock and Preferred Stock
will be available for future issuance without stockholder approval,
except as may be required under the listing rules of any stock
exchange on which our Common Stock is then listed. We may use
additional shares for a variety of corporate purposes, including
future public offerings to raise additional capital, corporate
acquisitions and employee benefit plans. The existence of
authorized but unissued shares of Common Stock and Preferred Stock
could render more difficult or discourage an attempt to obtain
control of us by means of a proxy contest, tender offer, merger or
otherwise.
Penny Stock Considerations
Our
shares will be “penny stocks” as that term is generally
defined in the Securities Exchange Act of 1934 to mean equity
securities with a price of less than $5.00 per share. Thus, our
shares will be subject to rules that impose sales practice and
disclosure requirements on broker-dealers who engage in certain
transactions involving a penny stock. Under the penny stock
regulations, a broker-dealer selling a penny stock to anyone other
than an established customer must make a special suitability
determination regarding the purchaser and must receive the
purchaser’s written consent to the transaction prior to the
sale, unless the broker-dealer is otherwise exempt.
In
addition, under the penny stock regulations, the broker-dealer is
required to:
●
Deliver, prior to
any transaction involving a penny stock, a disclosure schedule
prepared by the Securities and Exchange Commission relating to the
penny stock market, unless the broker-dealer or the transaction is
otherwise exempt;
●
Disclose
commissions payable to the broker-dealer and our registered
representatives and current bid and offer quotations for the
securities;
●
Send monthly
statements disclosing recent price information pertaining to the
penny stock held in a customer’s account, the account’s
value, and information regarding the limited market in penny
stocks; and
●
Make a special
written determination that the penny stock is a suitable investment
for the purchaser and receive the purchaser’s written
agreement to the transaction, prior to conducting any penny stock
transaction in the customer’s account.
Because
of these regulations, broker-dealers may encounter difficulties in
their attempt to sell shares of our Common Stock, which may affect
the ability of selling shareholders or other holders to sell their
shares in the secondary market and have the effect of reducing the
level of trading activity in the secondary market. These additional
sales practice and disclosure requirements could impede the sale of
our securities, if our securities become publicly traded. In
addition, the liquidity for our securities may be decreased, with a
corresponding decrease in the price of our securities. Our shares
in all probability will be subject to such penny stock rules and
our shareholders will, in all likelihood, find it difficult to sell
their securities.
INTERESTS OF NAMED EXPERTS AND COUNSEL
The
consolidated financial statements for the Company as of December
31, 2017 and 2016 and for the years then ended included in this
Prospectus have been audited by
BF
Borgers CPA PC, respectively, an independent registered public
accounting firm, to the extent and for the periods set forth in our
report and are incorporated herein in reliance upon such report
given upon the authority of said firm as experts in auditing and
accounting.
The
legality of the shares offered under this Registration Statement
will be passed upon by Lucosky Brookman LLP.
INFORMATION WITH RESPECT TO THE REGISTRANT
History
We were incorporated in the State of Colorado on August 31, 2006
under the name “Mountain West Business Solutions, Inc.”
Until October 2009, our business was to provide management
consulting with regard to accounting, computer and general business
issues for small and home-office based companies.
In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado
corporation holding an exclusive license to a new anticancer drug
bearing the laboratory name, Adva-27a. As a result of this
transaction we changed our name to “Sunshine Biopharma, Inc.
and our officers and directors resigned their positions with us and
were replaced by Sunshine’s management at the time, including
our current CEO, Dr. Steve N. Slilaty, and our current CFO, Camille
Sebaaly each of whom remain part of our current management. Our
principal business became that of a pharmaceutical company focusing
on the development of our licensed Adva-27a anticancer compound. In
December 2015 we acquired all issued and pending patents pertaining
to our Adva-27a technology and terminated the
license.
In July 2014, we formed a wholly owned Canadian subsidiary,
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for
the purposes of offering generic pharmaceutical products in Canada
and elsewhere around the world. Sunshine Canada has recently signed
licensing agreements for four (4) generic prescription drugs for
the treatment of cancer and BPH (Benign Prostatic
Hyperplasia).
In January 2018, we acquired Atlas Pharma Inc., a certified company
dedicated to chemical analysis of pharmaceutical and other
industrial samples whose operations are authorized by a Drug
Establishment License issued by Health Canada.
In March 2018, we formed NOX Pharmaceuticals, Inc., a Colorado
corporation and assigned all of our interest in our Adva-27a
anticancer compound to that company.
Our principal place of business is located at 6500 Trans-Canada
Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. . Our
phone number is (514) 426-6161and our website address is
www.sunshinebiopharma.com.
Business Operations
As of
the date of this Registration Statement on Form S-1 we are
operating through the following wholly owned
subsidiaries:
●
NOX
Pharmaceuticals, Inc., a recently formed Colorado company focused
on the research, development and commercialization of proprietary
drugs for the treatment of cancer including Adva-27a, a
multi-purpose anti-tumor compound targeted for the treatment of
multidrug resistant cancer;
●
Sunshine Biopharma
Canada Inc., a Canadian company, which offers generic prescription
drugs for the treatment of cancer and other acute and chronic
indications; and
●
Atlas Pharma Inc.,
a Canadian company acquired in January 2018, offering certified
chemical analysis of pharmaceutical and other industrial
samples.
Proprietary Drug Development Operations
Since inception, our proprietary drug development activities have
been focused on the development of a small molecule called Adva-27a
for the treatment of aggressive forms of cancer. A Topoisomerase II
inhibitor, Adva-27a has been shown to be effective at destroying
Multidrug Resistant Cancer cells including Pancreatic Cancer cells,
Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine
Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Sunshine Biopharma is direct owner of all
issued and pending worldwide patents pertaining to Adva-27a
including U.S. Patent Number 8,236,935. See
“
Intellectual
Property
.”
Adva-27a is a GEM-difluorinated C-glycoside derivative of
Podophyllotoxin. Another derivative of Podophyllotoxin called
Etoposide is currently on the market and is used to treat various
types of cancer including leukemia, lymphoma, testicular cancer,
lung cancer, brain cancer, prostate cancer, bladder cancer, colon
cancer, ovarian cancer, liver cancer and several other forms of
cancer. Etoposide is one of the most widely used anticancer drugs.
Adva-27a and Etoposide are similar in that they both attack the
same target in cancer cells, namely the DNA unwinding enzyme,
Topoisomerase II. Unlike Etoposide, and other anti-tumor drugs
currently in use, Adva-27a is able to destroy Multidrug Resistant
Cancer cells. Adva-27a is the only compound known today that is
capable of destroying Multidrug Resistant Cancer. In addition,
Adva-27a has been shown to have distinct and more desirable
biological and pharmacological properties compared to Etoposide. In
side-by-side studies using Multidrug Resistant Breast Cancer cells
and Etoposide as a reference, Adva-27a showed markedly improved
cell killing activity (see Figure below). Our preclinical studies
to date have shown that:
●
Adva-27a
is effective at killing different types of Multidrug Resistant
cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast
Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and
Uterine Sarcoma Cells (MES-SA/Dx5).
●
Adva-27a
is unaffected by P-Glycoprotein, the enzyme responsible for making
cancer cells resistant to anti-tumor drugs.
●
Adva-27a
has excellent clearance time (half-life = 54 minutes) as indicated
by human microsomes stability studies and pharmacokinetics data in
rats.
●
Adva-27a
clearance is independent of Cytochrome P450, a mechanism that is
less likely to produce toxic intermediates.
●
Adva-27a
is an excellent inhibitor of Topoisomerase II with an IC50 of only
13.7 micromolar (this number has recently been reduce to 1.44
micromolar as a result of resolving the two isomeric forms of
Adva-27a).
●
Adva-27a
has shown excellent pharmacokinetics profile as indicated by
studies done in rats.
●
Adva-27a
does not inhibit tubulin assembly.
These and other preclinical data have been published in ANTICANCER
RESEARCH, a peer-reviewed International Journal of Cancer Research
and Treatment. The publication which is entitled “Adva-27a, a
Novel Podophyllotoxin Derivative Found to Be Effective Against
Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH
32: 4423-4432 (2012)] is available on our website at
www.sunshinebiopharma.com
.
We have been delayed in our clinical development program due to
lack of funding. Our fund raising efforts are continuing and as
soon as adequate financing is in place we will continue our
clinical development program of Adva-27a by conducting the
following next sequence of steps:
●
GMP
Manufacturing of 2 kilogram for use in IND-Enabling Studies and
Phase I Clinical Trials
●
Regulatory
Filing (Fast-Track Status Anticipated)
●
Phase
I Clinical Trials (Pancreatic Cancer Indication)
On November 14, 2014, we entered into a Manufacturing Services
Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly
referred to as “Lonza”), whereby we engaged Lonza to be
the manufacturer of our Adva-27a anticancer drug. In June 2015 we
received a sample of the pilot manufacturing run for evaluation.
Our laboratory analyses showed that, while the sample meets all of
the required chemical, physical and biological specifications, the
amount of material generated (the “Yield”) by the pilot
run was found to be significantly lower than anticipated. We are
currently working towards finding possible solutions to increase
the Yield and define a path forward. During the course of our
discussions concerning the problem of the low Yield, Lonza informed
us that they required us to pay them $687,818 prior to moving
forward with any activity pertaining to the manufacturing agreement
we have with them. We have repeatedly indicated to Lonza that a
clear path defining exactly how the extremely low Yield issue would
be addressed is imperative prior to us making any payments. As of
the date of this Registration Statement on Form S-1, neither party
has changed its position.
Adva-27a’s initial indication will be pancreatic cancer for
which there are currently little or no treatment options available.
We are planning to conduct our clinical trials at McGill
University’s Jewish General Hospital in Montreal, Canada. All
aspects of the clinical trials in Canada will employ FDA standards
at all levels. We estimate that Phase I clinical trials will take
18 months to complete.
According to the American Cancer Society, nearly 1.5 million new
cases of cancer are diagnosed in the U.S. each year. We
believe that upon successful completion of Phase I Clinical Trials
we may receive one or more offers from large pharmaceutical
companies to buyout or license our drug. However, there
are no assurances that our Phase I Trials will be successful, or if
successful, that any pharmaceutical companies will make an
acceptable offer to us. In the event we do not
consummate such a transaction, we will require significant capital
in order to conduct additional clinical trials, manufacture and
market our new drug.
Our Lead Anti-Cancer Compound, Adva-27a, in 3D
Generic Pharmaceuticals Operations
In 2016, our Canadian wholly owned subsidiary, Sunshine Biopharma
Canada Inc. (“Sunshine Canada”), signed Cross
Referencing Agreements with a major pharmaceutical company for four
prescription generic drugs for the treatment of Breast Cancer,
Prostate Cancer and Enlarged Prostate. Following this acquisition
we have been working towards commencement of marketing of these
pharmaceutical products under our own Sunshine Biopharma label.
These four generic products are as follows:
●
Anastrozole
(brand name Arimidex® by AstraZeneca) for treatment of Breast
Cancer;
●
Letrozole
(brand name Femara® by Novartis) for treatment of Breast
Cancer;
●
Bicalutamide
(brand name Casodex® by AstraZeneca) for treatment of Prostate
Cancer;
●
Finasteride
(brand name Propecia® by Merck) for treatment of BPH (Benign
Prostatic Hyperplasia)
Worldwide sales of the brand name version of these products as
reported by the respective pharmaceutical company, owner of the
registered trademark are as follows:
●
Arimidex®
$232M in 2016
●
Propecia®
$183M in 2015
Sunshine Canada is currently in the process of securing a Drug
Identification Number (“DIN”) for each of these
products from Health Canada. We are planning to use part of the
already approved Atlas Pharma Inc. space as a drug warehouse to
facilitate the process of obtaining a Drug Establishment License
(“DEL”) from Health Canada. Upon receipt of the DEL and
DIN’s, we will be able to accept orders for our own label
SBI-Anastrozole, SBI-Letrozole, SBI-Bicalutamide and
SBI-Finasteride. We cannot estimate the timing in our obtaining
either the DIN’s or the DEL due to variables involved that
are out of our control. The figure below shows our 30-Pill blister
pack of Anastrozole.
We currently have twenty three (23) additional Generic
Pharmaceuticals under review for in-licensing. While no assurances
can be provided that we will acquire the rights to all or any of
these drugs, we are confident we will acquire most, if not all of
these rights. We believe that a larger product portfolio will
provide us with more opportunities and a greater reach into the
marketplace. We hope to further build our generics portfolio of
“SBI” label Generic Pharmaceuticals over time. There
are no assurances this will occur.
Various publicly available sources indicate that the worldwide
sales of generic pharmaceuticals are approximately $200 billion per
year. In the United States and Canada, the sales of generic
pharmaceuticals are approximately $50 billion and $5 billion,
respectively. The generic pharmaceuticals business is fairly
competitive and there are several multinational players in the
field including Teva (Israel), Novartis - Sandoz (Switzerland),
Hospira (USA), Mylan (Netherlands), Sanofi (France), Fresenius Kabi
(Germany) and Apotex (Canada). While no assurances can be provided,
with our offering of Canadian approved products we believe that we
will be able to access at least a small percentage of the generic
pharmaceuticals marketplace.
As part of a subscription agreement entered into in 2016, we have
an obligation to pay a royalty of 5% of net sales on one of our
generic products (Anastrozole) for a period of three (3) years from
the date of the first sale of that product. As of the date of this
Registration Statement on Form S-1 we have not yet commenced
marketing efforts and no sales or royalty payments have been made.
On May 28, 2018 we issued 1,000,000 shares of our Common Stock
valued at $5,900 in exchange for cancellation of this royalty
obligation.
While no assurances can be provided and subject to the availability
of adequate financing, of which there is no assurance, we
anticipate that profits from the sales of Generic Products will be
used to finance our proprietary drug development program, including
Adva-27a, our flagship anticancer compound. In addition to
near-term revenue generation, building the generics business
infrastructure and securing the proper permits will render us
appropriately positioned for the marketing and distribution of our
proprietary Adva-27a drug candidate, provided that Adva-27a is
approved for such marketing and distribution, of which there can be
no assurance.
Analytical Chemistry Services Operations
On January 1, 2018, we entered into an agreement (the “Atlas
Agreement”) to acquire Atlas Pharma Inc.
(“Atlas”). The purchase price was $848,000 Canadian
($684,697 US). Payment of the purchase price was comprised of (i) a
cash payment of $100,500 Canadian ($80,289 US), (ii) the issuance
of 20,000,000 shares of our Common Stock valued at $246,000, and
(iii) a promissory note in the principal amount of $450,000
Canadian ($358,407 US), with interest payable at the rate of 3% per
annum. We are required to make payments of $10,000 Canadian
(approximately $8,000 US) per calendar quarter, due and payable on
or before the end of each such calendar quarter through December
31, 2023.
Atlas is a certified company dedicated to chemical analysis of
pharmaceutical and other industrial samples. Atlas has 9 full-time
employees and generated revenues of approximately $500,000 Canadian
(approximately $400,000 US) in 2017. Housed in a 5,250 square foot
facility, Atlas’s operations are authorized by a Drug
Establishment License (DEL) issued by Health Canada and are fully
compliant with the requirements of Good Manufacturing Practices
(GMP). Atlas is also registered with the FDA.
Atlas is the owner of a relatively large portfolio of analytical
chemistry methodology and Standard Operating Procedure. This
intellectual property is protected as company secrets and
controlled through employee and management confidentiality
agreements.
On June 18, 2018, we purchased laboratory equipment at a total cost
of $235,870 Canadian (approximately $181,580 US) for Microbiology
Testing as part of our plan to expand the operations services
offering of Atlas. Presently, Atlas offers Analytical Chemistry
Testing and intends to offer Microbiology Testing
soon.
Government Regulations
All of our business operations, including the Generic
Pharmaceutical Operations, the Proprietary Drug Development
Operations, and our newly acquired Analytical Chemistry Services
Operations are subject to extensive and frequently changing
federal, state, provincial and local laws and
regulations.
In the U.S, the Federal Government agency responsible for
regulating drugs is the U.S. Food and Drug Administration
(“FDA”). The Canadian counterpart to the FDA is the
Health Products and Food Branch (“HPFB”) of Health
Canada. Both the FDA and HPFB have similar requirements for a drug
to be approved for marketing. In addition, the quality standards
for brand name drugs and generic drugs are the same. The
ingredients, manufacturing processes and facilities for all drugs
must meet the guidelines for Good Manufacturing Practices
(“GMP”). Moreover, all drug manufacturers must perform
a series of tests, both during and after production, to show that
every drug batch made meets the regulatory agency’s
requirements for that product.
In
connection with our development of the new chemical entity,
Adva-27a, we will be subject to significant regulations in the U.S.
in order to obtain the approval of the FDA to offer our product on
the market. The approximate procedure for obtaining FDA approval
involves an initial filing of an IND application following which
the FDA would review the application and if all the data are in
order and acceptable would give the go ahead for the drug sponsor
to proceed with Phase I clinical (human) trials. Following
completion of Phase I, the results are filed with the FDA and a
request is made to proceed to Phase II. Similarly, following
completion of Phase II the data are filed with the FDA and a
request is made to proceed to Phase III. Following completion of
Phase III, a request is made for marketing approval. Depending on
various issues and considerations, the FDA could provide limited
marketing approval on a humanitarian basis if the drug treats
terminally ill patients with limited treatment options available.
As of the date of this Registration Statement on Form S-1 we have
not made any filings with the FDA or other regulatory bodies in
other jurisdictions. We have however had extensive discussions with
clinicians at the McGill University’s Jewish General Hospital
in Montreal where we plan to undertake our Phase I study for
pancreatic cancer and multidrug resistant breast cancer they
believe that Health Canada is likely to grant us a so-called
fast-track process on the basis of the terminal nature of the
cancer types which we will be treating. There are no assurances
this will occur.
Employees
As of the date of this Registration Statement on Form S-1 we have a
total of twelve (12) employees. In addition to our management team
which is comprised of our three (3) officers and directors, new
wholly owned subsidiary acquired on January 1, 2018, Atlas Pharma
Inc., has 9 full-time employees. We anticipate that if we receive
financing we will need additional employees in both our generic
pharmaceutical and proprietary drug development operations
including accounting, regulatory affairs, marketing, sales and
laboratory personnel.
Competition
In the area of proprietary anticancer drug development, we will be
competing with large publicly and privately held companies engaged
in developing new cancer therapies. There are numerous other
entities engaged in this business that have greater resources, both
financial and otherwise, than the resources presently available to
us. Nearly all major pharmaceutical companies including
Amgen, Roche, Pfizer, Bristol-Myers Squibb and Novartis, to name
just a few, have on-going anti-cancer drug development programs and
some of the drug they may develop could be in direct competition
with our drug. Also, a number of small companies are
also working in the area of cancer and could develop drugs that may
be in competition with ours. However, none of these
competitor companies can use molecules similar to ours as they
would be infringing our patents.
The generic pharmaceuticals business is fairly competitive and
there are many players in the field including several
multinationals such as Teva (Israel), Novartis - Sandoz
(Switzerland), Hospira (USA), Mylan (Netherlands), Sanofi (France),
Fresenius Kabi (Germany) and Apotex (Canada)with annual sales in
the range of approximately $2 billion to over $10. With our
offering of Canadian approved generic products, we believe that we
will be able to access at least a small percentage of the generic
pharmaceuticals market.
Intellectual Property
Effective
October 8, 2015, we executed a Patent Purchase Agreement (the
“October Purchase Agreement”), with Advanomics, a
related party, pursuant to which we acquired all of the right,
title and interest in and to U.S. Patent Number 8,236,935 (the
“US Patent”) for our anticancer compound, Adva-27a. On
December 28, 2015, we executed a second Patent Purchase Agreement
(the “December Purchase Agreement”), with Advanomics,
pursuant to which we acquired all of the right, title and interest
in and to all of the remaining worldwide rights covered by issued
and pending patents under PCT/FR2007/000697 and PCT/CA2014/000029
(the “Worldwide Patents”) for our anticancer compound,
Adva-27a.
Effective
December 28, 2015, we entered into amendments (the
“Amendments”) of these Purchase Agreements pursuant to
which the total purchase price was reduced from $17,142,499 to
$618,810, the book value of this intellectual property on the
financial statements of Advanomics. Further, the Amendments
provided for automatic conversion of the promissory notes
representing the new purchase price into an aggregate of
321,305,415 shares of our Common Stock once we increase our
authorized capital such that these shares can be issued. In July
2016 we increased our authorized capital and issued the 321,305,415
Common shares to Advanomics thereby completing all aspects of the
patent purchase arrangements and securing direct ownership of all
worldwide patents and rights pertaining to Adva-27a.
In
addition, in 2016 we signed Cross Referencing Agreements with a
major pharmaceutical company for four (4) prescription generic
drugs for the treatment of Breast Cancer, Prostate Cancer and
Enlarged Prostate. These agreements give us the right to register
the four (4) generic products, Anastrozole, Letrozole, Bicalutamide
and Finasteride in Canada under our own label and obtain a DIN for
each in order to be able to place them on the market.
Our new
wholly owned subsidiary, Atlas Pharma Inc., which we acquired on
January 1, 2018 holds a Drug Establishment License from Health
Canada and is registered with the FDA. Atlas Pharma Inc. is the
owner of a relatively large portfolio of analytical chemistry
methodology and Standard Operating Procedure. This intellectual
property is protected as company secrets and controlled through
employee and management confidentiality
agreements.
Equity Financing Agreement and Registration Rights
Agreement
On September 10, 2018, Sunshine Biopharma, Inc., a Colorado
corporation (the “Company”), entered into an Equity
Financing Agreement (“Equity Financing Agreement”) and
Registration Rights Agreement (“Registration Rights
Agreement”) with GHS Investments LLC, a Nevada limited
liability company (“GHS”). Under the terms of the
Equity Financing Agreement, GHS agreed to provide the Company with
up to $10,000,000 upon effectiveness of a Registration Statement on
Form S-1 (the “Registration Statement”) filed with the
U.S. Securities and Exchange Commission (the
“Commission”).
Following effectiveness of the Registration Statement, the Company
shall have the discretion to deliver puts to GHS and GHS will be
obligated to purchase shares of the Company’s Common Stock,
par value $0.001 per share (the “Common Stock”) based
on the investment amount specified in each put notice. The maximum
amount that the Company shall be entitled to put to GHS in each put
notice shall not exceed two hundred fifty percent (250%) of the
average daily trading dollar volume of the Company’s Common
Stock during the ten (10) trading days preceding the put date, so
long as such amount does not exceed $300,000. Pursuant to the
Equity Financing Agreement, GHS and its affiliates will not be
permitted to purchase and the Company may not put shares of the
Company’s Common Stock to GHS that would result in
GHS’s beneficial ownership equaling more than 9.99% of the
Company’s outstanding Common Stock. The price of each put
share shall be equal to eighty one percent (81%) of the Market
Price (as defined in the Equity Financing Agreement). Puts may be
delivered by the Company to GHS until the earlier of thirty-six
(36) months after the effectiveness of the Registration Statement
or the date on which GHS has purchased an aggregate of $10,000,000
worth of Common Stock under the terms of the Equity Financing
Agreement. Additionally, in accordance with the Equity Financing
Agreement, the Company shall issue GHS a promissory note in the
principal amount of $20,000 to offset transaction costs (the
“Note”). The Note bears interest at the rate of 8% per
annum, is not convertible and is due on June 30, 2019.
The Registration Rights Agreement provides that the Company shall
(i) use its best efforts to file with the Commission the
Registration Statement within 30 days of the date of the
Registration Rights Agreement; and (ii) have the Registration
Statement declared effective by the Commission within 30 days after
the date the Registration Statement is filed with the Commission,
but in no event more than 90 days after the Registration Statement
is filed.
MARKET PRICE OF THE REGISTRANT’S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS
Market Information
Trading of our Common Stock commenced on the OTC MARKETS in
September 2007 under the symbol
“MWBN.” Effective November 30, 2009, the
trading symbol for our Common Stock was changed to
“SBFM” as a result of our name change discussed
above.
The table below sets forth the reported high and low bid prices for
the periods indicated. The bid prices shown reflect
quotations between dealers, without adjustment for markups,
markdowns or commissions, and may not represent actual transactions
in our Common Stock.
Quarter
Ended
|
|
|
|
|
|
March 31,
2016
|
$
0.0088
|
$
0.0052
|
June 30,
2016
|
$
0.0110
|
$
0.0061
|
September 30,
2016
|
$
0.0039
|
$
0.0030
|
December 31,
2016
|
$
0.0040
|
$
0.0032
|
|
|
|
March 31,
2017
|
$
0.0025
|
$
0.0025
|
June 30,
2017
|
$
0.0134
|
$
0.0110
|
September 30,
2017
|
$
0.0155
|
$
0.0141
|
December 31,
2017
|
$
0.0130
|
$
0.0100
|
|
|
|
March 31,
2018
|
$
$0.0175
|
$
0.0079
|
June 30,
2018
|
$
0.0087
|
$
0.0041
|
September 30, 2018
(through September 26, 2018)
|
$
$0.0078
|
$
0.0013
|
Trading volume in our Common Stock varies between a few hundred
thousand shares to several million shares per day. As a
result, the trading price of our Common Stock is subject to
significant fluctuations.
Holders of Common Equity
As of
the date hereof, there were approximately 146 stockholders of
record. An additional number of stockholders are beneficial holders
of our Common Stock in “street name” through banks,
brokers and other financial institutions that are the record
holders.
Dividend Information
We have
not paid any cash dividends to our holders of Common Stock or
Preferred Stock. The declaration of any future cash dividends is at
the discretion of our board of directors and depends upon our
earnings, if any, our capital requirements and financial position,
our general economic conditions, and other pertinent conditions. It
is our present intention not to pay any cash dividends in the
foreseeable future, but rather to reinvest earnings, if any, in our
business operations.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATION
You should read the following discussion of our financial condition
and results of operations in conjunction with financial statements
and notes thereto included elsewhere in this Prospectus. The
following discussion contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results could
differ materially from those discussed in the forward-looking
statements. Factors that could cause or contribute to these
differences include those discussed below and elsewhere in this
Prospectus, particularly in the section labeled “Risk
Factors.”
This
section of the Prospectus includes a number of forward-looking
statements that reflect our current views with respect to future
events and financial performance. Forward-looking statements are
often identified by words like “believe,”
“expect,” “estimate,”
“anticipate,” “intend,”
“project,” and similar expressions, or words that, by
their nature, refer to future events. You should not place undue
certainty on these forward-looking statements, which apply only as
of the date of this Prospectus. These forward-looking statements
are subject to certain risks and uncertainties that could cause
actual results to differ materially from historical results or our
predictions.
Overview And History
We were incorporated in the State of Colorado on August 31, 2006
under the name “Mountain West Business Solutions, Inc.”
Until October 2009, our business was to provide management
consulting with regard to accounting, computer and general business
issues for small and home-office based companies.
In October 2009, we acquired Sunshine Biopharma, Inc., a Colorado
corporation holding an exclusive license to a new anticancer drug
bearing the laboratory name, Adva-27a. As a result of this
transaction we changed our name to “Sunshine Biopharma,
Inc.” and our officers and directors resigned their positions
with us and were replaced by Sunshine Biopharma, Inc.’s
management at the time, including our current CEO, Dr. Steve N.
Slilaty, and our current CFO, Camille Sebaaly each of whom remain
part of our current management. Our principal business became that
of a pharmaceutical company focusing on the development of our
licensed Adva-27a anticancer compound. In December 2015 we acquired
all issued and pending patents pertaining to our Adva-27a
technology and terminated the license.
In July 2014, we formed a wholly owned Canadian subsidiary,
Sunshine Biopharma Canada Inc. (“Sunshine Canada”), for
the purposes of offering generic pharmaceutical products in Canada
and elsewhere around the world. Sunshine Canada has signed
licensing agreements for four (4) generic prescription drugs for
the treatment of breast cancer, prostate cancer and BPH (Benign
Prostatic Hyperplasia). We have applied for and are currently
awaiting the issuance by Health Canada of a Drug Establishment
License and a Drug Identification Number for each of our four (4)
generic products in order to begin marketing of the
same.
In January 2018, we acquired Atlas Pharma Inc.
(“Atlas”), a certified company dedicated to chemical
analysis of pharmaceutical and other industrial samples whose
operations are authorized by a Drug Establishment License issued by
Health Canada. Atlas has been generating revenues since its
inception in September 2013. The revenues reported in our
consolidated financial statements for the first calendar quarter of
2018 are a result of the Atlas operations.
In March 2018, we formed NOX Pharmaceuticals, Inc., a Colorado
corporation, and assigned all of our interest in our Adva-27a
anticancer compound to that company. NOX Pharmaceuticals
Inc.’s mission is to research, develop and commercialize
proprietary drugs including Adva-27a.
As a result, we are now a holding company operating through these
three wholly owned subsidiaries.
Our principal place of business is located at 6500 Trans-Canada
Highway, 4th Floor, Pointe-Claire, Quebec, Canada H9R 0A5. Our
phone number is (514) 426-6161and our website address is
www.sunshinebiopharma.com.
We have not been subject to any bankruptcy, receivership or similar
proceeding.
Operations
Proprietary Drug Development Operations
Since inception, our proprietary drug development activities have
been focused on the development of a small molecule called Adva-27a
for the treatment of aggressive forms of cancer. A Topoisomerase II
inhibitor, Adva-27a has been shown to be effective at destroying
Multidrug Resistant Cancer cells including Pancreatic Cancer cells,
Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine
Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages
4423-4432, October 2012). Sunshine Biopharma Inc. owns all of the
rights, as well as, all of the issued and pending worldwide patents
pertaining to Adva-27a, including U.S. Patent Number
8,236,935.
Adva-27a is a GEM-difluorinated C-glycoside derivative of
Podophyllotoxin. Another derivative of Podophyllotoxin called
Etoposide is currently on the market and is used to treat various
types of cancer including leukemia, lymphoma, testicular cancer,
lung cancer, brain cancer, prostate cancer, bladder cancer, colon
cancer, ovarian cancer, liver cancer and several other forms of
cancer. Etoposide is one of the most widely used anticancer drugs.
Adva-27a and Etoposide are similar in that they both attack the
same target in cancer cells, namely the DNA unwinding enzyme,
Topoisomerase II. Unlike Etoposide, and other anti-tumor drugs
currently in use, Adva-27a is able to destroy Multidrug Resistant
Cancer cells. Adva-27a is the only compound known today that is
capable of destroying Multidrug Resistant Cancer. In addition,
Adva-27a has been shown to have distinct and more desirable
biological and pharmacological properties compared to Etoposide. In
side-by-side studies using Multidrug Resistant Breast Cancer cells
and Etoposide as a reference, Adva-27a showed markedly improved
cell killing activity (see Figure below). Our preclinical studies
to date have shown that:
●
Adva-27a
is effective at killing different types of Multidrug Resistant
cancer cells, including Pancreatic Cancer Cells (Panc-1), Breast
Cancer Cells (MCF-7/MDR), Small-Cell Lung Cancer Cells (H69AR), and
Uterine Sarcoma Cells (MES-SA/Dx5).
●
Adva-27a
is unaffected by P-Glycoprotein, the enzyme responsible for making
cancer cells resistant to anti-tumor drugs.
●
Adva-27a
has excellent clearance time (half-life = 54 minutes) as indicated
by human microsomes stability studies and pharmacokinetics data in
rats.
●
Adva-27a
clearance is independent of Cytochrome P450, a mechanism that is
less likely to produce toxic intermediates.
●
Adva-27a
is an excellent inhibitor of Topoisomerase II with an IC50 of only
13.7 micromolar (this number has recently been reduce to 1.44
micromolar as a result of resolving the two isomeric forms of
Adva-27a).
●
Adva-27a
has shown excellent pharmacokinetics profile as indicated by
studies done in rats.
●
Adva-27a
does not inhibit tubulin assembly.
These and other preclinical data have been published in ANTICANCER
RESEARCH, a peer-reviewed International Journal of Cancer Research
and Treatment. The publication which is entitled “Adva-27a, a
Novel Podophyllotoxin Derivative Found to Be Effective Against
Multidrug Resistant Human Cancer Cells” [ANTICANCER RESEARCH
32: 4423-4432 (2012)] is available on our website at
www.sunshinebiopharma.com
.
We have been delayed in our clinical development program due to
lack of funding. Our fund raising efforts are continuing and as
soon as adequate financing is in place we will continue our
clinical development program of Adva-27a by conducting the
following next sequence of steps:
●
GMP
Manufacturing of 2 kilogram for use in IND-Enabling Studies and
Phase I Clinical Trials
●
Regulatory
Filing (Fast-Track Status Anticipated)
●
Phase
I Clinical Trials (Pancreatic Cancer Indication)
Adva-27a’s initial indication will be Pancreatic Cancer for
which there are currently little or no treatment options available.
We are planning to conduct our clinical trials at McGill
University’s Jewish General Hospital in Montreal, Canada. All
aspects of the clinical trials in Canada will employ FDA standards
at all levels. We estimate that the Pancreatic Cancer clinical
trials will take approximately 18 months from start to
finish.
Our Lead Anti-Cancer Compound, Adva-27a, in 3D
Generic Pharmaceuticals Operations
In 2016, our Canadian wholly owned subsidiary, Sunshine
Biopharma Canada Inc. (“Sunshine Canada”), signed Cross
Referencing Agreements with a major pharmaceutical company for four
prescription generic drugs for the treatment of Breast Cancer,
Prostate Cancer and Enlarged Prostate. Following this acquisition
we have been working towards commencement of marketing of these
pharmaceutical products under our own Sunshine Biopharma label.
These four generic products are as follows:
●
Anastrozole
(brand name Arimidex® by AstraZeneca) for treatment of Breast
Cancer;
●
Letrozole
(brand name Femara® by Novartis) for treatment of Breast
Cancer;
●
Bicalutamide
(brand name Casodex® by AstraZeneca) for treatment of Prostate
Cancer;
●
Finasteride
(brand name Propecia® by Merck) for treatment of BPH (Benign
Prostatic Hyperplasia)
Worldwide sales of the brand name version of these products as
reported by the respective pharmaceutical company, owner of the
registered trademark are as follows:
●
Arimidex®
$232M in 2016
●
Propecia®
$183M in 2015
In June 2017, Sunshine Canada submitted an application to Health
Canada for the procurement of a Drug Establishment License
(“DEL”), a requirement for the Company’s drug
handling and pharmaceutical operations. Health Canada has assigned
the Company DEL Application No. 3002475 and File No. 17938. We are
currently awaiting Health Canada to set a date for physical
inspection of our warehouse and drug management operations. In
addition, we are currently in the process of filing applications
for a Drug Identification Number (“DIN”) for each of
its four (4) generic products, Anastrozole, Letrozole, Bicalutamide
and Finasteride. The Figure below shows our 30-Pill blister pack of
Anastrozole.
We currently have twenty three (23) additional Generic
Pharmaceuticals under review for in-licensing. We believe that a
larger product portfolio will provide us with more opportunities
and a greater reach into the marketplace. Our plan is to fund our
Proprietary Drug Development Program, including Adva-27a, through
the sales of Generic Drugs. In addition to near-term revenue
generation, building the generics business infrastructure and
securing the proper permits will render us appropriately positioned
for the marketing and distribution of our own proprietary drugs as
they become available.
Analytical Chemistry Services Operations
On January 1, 2018, we entered into an agreement (the “Atlas
Agreement”) to acquire Atlas Pharma Inc.
(“Atlas”). The purchase price was $848,000 Canadian
($684,697 US). Payment of the purchase price was comprised of (i) a
cash payment of $100,500 Canadian ($80,289 US), (ii) the issuance
of 20,000,000 shares of our Common Stock valued at $246,000, and
(iii) a promissory note in the principal amount of $450,000
Canadian ($358,407 US), with interest payable at the rate of 3% per
annum. We are required to make payments of $10,000 Canadian
(approximately $8,000 US) per calendar quarter, due and payable on
or before the end of each such calendar quarter through December
31, 2023.
Atlas is a certified company dedicated to chemical analysis of
pharmaceutical and other industrial samples. Atlas has 9 full-time
employees and generated revenues of approximately $500,000 Canadian
(approximately $400,000 US) in 2017. Housed in a 5,250 square foot
facility, Atlas’s operations are authorized by a Drug
Establishment License (DEL) issued by Health Canada and are fully
compliant with the requirements of Good Manufacturing Practices
(GMP). Atlas is also registered with the FDA.
Atlas is the owner of a relatively large portfolio of analytical
chemistry methodology and Standard Operating Procedure. This
intellectual property is protected as company secrets and
controlled through employee and management confidentiality
agreements.
On June 18, 2018, we purchased laboratory equipment at a total cost
of $235,870 Canadian (approximately $181,580 US) for Microbiology
Testing as part of our plan to expand the operations services
offering of Atlas. Presently, Atlas offers Analytical Chemistry
Testing and intends to offer Microbiology Testing
soon.
Results Of Operations
Comparison of Results of Operations for the six months ended June
30, 2018 and 2017
During the six months ended June 30, 2018, we generated revenues of
$198,418 from the operations of our new wholly owned subsidiary,
Atlas Pharma Inc. (“Atlas”), which we acquired on
January 1, 2018. The direct cost for generating these revenues was
$190,913, which is comprised of salaries ($113,495), laboratory
supplies ($24,264), rent ($37,960) and depreciation ($15,194). We
did not generate any revenues during the comparable period in
2017.
General and administrative expense during the six months ended June
30, 2018 was $745,153, compared to $581,208 during the six months
ended June 30, 2017, an increase of $163,945. The principal reason
for this increase was an increase of $133,051 in executive
compensation, as well as increases in accounting, legal and office
expenses. These increases were a result of our increased business
activities relating to Atlas, as well as our continuing efforts to
raise additional funding. The only category that saw a decrease was
consulting fees by $32,067, as efforts were made to complete more
work in-house.
We incurred $93,338 in losses arising from debt conversion during
the six months ended June 30, 2018, compared to $76,929 in losses
from debt conversion during the similar period in 2017 as a result
of some convertible notes having been paid off or reduced prior to
maturity.
As a result, we incurred a net loss of $909,944 ($0.00 per share)
for the six month period ended June 30, 2018, compared to a net
loss of $681,146 ($0.00 per share) during the six month period
ended June 30, 2017.
Comparison of Results of Operations for the three months ended June
30, 2018 and 2017
For the three months ended June 30, 2018, we generated $107,250 in
revenues compared to no revenues for the same three months of 2017.
All of these revenues were generated from the operations of our new
wholly owned subsidiary, Atlas Pharma Inc. (“Atlas”),
which we acquired on January 1, 2018. The direct cost for
generating these revenues was $91,631, which is comprised of
salaries ($55,937), laboratory supplies ($10,194), rent ($16,438)
and depreciation ($9,062). We did not generate any revenues during
the comparable period in 2017.
General and administrative expenses during the three month period
ended June 30, 2018 were $586,570, compared to general and
administrative expense of $472,218 incurred during the three month
period ended June 30, 2017, an increase of $114,352. This increase
is attributable to an increase in executive compensation of
$98,229, as well as increases accounting fees, legal fees, and
office expenses due to costs associated with the acquisition of
Atlas. The only category that saw a decrease was consulting fees by
$10,248, as efforts were made to complete more work
in-house.
We also incurred $28,375 in interest expense during the three
months ended June 30, 2018, compared to $9,598 in interest expense
during the similar period in 2017 as a result of increased
borrowings. However, we incurred $54,998 in losses arising from
debt conversion during the three months ended June 30, 2018,
compared to $0 in losses from debt conversion during the similar
period in 2017 as a result of some convertible notes having been
paid off prior to maturity in the same period of 2017.
As a result, we incurred a net loss of $644,308 ($0.00 per share)
for the three month period ended June 30, 2018, compared to a net
loss of $485,444 ($0.00 per share) during the three month period
ended June 30, 2017.
Liquidity and Capital Resources
As of June 30, 2018, we had cash or cash equivalents of
$36,395.
Net cash used in operating activities was $292,898 during the six
month period ended June 30, 2018, compared to $185,850 for the six
month period ended June 30, 2017. We anticipate that
overhead costs and other expenses will increase in the future as we
move forward with our proprietary drug development activities and
expansion of our generic pharmaceuticals operations as well as our
newly acquired analytical chemistry services operations as
discussed above.
Cash flows from financing activities were $249,975 for the six
month periods ended June 30, 2018, compared to $275,665 during the
six months ended June 30, 2017. Cash flows used by
investing activities were $22,428 for the six month period ended
June 30, 2018 compared to $22,295 during the same six month period
in 2017.
During the three months period ended June 30, 2018, we issued a
total of 185,369,308 shares of our Common Stock. Of these,
42,584,566 shares valued at $290,039 were issued upon conversion of
outstanding notes payable, reducing debt by $188,568 and interest
payable by $8,133 and generating a loss on conversion of $93,585.
In addition, we issued 20,000,000 shares of our Common Stock valued
at $246,000 or $0.0123 per share as part of the acquisition of
Atlas Pharma Inc.
On January 12, 2018, we received net proceeds of $100,000 in
exchange for a note payable having a face value of $102,000 and
accruing interest at the rate of 8% per annum. The note, due on
October 30, 2018, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value. We
estimate that the fair value of this convertible debt approximates
the face value, so no value has been assigned to the beneficial
conversion feature.
On February 7, 2018, we received net proceeds of $142,500 in
exchange for a note payable having a face value of $150,000 and
accruing interest at the rate of 8% per annum. The note, due on
February 7, 2019, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value. We
estimate that the fair value of this convertible debt approximates
the face value, so no value has been assigned to the beneficial
conversion feature.
On February 22, 2018, we received net proceeds of $83,000 in
exchange for a note payable having a face value of $85,000 and
accruing interest at the rate of 8% per annum. The note, due on
November 30, 2018, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value. We
estimate that the fair value of this convertible debt approximates
the face value, so no value has been assigned to the beneficial
conversion feature.
On May 29, 2018, we received net proceeds of $25,000 in exchange
for a note payable having a face value of $26,750 and accruing
interest at the rate of 8% per annum. The note, due on February 28,
2019 is convertible after 180 days from issuance into $0.001 par
value Common Stock at a price 35% below market value. We estimate
that the fair value of this convertible debt approximates the face
value, so no value has been assigned to the beneficial conversion
feature.
On June 27, 2018, we issued a note payable having a face value of
$53,000 and accruing interest at the rate of 8% per annum. The net
proceeds of $51,000 from this note were received by us on July 2,
2018. The note, due on April 15, 2019 is convertible after 180 days
from issuance into $0.001 par value Common Stock at a price 35%
below market value. We estimate that the fair value of this
convertible debt approximates the face value, so no value has been
assigned to the beneficial conversion feature.
During the six month period ended June 30, 2018, the holders of
certain notes payable converted principal and interest of $290,039
into 42,584,566 shares of Common Stock.
As part of a subscription agreement entered into in 2016, we had an
obligation to pay a royalty of 5% of net sales on one of one of our
generic products (Anastrozole) for a period of three (3) years from
the date of the first sale of that product. On May 28, 2018 we
issued 1,000,000 shares of our Common Stock valued at $5,900 in
exchange for cancellation of this royalty obligation.
We are not generating adequate revenues from our operations to
fully implement our business plan as set forth herein. As a result,
our future success will depend on the future availability of
financing, among other things. Such financing will be required to
enable us to expand our Analytical Chemistry Services business and
further develop our Generic Pharmaceuticals operations and
Proprietary Drug Development program. We intend to raise funds
through private placements of our Common Stock and/or debt
financing. We estimate that we will require approximately $7
million ($2 million for the Analytical Chemistry and Generic
Pharmaceuticals operations and $5 million for the Proprietary Drug
Development program) to fully implement our business plan in the
future and there are no assurances that we will be able to raise
this capital. Our inability to obtain sufficient funds from
external sources when needed will have a material adverse effect on
our plan of operation, results of operations and financial
condition. Our plan is to fund our Proprietary Drug Development
Program, including Adva-27a, through the sales of Generic Drugs if
we are unable to find any additional financing. There are also no
assurances that we will generate sufficient revenues and profits
from our Proprietary Drug Development Program to accomplish these
objectives.
Our cost of operations is expected to increase as we move forward
with implementation of our business plan. We do not have sufficient
funds to cover the anticipated increase in the relevant expenses.
We need to raise additional capital in order to continue our
existing operations and finance our expansion plans for the next
year. If we are successful in raising additional funds, we expect
our operations and business efforts to continue and expand. There
are no assurances this will occur.
In August 2017 we signed an agreement with Jitney Trade Inc.
(“Jitney”), a Canadian broker-dealer, to raise up to
$10 million Canadian (approximately $8 million US) in a private
offering being undertaken only in Canada (the
“Offering”) in order to provide the funding we have
estimated we need to implement our business plan. The Offering
expired on February 28, 2018 without any funds having been raised.
On May 3, 2018, we signed an agreement with Jitney Trade Inc.
whereby the parties agreed to extend the proposed equity financing
that was previously announced of up to $10,000,000 Canadian
(approximately $8,000,000 US), until August 31, 2018. The terms and
conditions of the financing remained unchanged. We intend to offer
at up to 400,000,000 shares of our Common Stock at a price of
$0.025 Canadian (approximately $0.02 US) per share. As of the date
of this report no funds have been raised. There are no assurances
that Jitney will sell any shares of our Common Stock in this
proposed offering.
On July 5, 2018, the holder of a note payable dated November 14,
2017 elected to convert $20,000 in principal into 6,505,122 shares
of Common Stock leaving a principal balance of
$93,000.
On July 11, and August 2, 2018, the holder of a note payable dated
October 26, 2017 elected to convert a total of $44,000 in principal
and $2,531 in accrued interest into 20,821,004 shares of Common
Stock leaving a principal balance of $23,000.
On July 17, 23, 26, and August 2, 7, and 10, 2018, the holder of a
note payable dated January 12, 2018 elected to convert a total of
$81,000 in principal into an aggregate of 47,805,452 shares of
Common Stock leaving a principal balance of $21,000.
On September 10, 2018, Sunshine Biopharma, Inc., a Colorado
corporation (the “Company”), entered into an Equity
Financing Agreement (“Equity Financing Agreement”) and
Registration Rights Agreement (“Registration Rights
Agreement”) with GHS Investments LLC, a Nevada limited
liability company (“GHS”). Under the terms of the
Equity Financing Agreement, GHS agreed to provide the Company with
up to $10,000,000 upon effectiveness of a Registration Statement on
Form S-1 (the “Registration Statement”) filed with the
U.S. Securities and Exchange Commission (the
“Commission”).
Following effectiveness of the Registration Statement, the Company
shall have the discretion to deliver puts to GHS and GHS will be
obligated to purchase shares of the Company’s Common Stock,
par value $0.001 per share (the “Common Stock”) based
on the investment amount specified in each put notice. The maximum
amount that the Company shall be entitled to put to GHS in each put
notice shall not exceed two hundred fifty percent (250%) of the
average daily trading dollar volume of the Company’s Common
Stock during the ten (10) trading days preceding the put date, so
long as such amount does not exceed $300,000. Pursuant to the
Equity Financing Agreement, GHS and its affiliates will not be
permitted to purchase and the Company may not put shares of the
Company’s Common Stock to GHS that would result in
GHS’s beneficial ownership equaling more than 9.99% of the
Company’s outstanding Common Stock. The price of each put
share shall be equal to eighty one percent (81%) of the Market
Price (as defined in the Equity Financing Agreement). Puts may be
delivered by the Company to GHS until the earlier of thirty-six
(36) months after the effectiveness of the Registration Statement
or the date on which GHS has purchased an aggregate of $10,000,000
worth of Common Stock under the terms of the Equity Financing
Agreement. Additionally, in accordance with the Equity Financing
Agreement, the Company shall issue GHS a promissory note in the
principal amount of $20,000 to offset transaction costs (the
“Note”). The Note bears interest at the rate of 8% per
annum, is not convertible and is due on June 30, 2019.
The Registration Rights Agreement provides that the Company shall
(i) use its best efforts to file with the Commission the
Registration Statement within 30 days of the date of the
Registration Rights Agreement; and (ii) have the Registration
Statement declared effective by the Commission within 30 days after
the date the Registration Statement is filed with the Commission,
but in no event more than 90 days after the Registration Statement
is filed.
Off Balance Sheet Arrangements
None
Fiscal Years Ended 2017 And 2016
Results of Operations
Comparison of Results of Operations for the fiscal years ended
December 31, 2017 and 2016
During our fiscal years ended December 31, 2017 and 2016, we did
not generate any revenues.
Total expenses for our fiscal year ended December 31, 2017 were
$857,190, compared to $993,108 during our fiscal year ended
December 31, 2016, a decrease of $135,918. The expense
categories that saw a decrease were consulting fees by $80,388,
amortization and depreciation by $54,102, research and development
by $32,793, and licenses by $19,203. The decreases in
these categories of expenses were offset to some extent by
relatively modest increases in legal fees, accounting fees and
officer and director compensation. The decrease in consulting fees
in 2017 was due to the fact that a substantial amount of the work
required for setting up the generic pharmaceuticals operations had
been completed. Similarly, we incurred no licensing fees in 2017 as
we acquired the Adva-27a rights and as a result, terminated the
License Agreement we had for the same with Advanomics Corporation.
The license expense of $19,203 we paid in 2016 was incurred in
order to obtain the rights for our four (4) generic
products.
We also incurred $104,829 in interest expense and $76,929 in losses
from debt conversion during the year ended December 31, 2017,
compared to $34,732 in interest expense and $1,945,898 in losses
from debt conversion during the similar period in 2016. In
addition, we incurred a loss of $556,120 in 2016 as a result of
impairment of the patents we purchased in 2015.
As discussed elsewhere in this Registration Statement on Form S-1,
on October 8, 2015, we acquired U.S. Patent Number 8,236,935 (the
“US Patent”) for the anticancer compound, Adva-27a from
a related entity (Advanomics Corporation), which includes all
rights to this intellectual property within the United States, in
exchange for an interest-free note payable for $4,320,000 (the
“October Patent Purchase Agreement”). On
December 28, 2015, we acquired the remaining worldwide issued and
pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the
“Worldwide Patents”) for the Adva-27a anticancer
compound from the same related entity (Advanomics Corporation) in
exchange for a note payable for $12,822,499 (the “December
Patent Purchase Agreement”).
We believe that purchase of the US Patent and the Worldwide Patents
(the “Patents”) would facilitate our ability to obtain
the funding necessary to complete the development and FDA approval
process for Adva-27a. As a related party transaction, purchased
patents are required to be recorded at the purchase price or the
book value on the seller’s financial statements, whichever is
lower. Effective December 28, 2015, the parties agreed to amend the
October Patent Purchase Agreement and the December Patent Purchase
Agreement. Pursuant to the amendment agreements (the
“Amendments”), the Patents were purchased from a
related party, Advanomics Corporation, at Advanomics’ cost
less the amortization through December 28, 2015, the effective date
of the transfer. The Amendments amended the purchase price of the
Patents to $835,394, eliminated all cash payments obligations and
replaced the non-convertible notes totaling $17,142,499 with two
(2) convertible notes totaling $835,394 that automatically convert
into an aggregate of 321,305,415 shares of our Common Stock. We
needed to amend our Articles of Incorporation to establish
additional authorized common shares in order to issue this stock.
In July 2016, having completed the increase of our authorized
capital to 3 billion shares of Common Stock, we issued the
321,305,415 Common Shares to Advanomics thereby completing all
aspects of the patent purchase arrangements and securing direct
ownership of all worldwide patents and rights pertaining to
Adva-27a.
In 2016, following a review of the status of our intellectual
property, the remaining value of the Patents ($556,120) on our
Balance Sheet was impaired as required under applicable accounting
rules.
As a result, we incurred a net loss of $3,496,687 (approximately
$0.01 per share) for the year ended December 31, 2016, compared to
a net loss of $1,040,236 (approximately $0.00 per share) during the
year ended December 31, 2017.
Because we did not generate revenue in the last two years,
following is our Plan of Operation.
Plan of Operation
As of the date of this report we are operating through the
following wholly owned subsidiaries:
●
NOX
Pharmaceuticals, Inc., a recently formed Colorado company focused
on the research, development and commercialization of proprietary
drugs for the treatment of cancer including Adva-27a, a
multi-purpose anti-tumor compound targeted for the treatment of
multidrug resistant cancer;
●
Sunshine
Biopharma Canada Inc., a Canadian company formed in July 2014,
which offers generic prescription drugs for the treatment of cancer
and other acute and chronic indications; and
●
Atlas
Pharma Inc., a Canadian company acquired in January 2018, offers
certified chemical analysis of pharmaceutical and other industrial
samples.
NOX Pharmaceuticals, Inc. and Atlas Pharma Inc. are not included in
the 2017 and 2016 financials.
See Business, above, for a more detailed description of these
businesses.
Liquidity and Capital Resources
As of December 31, 2017, we had cash or cash equivalents of
$107,532.
Net cash used in operating activities was $543,520 during our
fiscal year ended December 31, 2017, compared to $314,182 during
our fiscal year ended December 31, 2016. We anticipate
that our cash requirements for our operations will increase in the
future before we reach profitability levels.
Cash flows used in investing activities were $84,008 during our
fiscal year ended December 31, 2017. For the fiscal year
ended December 31, 2016, cash flows used in investing activities
were $3,439 arising primarily out of the purchase of laboratory and
generic drugs warehouse equipment in 2017. Net cash
flows provided by financing activities totaled $670,705 in 2017,
compared to $324,622 during our fiscal year ended December 31,
2016.
We have issued convertible and non-convertible notes to both
related and unaffiliated parties in order to fund our
operations.
In December 2016, we received monies from our CEO in exchange for a
note payable having a principal amount of $90,000 Canadian ($67,032
US) with interest at 12% due March 31, 2017. The note was
convertible any time after the date of issuance into shares of our
Common Stock at a price 35% below market value. At the time, this
note was collateralized by all of our assets. In the event of
default, the interest rate will increased to 18% per annum and a
penalty of $1,000 Canadian ($752 US) per day will accrue. On March
31, 2017, the note, together with accrued interest of $3,021
Canadian ($2,271 US) and an additional principal amount of $3,000
Canadian ($2,247 US) was renewed for a 90-day period under the same
terms and conditions as the original note. The new note then having
a face value of $96,021 Canadian ($72,198 US) was due on June 30,
2017. On June 30, 2017, the note, together with accrued interest of
$2,873 Canadian ($2,005 US), was renewed for a 90-day period under
the same terms and conditions as the original note except that the
new note was not- convertible. The new note then having a face
value of $98,894 Canadian ($76,072US) was due on September 30,
2017. On September 30, 2017, the note, together with accrued
interest of $2,991 Canadian ($2,397 US) was renewed for a 90-day
period under the same terms and conditions as the June 2017 note.
The note, then having a principal balance of $101,885 Canadian
($81,640 US) matured December 31, 2017. On December 31, 2017 the
note was renewed for a 12-month period under the same terms and
conditions as the September 2017 note except that this new note is
unsecured and nonconvertible. The new note has a face value of
$104,942 Canadian ($83,649 US) and matures on December 31,
2018.
A note payable held by a private individual who subsequently became
a principal shareholder of our Company, having a face value of
$100,000 at December 31, 2016 and a maturity date of March 31,
2017, accrues interest at 12%. The Note is convertible any time
from the date of issuance into shares of our Common Stock at a 35%
discount from market price. On March 31, 2017, the note’s
principal balance of $100,000 plus accrued interest of $11,715 was
renewed for a period of 90 days under the same terms and conditions
as the original note. The new note then having a face value of
$111,715 matured on June 30, 2017. On June 30, 2017, the
note’s principal balance of $111,715, plus accrued interest
of $3,342 was renewed for a period of 90 days under the same terms
and conditions as the original note. The new note then had a face
value of $115,057 and matured on September 30, 2017. On September
30, 2017, the note’s principal balance of $115.057 plus
accrued interest of $3,480 was renewed for a period of 90 days
under the same terms and conditions as the original note. The new
note then had a principal balance of $118,537, which matured on
December 31, 2017. On December 31, 2017 the note was renewed for a
12-month period under the same terms and conditions as before. The
new note has a face value of $122,093 and matures on December 31,
2018.
A Note Payable having a Face Value of $21,439 at December 31, 2016,
and accruing interest at 12% was due December 31, 2017. On December
31, 2017, we renewed the note, together with accrued interest of
$2,573, for a 12-month period. The new note has a Face Value of
$24,012 and accrues interest at 12%. This note is convertible
anytime from the date of issuance into shares of our Common Stock
at a 35% discount from market price and is due December 31,
2018.
On April 1, 2017, we received monies in exchange for a note payable
having a Face Value of $100,000 Canadian ($79,710 US) with interest
payable quarterly at 9%, which is due April 1, 2019. The note is
convertible any time after issuance into shares of our Common Stock
at a price of $0.015 Canadian (approximately $0.012 US) per
share.
On September 22, 2017, we received monies in exchange for a note
having a Face Value of $62,000, with interest accruing at 8%, which
is due June 30, 2018. The note is convertible after 180 days from
issuance into shares of our Common Stock at a price 35% below
market value.
On October 26, 2017, we received monies in exchange for a note
payable having a Face Value of $115,000 with interest accruing at
8%, which is due October 26, 2018. The note is convertible after
180 days from issuance into shares of our Common Stock at a price
35% below market value.
On November 14, 2017, we received monies in exchange for a note
payable having a Face Value of $113,000 with interest accruing at
8%, which is due November 14, 2018. The note is convertible after
180 days from issuance into shares of our Common Stock at a price
35% below market value.
On December 1, 2017, we received monies in exchange for a note
payable having a Face Value of $50,000 Canadian ($39,855 US) with
interest accruing at 8%, due November 30, 2018. The note is
convertible after 180 days from issuance into shares of our Common
Stock at a price 35% below market value.
On February 10, 2017, we received monies in exchange for a note
payable having a Face Value of $50,000 with interest accruing at
8%, which is due November 20, 2017. The note is convertible after
180 days from issuance into $0.001 par value Common Stock at a
price 35% below market value. In August 2017, the note was paid off
with an additional $17,422 as a prepayment penalty.
On April 26, 2017, we received monies in exchange for a note
payable having a Face Value of $ 65,000 with interest accruing at
8%, which is due April 26, 2018. The note is convertible after 180
days from issuance into $0.001 par value Common Stock at a price
35% below market value. In October 2017, we issued payment in the
amount of $85,107 to pay off the note including a prepayment
penalty of $20,107.
On August 3, 2017, we received monies in exchange for a note
payable having a Face Value of $80,000 with interest accruing at
8%, which is due August 3, 2018. The note is convertible after 180
days from issuance into $0.001 par value Common Stock at a price
35% below market value.
On August 21, 2017, we received monies in exchange for a note
payable having a Face Value of $83,000 with interest accruing at
8%, which is due May 30, 2018. The Note is convertible after 180
days from issuance into $0.001 par value Common Stock at a price
35% below market value. In February 2018, the note was paid off
with an additional $32, 370 as a prepayment penalty.
On July 1, 2016, we received monies in exchange for a note payable
having a Face Value of $55,000 with interest accruing at 10%, which
is due April 1, 2017. The note is convertible after 180 days from
issuance into $0.001 par value Common Stock at a price 40% below
market value. In December 2016 and January 2017, the note, together
with $3,022 in accrued interest, was fully converted into
47,528,125 shares of our Common Stock.
During the fiscal year ended December 31, 2017, we issued an
aggregate of 149,336,640 shares of our Common Stock as
follows:
●
40,000,000
shares for cash in the amount of $100,000 Canadian or $78,312
US
●
11,004,167
shares for the purchase of laboratory and generic drugs warehouse
equipment valued at $56,700
●
42,000,000
shares valued at $336,000 as compensation to the Company’s
Directors and Officers
●
13,804,348
shares for services rendered to the Company by third parties valued
at $77,000
●
42,528,125
shares valued at $128,451 in connection with the conversion of
$48,500 in debt and interest of $3,022 resulting in a $76,929 loss
on conversion
Except as indicated, we relied upon the exemption from registration
provided by Regulation D and Section 4(a)(1) of the Securities Act
of 1933, as amended, to issue the respective shares.
We are not generating revenue from our operations, and our ability
to implement our business plan as set forth herein will depend on
the future availability of financing. Such financing
will be required to enable us to further develop our generic
pharmaceuticals business, proprietary drug development program, and
analytical chemistry operations acquired in January
2018. We intend to raise funds through private
placements of our Common Stock and/or debt financing. We estimate
that we will require approximately $8 million ($1 million for the
generic pharmaceutical operations, $1 million for expansion of the
analytical chemistry operations, and $6 million for the proprietary
drug development program) to fully implement our business plan in
the future and there are no assurances that we will be able to
raise this capital.
In late 2017 we signed an agreement with Jitney Trade Inc.
(“Jitney”), a Canadian broker-dealer, to raise up to
$10 million Canadian (approximately $8 million US) in a private
offering being undertaken only in Canada (the
“Offering”) in order to provide the funding we have
estimated we need to implement our business plan. The Offering
expired on February 28, 2018 without any funds having been raised.
As of the date of this Registration Statement on Form S-1, we are
engaged in negotiations with Jitney concerning the terms for
extending the Offering. There are no assurances that any funds will
be raised for us in this situation.
Our cost to continue operations as they are now conducted is
nominal, but these are expected to increase as we move forward with
implementation of our enhanced business plan. We do not
have sufficient funds to cover the anticipated increase in the
relevant expenses. We need to raise additional funds in
order to continue our existing operations and planned
expansions.
Going Concern
Our financial statements accompanying this Registration Statement
on Form S-1 have been prepared assuming that we will continue as a
going concern, which contemplates the realization of assets and
liquidation of liabilities in the normal course of business. The
financial statements do not include any adjustment that might
result from the outcome of this uncertainty. We have a minimal
operating history and minimal revenues or earnings from operations.
We have no significant assets or financial resources. We will, in
all likelihood, sustain operating expenses without corresponding
revenues for the immediate future. See “Financial
Statements and Notes.”
Inflation
Although our operations are influenced by general economic
conditions, we do not believe that inflation had a material effect
on our results of operations during our fiscal year ended December
31, 2017.
Critical Accounting Policies and Estimates
Critical Accounting Estimates
The discussion and analysis of our financial condition and results
of operations are based upon our financial statements, which have
been prepared in accordance with accounting principles generally
accepted in the United States. The preparation of these
financial statements requires us to make estimates and judgments
that affect the amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and
liabilities. On an on-going basis, we evaluate our estimates based
on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates
under different assumptions or conditions.
Leases
We follow the guidance in SFAS No. 13 “
Accounting for
Leases
,” as amended,
which requires us to evaluate the lease agreements we enter into to
determine whether they represent operating or capital leases at the
inception of the lease.
Recently Adopted Accounting Standards
In November 2016, the FASB issued ASU No. 2016-17, Income Taxes
(Topic 740): Balance Sheet Classification of Deferred Taxes. The
standard requires that deferred tax assets and liabilities be
classified as noncurrent on the balance sheet rather than being
separated into current and noncurrent. ASU 2016-17 is effective for
fiscal years, and interim periods within those years, beginning
after December 15, 2017. Early adoption is permitted and the
standard may be applied either retrospectively or on a prospective
basis to all deferred tax assets and liabilities. We adopted ASU
2016-17 during our first quarter of the year ended December 31,
2017, on a retrospective basis. The adoption of 2016-17 had no
impact on our financial statements.
In February 2017, the FASB issued ASU No. 2017-02, Leases (Topic
842), to provide guidance on recognizing lease assets and lease
liabilities on the balance sheet and disclosing key information
about leasing arrangements, specifically differentiating between
different types of leases. The core principle of Topic 842 is that
a lessee should recognize the assets and liabilities that arise
from all leases. The recognition, measurement, and presentation of
expenses and cash flows arising from a lease by a lessee have not
significantly changed from previous GAAP. There continues to be a
differentiation between finance leases and operating leases.
However, the principal difference from previous guidance is that
the lease assets and lease liabilities arising from operating
leases should be recognized in the balance sheet. The accounting
applied by a lessor is largely unchanged from that applied under
previous GAAP. The amendments will be effective for fiscal years
beginning after December 15, 2018, including interim periods within
those fiscal years, and early adoption is permitted. In transition,
lessees and lessors are required to recognize and measure leases at
the beginning of the earliest period presented using a modified
retrospective approach.
The modified retrospective approach includes a number of optional
practical expedients that entities may elect to apply. These
practical expedients relate to the identification and
classification of leases that commenced before the effective date,
initial direct costs for leases that commenced before the effective
date, and the ability to use hindsight in evaluating lessee options
to extend or terminate a lease or to purchase the underlying
asset.
An entity that elects to apply the practical expedients will, in
effect, continue to account for leases that commence before the
effective date in accordance with previous GAAP unless the lease is
modified, except that lessees are required to recognize a
right-of-use asset and a lease liability for all operating leases
at each reporting date based on the present value of the remaining
minimum rental payments that were tracked and disclosed under
previous GAAP. We are currently evaluating the impact of these
amendments on our financial statements.
In March 2017, the FASB issued ASU No. 2017-08, Revenue from
Contracts with Customers (Topic 606): Principal versus Agent
Considerations, to clarify the implementation guidance on principal
versus agent considerations and address how an entity should assess
whether it is the principal or the agent in contracts that include
three or more parties. The effective date and transition
requirements for these amendments are the same as the effective
date and transition requirements of ASU 2014-09 (discussed above).
We are currently evaluating the impact of these amendments on our
financial statements.
In March 2017, the FASB issued ASU No. 2017-09, Compensation-Stock
Compensation (Topic 718): Improvements to Employee Share-Based
Payment Accounting, to reduce complexity in accounting standards
involving several aspects of the accounting for employee
share-based payment transactions, including (1) the income tax
consequences, (2) classification of awards as either equity or
liabilities, and (3) classification on the statement of cash flows.
The amendments will be effective for financial statements issued
for fiscal years beginning after December 15, 2017, including
interim periods within those fiscal years, and early adoption is
permitted. Amendments related to the timing of when excess tax
benefits are recognized, minimum statutory withholding
requirements, forfeitures, and intrinsic value should be applied
using a modified retrospective transition method, amendments
related to the presentation of employee taxes paid on the statement
of cash flows when an employer withholds shares to meet the minimum
statutory withholding requirement should be applied
retrospectively, amendments requiring recognition of excess tax
benefits and tax deficiencies in the income statement and the
practical expedient for estimating expected term should be applied
prospectively, and amendments related to the presentation of excess
tax benefits on the statement of cash flows can be applied using
either a prospective transition method or a retrospective
transition method. An entity that elects early adoption must adopt
all of the amendments in the same period. We are currently
evaluating the impact of these amendments on our financial
statements.
In April 2017, the FASB issued ASU No. 2017-10, Revenue from
Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensing, to clarify the following two aspects of
Topic 606: 1) identifying performance obligations, and 2) the
licensing implementation guidance. The effective date and
transition requirements for these amendments are the same as the
effective date and transition requirements of ASU 2014-09
(discussed above). We are currently evaluating the impact of these
amendments on our financial statements.
In May 2017, the FASB issued ASU No. 2017-10, Revenue from
Contracts with Customers (Topic 606): Identifying Performance
Obligations and Licensing, to clarify certain core recognition
principles including collectability, sales tax presentation,
noncash consideration, contract modifications and completed
contracts at transition and disclosures no longer required if the
full retrospective transition method is adopted.
The effective date and transition requirements for these amendments
are the same as the effective date and transition requirements of
ASU 2014-09 (discussed above). We are currently evaluating the
impact of these amendments on our financial
statements.
In August 2017, the FASB issued ASU No. 2017-15, Statement of Cash
Flows (Topic 230): Classification of Certain Cash Receipts and Cash
Payments, to clarify how certain cash receipts and cash payments
are presented and classified in the statement of cash flows. The
amendments should be applied using a retrospective transition
method, and are effective for fiscal years beginning after December
15, 2017, including interim periods within those fiscal years. We
are currently evaluating the impact of these amendments on our
financial statements.
In November 2017, the FASB issued ASU No. 2017-18, Statement of
Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB
Emerging Issues Task Force), to provide guidance on the
presentation of restricted cash or restricted cash equivalents in
the statement of cash flow. The amendments should be applied using
a retrospective transition method, and are effective for fiscal
years beginning after December 15, 2017, including interim periods
within those fiscal years. We are currently evaluating the impact
of these amendments on our financial statements.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on
our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures
or capital resources and would be considered material to
investors.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
None.
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL
PERSONS
Following is a list of our officers and directors:
Name
|
|
Age
|
|
Position(s)
|
|
|
|
|
|
Dr.
Steve N. Slilaty
|
|
66
|
|
President,
Chief Executive Officer, and Chairman
|
|
|
|
|
|
Dr.
Abderrazzak Merzouki
|
|
55
|
|
Chief
Operating Officer and Director
|
|
|
|
|
|
Camille
Sebaaly
|
|
59
|
|
Chief
Financial Officer, Secretary and Director
|
Our directors serve as directors until our next Annual Meeting of
Stockholders and the election and qualification of the
director’s respective successor or until the director’s
earlier death, removal or resignation.
Following is biographical information of our current
management:
Dr. Steve N. Slilaty
was
appointed as our CEO, President and Chairman of our Board of
Directors on October 15, 2009. Dr. Slilaty is an
accomplished scientist and business executive. His scientific
publications are widely cited including university textbooks.
Sunshine Biopharma is the third in a line of biotechnology
companies that Dr. Slilaty founded and managed through their early
and mid-stages of development. The first,
Quantum
Biotechnologies Inc.
later
known as
Qbiogene
Inc.
, was founded in 1991 and
grew to over $60 million in annual sales. Today,
Qbiogene
is a member of a family of companies
owned by
MP
Biomedicals
, one of the largest
international suppliers of biotechnology reagents and other
research products. The second company which Dr. Slilaty
founded,
Genomics One
Corporation
, later known
as
Alert
B&C Corporation
, conducted
an initial public offering (IPO) of its capital stock in 1999 and,
on the basis of its ownership of Dr. Slilaty’s patented
TrueBlue® Technology,
Genomics One
became one of the key participants in
the Human Genome Project. Formerly a research team
leader of the
Biotechnology Research
Institute
, a division of
the
National Research Council of
Canada
, Dr. Slilaty also served
as a consultant in a management and advisory capacity for a major
Canadian biotechnology company between 1995 and 1997 during which
time the company completed one of the largest biotechnology
IPO‘s in Canada. Dr. Slilaty is one of the pioneers of
Gene Therapy having developed the first gene delivery system
applicable to humans in 1983 [Science 220:725-727 (1983)]. Dr.
Slilaty's other distinguished scientific career accomplishments
include the discovery of a new class of enzymes, the S24 Family of
Proteases (IUBMB Enzyme Nomenclature: EC 3.4.21.88), development of
the first site-directed mutagenesis system applicable to
double-stranded DNA, cloning the gene for the first yeast-lytic
enzyme (lytic b-1,3-glucanase), developing a new molecular strategy
for increasing the rate of enzyme reactions, inventing a powerful
new cloning system for genomic cloning and gene discovery
(TrueBlue® Technology) and developing a new transcriptomics
technology for generating entire RNA profiles. These and other
works of Dr. Slilaty are cited in research papers, editorials,
review articles and textbooks. Dr. Slilaty received his
Ph.D. degree in Molecular Biology from the University of Arizona in
1983 and Bachelor of Science degree in Genetics and Biochemistry
from Cornell University in 1976. In addition, Dr.
Slilaty holds a position as Adjunct Professor at Université du
Québec in the Department of Microbiology and
Biotechnology.
Dr. Abderrazzak Merzouki
was
appointed as a Director and our Chief Operating Officer in February
2016. In addition to his new positions with our Company,
since January 2016 he has been self-employed as a consultant in the
fields of biotechnology and pharmacology. From July 2007
through December 2016, Dr. Merzouki worked at the Institute of
Biomedical Engineering in the Department of Chemical Engineering at
Ecole Polytechnique de Montreal, where he taught and acted as a
senior scientist involved in the research and development of
plasmid and siRNA-based therapies. Dr. Merzouki is a
molecular biologist and an immunologist with extensive experience
in the area of gene therapy where he performed several preclinical
studies for pharmaceutical companies involving the use of
adenoviral vectors for cancer therapy and plasmid vectors for
the treatment of peripheral arterial occlusions. Dr.
Merzouki also has extensive expertise in the design of expression
vectors, and production and purification of recombinant
proteins. He developed technologies for production of
biogeneric therapeutic proteins for the treatment of various
diseases including cancer, diabetes, hepatitis and multiple
sclerosis. Dr. Merzouki obtained his Ph.D. in Virology
and Immunology from Institut Armand-Frappier in Quebec and received
his post-doctoral training at the University of British Columbia
and the BC Center for Excellence in HIV/AIDS
research. Dr. Merzouki has over 30 publications and 70
communications in various, highly respected scientific journals in
the field of cellular and molecular biology.
Camille Sebaaly
was appointed
as our Chief Financial Officer, Secretary and a Director of our
Company on October 15, 2009. Since 2001, Mr. Sebaaly has
been self-employed as a business consultant, primarily in the
biotechnology and biopharmaceutical sectors. He held a
number of senior executive positions in various areas including,
financial management, business development, project management and
finance. As an executive and an entrepreneur, he combines expertise
in strategic planning and finance with strong skills in business
development and deal structure and negotiations. In
addition, Mr. Sebaaly worked in operations, general management,
investor relations, marketing and business development with
emphasis on international business and marketing of advanced
technologies including hydrogen generation and energy
saving. In the area of marketing, Mr. Sebaaly has
evaluated market demands and opportunities, created strategic
marketing and business development plans, designed marketing
communications and launched market penetration
programs. Mr. Sebaaly was a cofounder of Advanomics
Corporation with Dr. Slilaty. Mr. Sebaaly graduated from
State University of New York at Buffalo with an Electrical and
Computer Engineering Degree in 1987.
There are no family relationships between any of our former or
current officers and directors.
SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING
COMPLIANCE
Section 16(a) of the Securities Exchange Act of 1934 (the “34
Act”) requires our officers and directors and persons owning
more than ten percent of the Common Stock, to file initial reports
of ownership and changes in ownership with the Securities and
Exchange Commission (“SEC”). Additionally,
Item 405 of Regulation S-K under the 34 Act requires us to
identify in our Form 10-K and proxy statement those individuals for
whom one of the above referenced reports was not filed on a timely
basis during the most recent year or prior years. To our best
knowledge, all reports that were required to be filed were filed,
but were filed late.
CODE OF ETHICS
Our
board of directors has not adopted a code of ethics but plans to do
so in the near future.
COMMITTEES OF OUR BOARD OF DIRECTORS
There
are no committees of the Board of Directors but it is anticipated
that we will establish an audit committee, nominating committee and
governance committee once independent directors are appointed,
which is expected to occur in the near future.
INVOLVEMENT IN CERTAIN LEGAL PROCEEDINGS
On
November 14, 2014, we entered into a Manufacturing Services
Agreement with Lonza Ltd. and Lonza Sales Ltd. (hereinafter jointly
referred to as “Lonza”), whereby we engaged Lonza to be
the manufacturer of our Adva-27a anticancer drug. In June 2016 we
received a sample of the pilot manufacturing run for evaluation.
Our laboratory analyses showed that, while the sample meets all of
the required chemical, physical and biological specifications, the
amount of material generated (the “Yield”) by the pilot
run was found to be significantly lower than anticipated. We are
currently working towards finding possible solutions to increase
the Yield and define a path forward. During the course of our
discussions concerning the problem of the low Yield, Lonza informed
us that they required us to pay them $687,818 prior to moving
forward with any activity pertaining to the manufacturing agreement
we have with them. We have repeatedly indicated to Lonza that a
clear path defining exactly how the extremely low Yield issue would
be addressed is imperative prior to us making any payments. We
issued a letter to them in June 2017 advising of our position. As
of the date of this Report we have not received a response to our
letter and no further action has been taken by either
party.
In June
2018 we filed an action in the Superior Court of the Province of
Quebec in the District of Montreal (Canada) against one of our
existing shareholders residing in Quebec City (Canada) arising out
of a possible equity investment intended to be completed in the
near future. The complaint alleges among other things, claims of
misrepresentations and misleading conduct resulting in damages to
the Company. As of the date of this report we are awaiting a court
date for the hearings to commence.
Other
than the foregoing, there are no known pending legal proceedings to
which the Company is a party or in which any director, officer or
affiliate of the Company, any owner of record or beneficially of
more than 5% of any class of voting securities of the Company, or
security holder is a party adverse to the Company or has a material
interest adverse to the Company. The Company’s property is
not the subject of any other pending legal proceedings
EXECUTIVE COMPENSATION
The
following table sets forth information concerning all cash and
non-cash compensation awarded to, earned by or paid to our
executive officers. We do not currently have an established policy
to provide compensation to members of our Board of Directors for
their services in that capacity, although we may choose to adopt a
policy in the future.
|
|
|
Bonus
|
|
Option
Awards
|
|
|
Name and
Principal Position
|
|
|
($)
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
Dr. Steve N. Slilaty
,
Chief
Executive Officer and Director
|
|
-0-
|
|
|
|
50,000
(1)
|
50,000
|
|
|
1,000
|
|
|
|
164,600
(2)
|
165,600
|
|
|
155,641
(4)
|
|
|
|
112,000
(3)
|
267,641
|
|
|
|
|
|
|
|
|
Camille Sebaaly
,
Chief
Financial Officer and Director
|
2015
|
-0-
|
|
|
|
-0-
|
-0-
|
|
2016
|
4,597
|
|
|
|
164,600
(2)
|
169,197
|
|
2017
|
16,099
|
|
|
|
112,000
(3)
|
128,099
|
|
|
|
|
|
|
|
|
Abderrazzak Merzouki
,
Chief
Operating Officer and Director
|
2015
|
-0-
|
|
|
|
-0-
|
-0-
|
|
2016
|
-0-
|
|
|
|
164,600
(2)
|
164,600
|
|
2017
|
12,531
|
|
|
|
112,000
(3)
|
124,531
|
1)
In consideration
for services valued at $50,000, Dr. Slilaty was issued 500,000
shares of Series “B” Preferred Stock having 1,000 votes
per share. The Series “B” Preferred Stock is
non-convertible, non-redeemable, non-retractable and has a stated
value of $0.10 per share. These shares of Series B Preferred Stock
are restricted and may not be sold or transferred without prior
written consent of the Board of Directors of the
Company.
2)
In 2016, each
member of our Board of Directors was issued 26,000,000 and
12,000,000 shares of our Common Stock valued at $80,600 and 84,000,
respectively. These Officers and Directors shares are restricted
and may not be sold without prior written consent of the Board of
Directors of the Company.
3)
In 2017, each
member of our Board of Directors was issued 14,000,000 shares of
our Common Stock valued at $112,000. These Officers and Directors
shares are restricted and may not be sold without prior written
consent of the Board of Directors of the Company.
4)
Includes $147,695
paid to Advanomics Corporation, a company controlled by our
CEO.
Salaries
are established by our Board of Directors. We currently
do not have a Compensation Committee but expect to have one in
place in the future once we have independent
directors. We have not and do not expect to pay any
other compensation to our current executive officers or directors
until such time as we are able to secure adequate funding for our
operations.
EMPLOYMENT AGREEMENTS
None of
our executive officers is party to an employment agreement with
us.
STOCK PLAN
We have
not adopted any stock option or other employee plans as of the date
of this Registration Statement on Form S-1. We may adopt
such plans in the future.
DIRECTOR COMPENSATION
We have
not established standard compensation arrangements for our
directors and the compensation, if any payable to each individual
for their service on our Board will be determined from time to time
by our Board of Directors based upon the amount of time expended by
each of the directors on our behalf. No member of our Board of
Directors received compensation for their services for the fiscal
year ended December 31, 2017.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The
following table sets forth certain information regarding the
ownership of Common Stock and Preferred Stock voting with the
Common Stock as of the date of this Registration Statement on Form
S-1 by (i) each person known to us to own more than 5% of our
outstanding Common Stock as of the date of this Registration
Statement on Form S-1, (ii) each of our directors, (iii) each of
our executive officers, and (iv) all of our directors and executive
officers as a group. Unless otherwise indicated, all
shares are owned directly and the indicated person has sole voting
and investment power. The information provided is based upon
1,585,628,494 Common Shares and 500,000 shares of Series B
Preferred Stock issued and outstanding as of the date of this
Registration Statement on Form S-1.
Title of Class
|
|
Name and Address of Beneficial Owner
|
|
Amount and Nature of Beneficial Ownership
|
|
Percent of Common Class(5)(6)
|
|
Percent of Voting Shares
|
|
|
|
|
|
|
|
|
|
Common
Series B Preferred
|
|
Dr. Steve N. Slilaty
(1)
579 rue Lajeunesse
Laval, Quebec
Canada H7X 3K4
|
|
332,398,597
(2)
500,000,000
(3)
|
|
21.0%
0%
|
|
15.9%
24.0%
|
|
|
|
|
|
|
|
|
|
Common
|
|
Dr. Abderrazzak Merzouki
(1)
731 Place de l’Eeau Vive
Laval, Quebec
Canada H7Y 2E1
|
|
118,467,000
|
|
7.5%
|
|
5.7%
|
|
|
|
|
|
|
|
|
|
Common
|
|
Camille Sebaaly
(1)
14464 Gouin West, #B
Montreal, Quebec
Canada H9H 1B1
|
|
246,703,300
(4)
|
|
15.6%
|
|
11.8%
|
|
|
|
|
|
|
|
|
|
Common
|
|
All Officers and Directors
As Group (3 persons)
|
|
697,568,897
|
|
44.0%
|
|
57.4%
|
(1) Officer
and Director.
(2) Includes
215,014,224 shares held in the name of Advanomics Corporation. Dr.
Slilaty is an officer, director and principal shareholder of
Advanomics Corporation and, as a result, controls the disposition
of these shares.
(3) Comprised
of 500,000 shares of $0.10 par value Series “B”
Preferred Stock having 1,000 votes per share. The Series
“B” Preferred Stock is non-convertible, non-redeemable,
non-retractable and has a superior liquidation value of $0.10 per
share.
(4)
Includes 129,488,927 shares held in the name of 4019318 Canada,
Inc. Mr. Sebaaly is the sole officer and director of this company
and, as a result, controls the disposition of these
shares.
(5)
Beneficial ownership is determined in accordance with Rule 13D-3(a)
of the Exchange Act and generally includes voting or investment
power with respect to securities.
(6) The
percentages in the table have been calculated on the basis of
treating as outstanding for a particular person, all shares of our
common stock outstanding on that date and all shares of our common
stock issuable to that holder in the event of exercise of
outstanding options, warrants, rights or conversion privileges
owned by that person at that date which are exercisable within 60
days of that date. Based on 1,585,628,494 shares of common stock as
of September 27, 2018
TRANSACTIONS WITH RELATED PERSONS
On November 27, 2014, we issued a note payable in the principal
amount of $128,000 to an individual who subsequently became a
principal shareholder. The note accrues interest at 10% per annum
and was convertible into shares of our Common Stock at a price of
$0.20 per share. On June 30, 2015, we renewed this note with the
addition of accrued interest of $7,540 and an origination fee of
$25,600. The new Note had a face value of $161,140 and accrued
interest at 12% per annum. The new note was due December 31, 2015,
and was convertible any time from the date of issuance into shares
of our Common Stock at a 35% discount from market price. On
December 31, 2015, we again renewed this note with the addition of
accrued interest amounting to $9,668 and an origination fee of
$32,228. The new note now has a face value of $203,036 and accrues
interest at 12% per annum. The new note was due June 30, 2016 and
was convertible anytime from the date of issuance into shares of
our Common Stock at a 35% discount from market price. In January
2016, $38,036 of the principal was converted, leaving a principal
balance of $165,000. In connection therewith, 7,705,186 shares of
our Common Stock, valued $231,156 were issued generating a loss on
conversion of $193,120. On June 30, 2016, we renewed this note
again with the addition of accrued interest amounting to $9,852.
The renewed note had a face value of $174,852 and accrues interest
at 12% per annum. It was due on March 31, 2017. In October 2016,
$74,852 of the principal amount was converted, leaving a principal
balance of $100,000. On March 31, 2017, the note’s principal
balance of $100,000 plus accrued interest of $11,715 was renewed
for a period of 90 days under the same terms and conditions as the
previous note. The new note now had a face value of $111,715 and
matured on June 30, 2017. On June 30, 2017, the note’s
principal balance of $111,715 plus accrued interest of $3,342 was
renewed for a period of 90 days under the same terms and conditions
as its predecessor. The new note had a face value of $115,057 and
matured on September 30, 2017. On September 30, 2017, the
note’s principal balance of $115.057 plus accrued interest of
$3,480 was renewed for a period of 90 days under the same terms and
conditions as the previous note. The new note had a principal
balance of $118,537 and matured on December 31, 2017. On December
31, 2017 the note was renewed for a 12-month period under the same
terms and conditions as the prior note. The new note has a face
value of $122,093 and matures on December 31, 2018.
In December 2016, we received monies from our CEO in exchange for a
note payable having a principal amount of $90,000 Canadian ($67,032
US) with interest at 12%. The note was convertible any time after
the date of issuance into shares of our Common Stock at a price 35%
below market value. In addition, the note was collateralized by all
our assets. On March 31, 2017, the note, together with all accrued
interest thereon and an additional principal amount of $3,000
Canadian paid to us in March 2017, was renewed for a 90-day period
under the same terms and conditions as the original note. The new
note now having a face value of $96,021 Canadian ($72,198 US) was
due on June 30, 2017. On June 30, 2017, the note, together with
accrued interest of $2,873 Canadian ($2,005 US), was renewed for a
90-day period under the same terms and conditions as the original
note except that the new note is nonconvertible. The new note now
having a face value of $98,894 Canadian ($76,072US) was due on
September 30, 2017. On September 30, 2017, the note, together with
accrued interest of $2,991 Canadian ($2,397 US), was renewed for a
90-day period under the same terms and conditions as its
predecessor. The new note now having a principal balance of
$101,885 Canadian ($81,640 US) matured on December 31, 2017. On
December 31, 2017 the note was renewed for a 12-month period under
the same terms and conditions as before except that this new note
is unsecured and now non-convertible. The new note has a face value
of $104,942 Canadian ($83,649 US) and matures on December 31,
2018.
On October 8, 2015, we acquired U.S. Patent Number 8,236,935 (the
“US Patent”) for the anticancer compound, Adva-27a from
a related entity (Advanomics Corporation), which includes all
rights to this intellectual property within the United States, in
exchange for an interest-free note payable for $4,320,000 (the
“October Patent Purchase Agreement”). On
December 28, 2015, we acquired the remaining worldwide issued and
pending patents under PCT/FR2007/000697 and PCT/CA2014/000029 (the
“Worldwide Patents”) for the Adva-27a anticancer
compound from the same related entity (Advanomics Corporation) in
exchange for a note payable for $12,822,499 (the “December
Patent Purchase Agreement”). We believe that purchase of the
US Patent and the Worldwide Patents (the “Patents”)
would facilitate our ability to obtain the funding necessary to
complete the development and FDA approval process for Adva-27a. In
related party transactions, purchased patents are required to be
recorded at the purchase price or the book value on the
seller’s financial statements, whichever is lower. Effective
December 28, 2015, the parties agreed to amend the October Patent
Purchase Agreement and the December Patent Purchase Agreement.
Pursuant to the amendment agreements (the
“Amendments”), the Patents were purchased from the
related party, Advanomics Corporation, at Advanomics’ cost
less the amortization through December 28, 2015, the effective date
of the transfer. The Amendments amended the purchase price of the
Patents to $835,394, eliminated all cash payments obligations and
replaced the non-convertible notes totaling $17,142,499 with two
(2) convertible notes totaling $835,394 that automatically convert
into an aggregate of 321,305,415 shares of our Common Stock when we
successfully amend our Articles of Incorporation to increase our
authorized capital of Common Stock to 3 billion. In July 2016,
having completed the increase of our authorized capital to 3
billion shares of Common Stock, we issued the 321,305,415 Common
Shares to Advanomics thereby completing all aspects of the patent
purchase arrangements and securing direct ownership of all
worldwide patents and rights pertaining to Adva-27a.
In 2016 and 2017 our principal place of business was located at 469
Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada, H3N
1R4. This was also the location of our former licensor,
Advanomics Corporation, who provided this space to us on a rent
free basis.. Dr. Steve N. Slilaty, our Chief Executive
Officer and a Director, is an Officer, Director and principal
shareholder of Advanomics. Starting January 1, 2017 we
took over the lease from Advanomics until we moved to our current
location on June 1, 2017.
In February and April 2016, we paid $30,000 and $50,487 to
Advanomics for the balance of 2015 licensing fees.
During the fiscal year ended December 31, 2016, Advanomics
Corporation paid on our behalf $13,725 Canadian in patenting fees.
Advanomics was fully reimbursed by us in January 2017.
During the fiscal ended December 31, 2017, we issued to our Board
of Directors 42,000,000 shares of par value $0.001 Common Stock
valued at $336,000 or $0.008 per share. During the same period, our
Directors and Officers were paid $184,271 in cash. Of this amount,
$147,695 was paid to Advanomics Corporation, a company controlled
by our CEO.
During the period ended December 31, 2016, we issued 78,000,000
shares of par value $0.001 Common Stock to our Directors and
Officers valued at $241,800 or $0.0031 per share. We also issued to
the Board of Directors 36,000,000 shares of $0.001Common Stock
valued at $252,000 or $0.0078 per share. In addition, we paid or
Directors and Officers $5,597 in cash.
Certain members of our management, including Dr. Steve N. Slilaty,
our President, CEO and a Director and Camille Sebaaly, our
Secretary, CFO and a Director, hold similar positions with
Advanomics.
There are no other related party transactions that are required to
be disclosed pursuant to Regulation S-K promulgated under the
Securities Act of 1933, as amended.
On January 1, 2018 as part of the acquisition of Atlas Pharma Inc.,
the Company issued a note payable in the amount of $450,000
Canadian ($358,407 US) and accruing interest at the rate of 3% per
annum. The note is due on December 31, 2023. Payments on this note
are $10,000 Canadian (approximately $8,000 US) per quarter. The
outstanding principal balance at June 30, 2018 is $331,668. The
note is secured by the Atlas Pharma Inc. shares held by the
Company.
The Company paid its Officers and Directors cash compensation
totaling $17,344 and $12,415 and $95,131 and $55,380 for the three
and six month periods ended June 30, 2018 and 2017, respectively.
The Company also paid its Officers and Directors non-cash
compensation in the form of shares of Common Stock valued at
$429,300 and $336,000 and $429,300 and $336,000 during the three
and six month periods ended June 30, 2018 and 2017 respectively. In
June 2018 the Company expensed an additional $429,300 in
compensation to the directors in exchange for 81,000,000 shares of
$0.001 par value Common Stock issued in June 2018 valued at $0.0053
per share. Stock issued for executive compensation is valued at the
closing price on the date of issuance.
DIRECTOR INDEPENDENCE
None of
our current directors are deemed “independent” pursuant
to SEC rules. We anticipate appointing independent directors in the
foreseeable future.
PART I – FINANCIAL INFORMATION
|
|
|
|
|
|
Page
No.
|
|
|
|
Item 1.
|
Unaudited
Consolidated Financial Statements
|
F-1
|
|
|
|
|
Unaudited
Consolidated Balance Sheets as of June 30, 2018 and December 31,
2017
|
F-1
|
|
|
|
|
Unaudited
Consolidated Statements of Operations and Comprehensive Loss for
the
|
|
|
Six
Months Ended June 30, 2018 and 2017
|
F-2
|
|
|
|
|
Unaudited
Consolidated Statements of Cash Flows for the Six Months
Ended
|
|
|
June
30, 2018 and 2017
|
F-3
|
|
|
|
|
Notes
to Consolidated Financial Statements (Unaudited)
|
F-4
|
Item 1. Unaudited Consolidated Financial
Statements
S
unshine Biopharma, Inc.
|
Consolidated
Condensed Balance Sheet
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
Current Assets:
|
|
|
Cash and cash
equivalents
|
$
36,395
|
$
107,532
|
Accounts
receivable
|
108,230
|
-
|
Other receivable
|
51,000
|
-
|
Prepaid expenses
|
1,089
|
9,667
|
|
|
|
Total Current
Assets
|
196,714
|
117,199
|
|
|
|
Equipment (net of $25,864 and $9,132
depreciation resepctively)
|
299,946
|
59,996
|
Patents (net of $58,918 amortization
and $556,120
impairment)
|
-
|
-
|
Deposits
|
-
|
80,290
|
Goodwill
|
673,646
|
-
|
|
|
|
TOTAL ASSETS
|
$
1,170,306
|
$
257,485
|
|
|
|
LIABILITIES AND SHAREHOLDERS'
EQUITY
|
|
|
|
|
|
Current
Liabilities:
|
|
|
Notes payable
|
719,730
|
516,867
|
Notes payable - related
party
|
242,672
|
205,742
|
Bank overdraft
|
1,012
|
-
|
Accounts payable & accrued
expenses
|
139,020
|
19,314
|
Interest payable
|
34,334
|
9,215
|
|
|
|
Total Current
Liabilities
|
1,136,768
|
751,138
|
|
|
|
Long-term
Liabilities:
|
|
|
Note payable
|
-
|
79,710
|
Related party note
payable
|
309,668
|
-
|
|
|
|
TOTAL
LIABILITIES
|
1,446,436
|
830,848
|
|
|
|
COMMITMENTS AND
CONTINGENCIES
|
|
|
|
|
|
SHAREHOLDERS' EQUITY
(DEFICIT)
|
|
|
|
|
|
Preferred stock, Series A $0.10 par
value per share;
|
|
|
Authorized 850,000 Shares;
Issued
and outstanding -0-
shares.
|
-
|
-
|
|
|
|
Preferred stock, Series B $0.10 par
value per share;
|
|
|
Authorized 500,000 Shares;
Issued
and outstanding 500,000
shares.
|
50,000
|
50,000
|
|
|
|
Common Stock, $0.001 par value per
share;
|
|
|
Authorized 3,000,000,000
Shares; Issued
|
|
|
and outstanding 1,104,105,806
and 918,736,498 at
|
|
|
June 30, 2018 and December 31,
2017 respectively
|
1,104,106
|
918,737
|
Reserved for issuance 572,727,700
shares at June 30, 2018
|
|
|
|
|
|
Capital paid in excess of par
value
|
13,106,164
|
12,075,586
|
|
|
|
Accumulated comprehensive
income
|
(8,266
)
|
504
|
|
|
|
Accumulated
(Deficit)
|
(14,528,134
)
|
(13,618,190
)
|
|
|
|
TOTAL SHAREHOLDERS' EQUITY
(DEFICIT)
|
(276,130
)
|
(573,363
)
|
|
|
|
TOTAL LIABILITIES AND SHAREHOLDERS'
EQUITY (DEFICIT)
|
$
1,170,306
|
$
257,485
|
See Accompanying
Notes To These Financial Statements.
S
unshine Biopharma, Inc.
|
Unaudited
Consolidated Condensed Statement Of Operations and Comprehensive
Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue:
|
$
107,250
|
$
-
|
$
198,418
|
$
-
|
Cost of
Revenue
|
91,631
|
-
|
190,913
|
-
|
|
|
|
|
|
|
15,619
|
-
|
7,505
|
-
|
|
|
|
|
|
General & Administrative
Expenses
|
|
|
|
|
Accounting
|
61,939
|
48,415
|
89,939
|
64,015
|
Consulting
|
23,682
|
33,930
|
27,800
|
59,867
|
Legal
|
31,600
|
27,920
|
59,085
|
42,824
|
Office
|
20,068
|
13,032
|
39,116
|
22,098
|
Officer & director
renumeration
|
446,644
|
348,415
|
524,431
|
391,380
|
Rent
|
2,035
|
|
3,572
|
|
Depreciation
|
602
|
506
|
1,210
|
1,024
|
|
|
|
|
|
Total G & A
|
586,570
|
472,218
|
745,153
|
581,208
|
|
|
|
|
|
(Loss) from
operations
|
(570,951
)
|
(472,218
)
|
(737,648
)
|
(581,208
)
|
|
|
|
|
|
Other Income
(expense):
|
|
|
|
|
Foreign exchange gain
(loss)
|
10,016
|
(3,628
)
|
24,884
|
(4,267
)
|
Interest expense
|
(28,375
)
|
(9,598
)
|
(103,842
)
|
(18,742
)
|
Loss on debt
conversions
|
(54,998
)
|
-
|
(93,338
)
|
(76,929
)
|
|
|
|
|
|
Total Other
(Expense)
|
(73,357
)
|
(13,226
)
|
(172,296
)
|
(99,938
)
|
|
|
|
|
|
Net
(loss)
|
$
(644,308
)
|
$
(485,444
)
|
$
(909,944
)
|
$
(681,146
)
|
|
|
|
|
|
Basic (Loss) per common
share
|
$
0.00
|
$
0.00
|
$
0.00
|
$
0.00
|
|
|
|
|
|
Weighted Average Common Shares
Outstanding
|
1,000,371,607
|
857,473,771
|
971,151,423
|
811,800,080
|
|
|
|
|
|
Net Income
(Loss)
|
$
(644,308
)
|
$
(485,444
)
|
$
(909,944
)
|
$
(681,146
)
|
Other comprehensive
income:
|
|
|
|
|
Gain (Loss) from foreign exchange
translation
|
(4,056
)
|
2,680
|
(5,786
)
|
3,795
|
Comprehensive
(Loss)
|
(648,364
)
|
(482,764
)
|
(915,730
)
|
(677,351
)
|
|
|
|
|
|
Basic (Loss) per Common
Share
|
$
0.00
|
$
0.00
|
$
0.00
|
$
0.00
|
|
|
|
|
|
Weighted Average Common Shares
Outstanding
|
1,000,371,607
|
857,473,771
|
971,151,423
|
811,800,080
|
See Accompanying Notes To These Financial
Statements.
S
unshine Biopharma, Inc.
|
Unaudited
Consolidated Condensed Statement Of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
Flows From Operating Activities:
|
|
|
Net Loss
|
$
(909,944
)
|
$
(681,146
)
|
Depreciation and
amortization
|
16,404
|
1,024
|
Foreign exchange
loss
|
(24,884
)
|
4,267
|
Stock issued for licenses, services,
and other assets
|
505,100
|
64,000
|
Stock issued for payment
interest
|
7,886
|
3,022
|
Loss on debt
conversion
|
93,585
|
76,929
|
Interest
forgiven
|
(247
)
|
|
Stock issued for payment of
expenses
|
-
|
14,400
|
(Increase) decrease in accounts
receivable
|
(28,722
)
|
-
|
(Increase) decrease in prepaid
expenses
|
8,578
|
(7,530
)
|
Increase (decrease) in Accounts
Payable & accrued expenses
|
14,227
|
342,773
|
Increase (decrease) in interest
payable
|
25,119
|
(3,589
)
|
|
|
|
Net Cash Flows Used in
Operations
|
(292,898
)
|
(185,850
)
|
|
|
|
Cash
Flows From Investing Activities:
|
|
|
Cash received from acquisition of
subsidiary
|
4,942
|
|
Purchase of
equipment
|
(27,370
)
|
(22,295
)
|
|
|
|
Net Cash Flows Used in Investing
Activities
|
(22,428
)
|
(22,295
)
|
|
|
|
Cash
Flows From Financing Activities:
|
|
|
Proceed from notes
payables
|
381,885
|
188,444
|
Sale of common
stock
|
|
63,912
|
Payment of notes
payable
|
(146,184
)
|
-
|
Advances from related
parties
|
12,240
|
|
Payments to related
parties
|
(13,216
)
|
|
Note payable used to pay
expenses
|
|
13,962
|
Note payable used to pay origination
fees & interest
|
15,250
|
9,347
|
|
|
|
Net Cash Flows Provided by Financing
Activities
|
249,975
|
275,665
|
|
|
|
|
|
|
Net Increase (Decrease) In Cash and
cash equivalents
|
(65,351
)
|
67,520
|
Foreign currency translation
adjustment
|
(5,786
)
|
3,795
|
Cash and cash equivalents at
beginning of period
|
107,532
|
57,453
|
|
|
|
Cash and cash equivalents at end of
period
|
$
36,395
|
$
128,768
|
|
-
|
|
Supplementary Disclosure Of Cash Flow
Information:
|
|
|
Stock issued for services, licenses
and other assets
|
$
679,908
|
$
78,400
|
Stock issued for note conversions
including interest
|
$
290,039
|
$
128,451
|
Stock issued for acqusition of
subsidiary
|
$
246,000
|
$
-
|
Note payable issued for acquisition
of subsidiary
|
$
358,407
|
$
-
|
Cash paid for
interest
|
$
13,622
|
$
-
|
Cash paid for income
taxes
|
$
-
|
$
-
|
See Accompanying Notes To These Financial
Statements.
S
unshine Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
Note 1 – Nature of Business and Basis of
Presentation
The
Company was originally incorporated under the name Mountain West
Business Solutions, Inc. (“MBS”) on August 31, 2006 in
the State of Colorado. Until October 2009, the Company was
operating as a business consultancy firm. Effective October 15,
2009, the Company acquired Sunshine Biopharma, Inc. in a
transaction classified as a reverse acquisition. Sunshine
Biopharma, Inc. was holding an exclusive license to a new
anticancer drug bearing the laboratory name, Adva-27a. Upon
completion of the reverse acquisition transaction, the Company
changed its name to Sunshine Biopharma, Inc. and began operating as
a pharmaceutical company focusing on the development the licensed
Adva-27a anticancer drug.
In July
2014, the Company formed a wholly owned Canadian subsidiary,
Sunshine Biopharma Canada Inc. (“Sunshine Canada”) for
the purposes of offering generic pharmaceutical products in Canada
and elsewhere around the world. Sunshine Canada has signed
licensing agreements for four (4) generic prescription drugs for
treatment of breast cancer, prostate cancer and BPH (Benign
Prostatic Hyperplasia). Sunshine Canada is currently evaluating
several other generic products for in-licensing and is working on
securing a Drug Establishment License (“DEL”) and a
Drug Identification Number (“DIN”) per product from
Health Canada. Once the DEL and the DIN’s are secured,
Sunshine Canada will begin its generic pharmaceuticals marketing
and sales program in Canada and overseas.
On
January 1, 2018 the Company acquired all of the issued and
outstanding shares of Atlas Pharma Inc. (“Atlas”), a
Canadian privately held company. The purchase price for the shares
was Eight Hundred Forty Eight Thousand Dollars $848,000 Canadian
($684,697 US). The purchase price included a cash payment of
$100,500 Canadian ($80,289 US), plus the issuance of 20,000,000
shares of the Company’s Common Stock valued at $246,000 or
$0.0123 per share, and a promissory note in the principal amount of
$450,000 Canadian ($358,407 US), with interest payable at the rate
of 3% per annum. Atlas is a certified company dedicated to chemical
analysis of pharmaceutical and other industrial samples.
Atlas’ operations are authorized by a Drug Establishment
License issued by Health Canada. Atlas is also registered with the
FDA.
The Company has performed analysis of the fair market value of
Atlas Pharma Inc. assets and liabilities. The following table
summarizes the allocation of the purchase price as of the
acquisition date:
Cash
|
$
4,942
|
Accounts
receivable
|
79,508
|
Prepaids
|
1,428
|
Property
and equipment
|
62,990
|
Goodwill
|
673,646
|
|
|
Less:
Liabilities assumed ($172,899 Canadian)
|
( 137,817
)
|
|
|
Total
consideration
|
$
684,697
|
While
the agreement to acquire Atlas Pharma Inc. was signed effective
January 1, 2018, there are several matters which are yet to be
completed. In addition, as of the date of this report, the audit of
Atlas Pharma Inc. has not been completed. As a result, various
disclosures in this report may have to be updated. The updated
information may differ and the difference may be
material.
In
March 2018, the Company formed NOX Pharmaceuticals, Inc., a wholly
owned Colorado corporation and assigned all of the Company’s
interest in the Adva27a anticancer drug to that company. NOX
Pharmaceuticals Inc.’s mission is to research, develop and
commercialize proprietary drugs including Adva-27a.
The
financial statements represent the consolidated activity of
Sunshine Biopharma, Inc., Sunshine Biopharma Canada Inc., Atlas
Pharma Inc. and NOX Pharmaceuticals, Inc. (herein collectively
referred to as the "Company").
Sunshine
Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
The
Company has been and continues to work on the development of its
proprietary anticancer drug, Adva-27a. The next series of steps in
the development of Adva-27a include (i) GMP-manufacturing of a
2-kilogram quantity of the drug, (ii) completing the requisite
IND-enabling studies, and (iii) conducting Phase I clinical trials.
In the preclinical studies, Adva-27a was shown to be effective at
destroying multidrug resistant cancer cells including Pancreatic
Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells,
and Uterine Sarcoma cells.
During
the last three month period the Company has continued to raise
money through stock sales and borrowings.
The
Company’s activities are subject to significant risks and
uncertainties, including failing to secure additional funding to
operationalize the Company’s generics business and
proprietary drug development program.
Basis of Presentation of Unaudited Condensed Financial
Information
The
unaudited condensed financial statements of the Company for the
three and six month periods ended June 30, 2018 and 2017 have been
prepared in accordance with accounting principles generally
accepted in the United States of America for interim financial
information and pursuant to the requirements for reporting on Form
10-Q and Regulation S-K. Accordingly, they do not include all the
information and footnotes required by accounting principles
generally accepted in the United States of America for complete
financial statements. However, such information reflects all
adjustments (consisting solely of normal recurring adjustments),
which are, in the opinion of management, necessary for the fair
presentation of the financial position and the results of
operations. Results shown for interim periods are not necessarily
indicative of the results to be obtained for a full fiscal year.
The balance sheet information as of June 30, 2018 was derived from
the audited financial statements included in the Company's
financial statements as of and for the year ended December 31, 2017
included in the Company’s Annual Report on Form 10-K filed
with the Securities and Exchange Commission (the “SEC”)
on April 2, 2018. These financial statements should be read in
conjunction with that report.
Recently Issued Accounting Pronouncements
Recently
issued amendments by the FASB are effective for fiscal years
beginning after December 15, 2017, and should be applied
prospectively on or after the adoption date. Early adoption is
permitted, including adoption in an interim period. The Company
does not expect these amendments to have a material impact on its
financial statements.
In
March 2017, the FASB issued ASU No. 2017-08,
Receivables—Nonrefundable Fees and Other Costs (Subtopic
310-20): Premium Amortization on Purchased Callable Debt
Securities, to amend the amortization period for certain purchased
callable debt securities held at a premium. The ASU shortens the
amortization period for the premium to the earliest call date.
Under current Generally Accepted Accounting Principles
(“GAAP”), entities generally amortize the premium as an
adjustment of yield over the contractual life of the instrument.
The amendments should be applied on a modified retrospective basis,
and are effective for fiscal years beginning after December 15,
2018. Early adoption is permitted, including adoption in an interim
period. The Company is currently evaluating the impact of this
amendment on its financial statements.
In
February 2016, the FASB issued ASU 2016-02, Leases, effective for
annual reporting periods beginning on or after December 15, 2018,
and interim periods within those annual periods. Earlier
application is permitted as of the beginning of an interim or
annual period. This update requires organizations to recognize
lease assets and lease liabilities on the balance sheet with lease
terms of more than 12 months and also disclose certain qualitative
and quantitative information about leasing arrangements. The
Company does not expect adoption of this amendment to have a
material impact on the financial statements.
Sunshine
Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
Note 2 – Going Concern
The
accompanying financial statements have been prepared on a going
concern basis, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. Since
inception, the Company has had recurring operating losses and
negative operating cash flows. These factors raise substantial
doubt about the Company’s ability to continue as a going
concern.
The
Company’s continuation as a going concern is dependent on its
ability to obtain additional financing to fund operations,
implement its business, and ultimately, attain profitability. The
Company will need to secure additional funds through various means,
including equity and debt financing. There can be no assurance that
the Company will be able to obtain additional equity or debt
financing, if and when needed, on terms acceptable to the Company,
or at all. Any additional equity or debt financing may involve
substantial dilution to the Company’s stockholders,
restrictive covenants or high interest costs. The Company’s
long-term liquidity also depends upon its ability to generate
revenues and achieve profitability.
Note 3 – Notes Payable
On
January 12, 2018, the Company received net proceeds of $100,000 in
exchange for a note payable having a face value of $102,000 and
accruing interest at the rate of 8% per annum. The note, due on
October 30, 2018, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value.
The Company estimates that the fair value of this convertible debt
approximates the face value, so no value has been assigned to the
beneficial conversion feature.
On
February 7, 2018, the Company received net proceeds of $142,500 in
exchange for a note payable having a face value of $150,000 and
accruing interest at the rate of 8% per annum. The note, due on
February 7, 2019, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value.
The Company estimates that the fair value of this convertible debt
approximates the face value, so no value has been assigned to the
beneficial conversion feature.
On
February 20, 2018, the Company received net proceeds of $83,000 in
exchange for a note payable having a face value of $85,000 and
accruing interest at the rate of 8% per annum. The note, due on
November 30, 2018, is convertible after 180 days from issuance into
$0.001 par value Common Stock at a price 35% below market value.
The Company estimates that the fair value of this convertible debt
approximates the face value, so no value has been assigned to the
beneficial conversion feature.
On May
29, 2018, the Company received net proceeds of $25,000 in exchange
for a note payable having a face value of $26,750 and accruing
interest at the rate of 8% per annum. The note, due on February 28,
2019 is convertible after 180 days from issuance into $0.001 par
value Common Stock at a price 35% below market value. The Company
estimates that the fair value of this convertible debt approximates
the face value, so no value has been assigned to the beneficial
conversion feature.
On June
27, 2018, the Company issued a note payable having a face value of
$53,000 and accruing interest at the rate of 8% per annum. The net
proceeds of $51,000 from this note were received by the Company on
July 2, 2018. The note, due on April 15, 2019 is convertible after
180 days from issuance into $0.001 par value Common Stock at a
price 35% below market value. The Company estimates that the fair
value of this convertible debt approximates the face value, so no
value has been assigned to the beneficial conversion
feature.
At June
30, 2018 and December 31, 2017, accrued interest on Notes Payable
was $34,334 and $9,481, respectively.
Sunshine
Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
Note 4 – Notes Payable - Related Party
On
January 1, 2018 as part of the acquisition of Atlas Pharma Inc.,
the Company issued a note payable in the amount of $450,000
Canadian ($358,407 US) and accruing interest at the rate of 3% per
annum. The note is due on December 31, 2023. Payments on this note
are $10,000 Canadian (approximately $8,000 US) per quarter. The
outstanding principal balance at June 30, 2018 is $331,668. The
note is secured by the Atlas Pharma Inc. shares held by the
Company.
In
addition to the above, on June 30, 2018 the Company had notes
payable from related parties amounting to $201,786 and accrued
interest of $12,125.
Note 5 – Issuance of Common Stock
During
the six months ended June 30, 2018, the Company issued a total of
185,369,308 shares of $0.001 par value Common Stock. Of these,
42,584,566 shares valued at $290,286 were issued upon conversion of
outstanding notes payable, reducing the debt by $188,568 and
interest payable by $8,133 and generating a loss on conversion of
$93,585. The Company also issued 92,650,000 shares valued at
$499,200 for services, and 29,134,742 shares valued at $174,808 in
exchange for equipment.
In
addition, 20,000,000 shares valued at $246,000 or $0.0123 per share
were issued as part of the acquisition of Atlas Pharma Inc.
The Company also
issued 1,000,000
shares valued at $5,900 in exchange for cancellation of a royalty
obligation.
The
Company declared no dividends through June 30, 2018.
Note 6 – Commitments
The Company’s subsidiary, Atlas Pharma Inc., has entered into
long-term lease agreements for the rental of buildings which call
for minimum lease payments of $228,113 and additional lease
payments based on operating expenses. The lease expires on May 21,
2021. Minimum lease payments for the next four years are $62,213 in
2018, $62,213 in 2019, $62,213 in 2020, and $41,474 in
2021.
Note 7 – Earnings (Loss) Per Share
Earnings
(loss) per share is computed using the weighted average number of
Common Shares outstanding during the period. The Company has
adopted ASC 260 (formerly SFAS128), “Earnings per
Share”.
Note 8 – Goodwill
On January 1, 2018, the Company acquired all of the issued and
outstanding shares of Atlas Pharma Inc. ("Atlas"), a Canadian
privately held company. The purchase price for the shares was Eight
Hundred Forty Eight Thousand Dollars ($848,000) Canadian ($684,697
US). The book value of the fixed assets acquired was $11,051. The
remainder of the purchase price ($673,646) was applied to
Goodwill.
Sunshine
Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
Note 9 – Income Taxes
Deferred
income taxes arise from the temporary differences between financial
statement and income tax recognition of net operating losses and
other items. Loss carryovers are limited under the Internal Revenue
Code should a significant change in ownership occur.
A
deferred tax asset at each date has been offset by a 100% valuation
allowance.
Note 10 – Royalties Payable
As part
of a subscription agreement entered into in 2016, the Company has
an obligation to pay a royalty of 5% of net sales on one of its
generic products (Anastrozole) for a period of three (3) years from
the date of the first sale of that product. During the period ended
June 30, 2018 1,000,000 shares of the Company’s common stock
valued at $5,900 was issued in exchange for cancellation of this
royalty obligation.
Note 11 – Related Party Transactions
In
addition to the related party transactions detailed in Note 4
above, the Company paid its Officers and Directors cash
compensation totaling $17,344 and $12,415 and $95,131 and $55,380
for the three and six month periods ended June 30, 2018 and 2017,
respectively. The Company also paid its Officers and Directors
non-cash compensation in the form of shares of common stock valued
at $429,300 and $336,000 and $429,300 and $336,000 during the three
and six month periods ended June 30, 2018 and 2017 respectively. In
June 2018 the Company expensed an additional $429,300 in
compensation to the directors in exchange for 81,000,000 shares of
$0.001 par value common stock issued in June 2018 valued at $0.0053
per share. Stock issued for executive compensation is valued at the
closing price on the date of issuance.
Note 12 – Revenue Recognition
As of
January 1, 2018, the Company adopted ASU No. 201409, “Revenue
from Contracts with Customers” (ASU 201409). Under the new
guidance, an entity will recognize revenue to depict the transfer
of promised goods or services to customers at an amount that the
entity expects to be entitled to in exchange for those goods or
services. A five-step model has been introduced for an entity to
apply when recognizing revenue. The new guidance also includes
enhanced disclosure requirements. The guidance was effective
January 1, 2018 and was applied on a modified basis. The adoption
did not have an impact on the Company's financial statements.
A
ll of the revenues
of the Company are generated by Atlas Pharma Inc., the Company's
wholly owned Canadian subsidiary which provides laboratory testing
services. Local governmental regulations require that companies
recognize revenues upon completion of the work by issuing an
invoice and remitting the applicable sales taxes (GST and QST) to
the appropriate government agency. Atlas Pharma Inc.'s revenue
recognition policy is in compliance with these local
regulations.
Note 13 – Accounts Receivable
Accounts
receivable consist of trade accounts arising in the normal course
of business and are classified as current assets and carried at
original invoice amounts less an estimate for doubtful receivables
based on a review of outstanding balances on a monthly basis. The
estimate of allowance for doubtful accounts is based on the
Company's bad debt experience, market conditions, and aging of
accounts receivable, among other factors. If the financial
condition of the Company's customers deteriorates resulting in the
customer's inability to pay the Company's receivables as they come
due, additional allowances for doubtful accounts will be
required.
Sunshine
Biopharma, Inc.
Notes
To Unaudited Consolidated Financial Statements
For The
Three and Six Month Interim Period Ended June 30, 2018
Note 14 – Subsequent Events
On July
5, 2018, the holder of a note payable dated November 14, 2017
elected to convert $20,000 in principal into 6,505,122 shares of
Common Stock leaving a principal balance of $93,000.
On July
11, and August 2, 2018, the holder of a note payable dated October
26, 2017 elected to convert a total of $44,000 in principal and
$2,531 in accrued interest into 20,821,004 shares of Common Stock
leaving a principal balance of $23,000.
On July
17, 23, 26, and August 2,
7, and 10
,
2018, the holder of a note payable dated January 12, 2018 elected
to convert a total of $81,000 in principal into an aggregate
of
47,805,452
shares of Common Stock leaving a principal balance of
$21,000.
|
Page No.
|
|
|
Report
of Independent Registered Public Accounting Firm
|
F-11
|
|
|
Consolidated
Balance Sheets as of December 31, 2017 and 2016
|
F-12
|
|
|
Consolidated Statements of Operations and Comprehensive Loss for
the years ended
December 31, 2017 and 2016
|
F-13
|
|
|
Consolidated
Statements of Cash Flows for the years ended December 31, 2017 and
2016
|
F-14
|
|
|
Consolidated Statements of Changes in Stockholders’ Equity
for the years ended
December 31, 2017 and 2016
|
F-15
|
|
|
Notes
to Consolidated Financial Statements
|
F-16
|
Report of Independent Registered Public Accounting
Firm
To the shareholders and the board of directors of Sunshine
Biopharma, Inc.
Opinion on the Financial Statements
We have
audited the accompanying consolidated balance sheets of
Sunshine Biopharma, Inc.
(the
"Company") as of December 31, 2017 and 2016, the related statements
of operations, stockholders' equity (deficit), and cash flows for
the years then ended, and the related notes (collectively referred
to as the "financial statements"). In our opinion, the financial
statements present fairly, in all material respects, the financial
position of the Company as of December 31, 2017 and 2016, and the
results of its operations and its cash flows for the years then
ended, in conformity with accounting principles generally accepted
in the United
States.
Substantial Doubt about the Company’s Ability to Continue as
a Going Concern
The
accompanying financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note
3 to the financial statements, the Company has suffered recurring
losses from operations and has a significant accumulated deficit.
In addition, the Company continues to experience negative cash
flows from operations. These factors raise substantial doubt about
the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 3. The
financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
Basis for Opinion
These
financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on the
Company's financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be
independent with respect to the Company in accordance with the U.S.
federal securities laws and the applicable rules and regulations of
the Securities and Exchange Commission and the PCAOB.
We
conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engage to perform,
an audit of its internal control over financial reporting. As part
of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose
of expressing an opinion on the effectiveness of the
Company’s internal control over financial reporting.
Accordingly, we express no such opinion.
Our
audits included performing procedures to assess the risks of
material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial
statements. We believe that our audits provide a reasonable basis
for our opinion.
/s/ BF
Borgers CPA PC
We have
served as the Company's auditor since 2013.
Lakewood,
CO
April
2, 2018
Sunshine
Biopharma, Inc.
|
Consolidated
Balance Sheet
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
Current
Assets:
|
|
|
|
|
|
Cash and cash
equivalents
|
$
107,532
|
$
57,453
|
Prepaid
expenses
|
9,667
|
1,007
|
|
|
|
Total Current
Assets
|
117,199
|
58,460
|
|
|
|
Equipment (net of
$9,132 and $2,228 depreciation)
|
59,996
|
5,944
|
|
|
|
Patents (net of
$58,918 amortization
and $556,120
impairment)
|
-
|
-
|
|
|
|
Non-current asset -
Deposits
|
80,290
|
-
|
|
|
|
TOTAL
ASSETS
|
$
257,485
|
$
64,404
|
|
|
|
LIABILITIES AND
SHAREHOLDERS' EQUITY
|
|
|
|
|
|
Current
Liabilities:
|
|
|
|
|
|
Current portion of
notes payable
|
516,867
|
69,939
|
Current portion of
notes payable - related entity
|
205,742
|
167,032
|
Accounts
payable
|
19,314
|
28,122
|
Interest
payable
|
9,215
|
9,011
|
|
|
|
Total Curent
Liabilities
|
751,138
|
274,104
|
|
|
|
Long-term
liabilities - Notes payable
|
79,710
|
-
|
|
|
|
|
|
|
TOTAL
LIABILITIES
|
830,848
|
274,104
|
|
|
|
|
|
|
SHAREHOLDERS'
EQUITY
|
|
|
|
|
|
Preferred Stock,
Series A, $0.10 par value per share;
Authorized
5,000,000 Shares; Issued
and outstanding -0-
shares
at December 31, 2017 and 2016,
respectively.
|
-
|
-
|
|
|
|
Preferred Stock,
Series B $0.10 par value per share;
Authorized 500,000
Shares; Issued
and outstanding 500,000 and 500,000
shares
at December 31, 2017 and 2016,
respectively.
|
50,000
|
50,000
|
|
|
|
Common Stock,
$0.001 par value per share;
Authorized 3,000,000,000 Shares;
Issued
and outstanding 918,736,498 and 769,399,858 at
December 31, 2017 and 2016, respectively
|
918,736
|
769,400
|
|
|
|
Reserved for
issuance 394,808,684 at December 31, 2017
|
|
|
|
|
|
Capital paid in
excess of par value
|
12,075,586
|
11,548,460
|
|
|
|
Accumulated other
comprehesive income
|
504
|
394
|
|
|
|
Accumulated
(Deficit)
|
(13,618,190
)
|
(12,577,954
)
|
|
|
|
TOTAL SHAREHOLDERS'
DEFICIT
|
(573,363
)
|
(209,700
)
|
|
|
|
TOTAL LIABILITIES
AND SHAREHOLDERS' DEFICIT
|
$
257,485
|
$
64,404
|
|
|
|
S
ee Accompanying
Notes To These Financial Statements.
|
Sunshine
Biopharma, Inc.
|
Consolidated
Statement Of Operations and comprehensive loss
|
|
|
|
|
|
|
Revenue:
|
$
-
|
$
-
|
|
|
|
General &
Administrative Expenses
|
|
|
|
|
|
Accounting
|
81,643
|
70,413
|
Legal
|
75,908
|
57,955
|
Consulting
|
127,013
|
207,401
|
Office
|
45,726
|
45,215
|
Licenses
|
-
|
19,203
|
Officer &
director renumeration
|
520,271
|
499,397
|
Research &
development
|
-
|
32,793
|
Amortization &
depreciation
|
6,629
|
60,731
|
|
|
|
Total G &
A
|
857,190
|
993,108
|
|
|
|
(Loss) from
operations
|
(857,190
)
|
(993,108
)
|
|
|
|
Other
(expense):
|
|
|
Interest
expense
|
(104,829
)
|
(34,732
)
|
Loss on conversion
of notes payable
|
(76,929
)
|
(1,945,898
)
|
Loss on impairment
of patents
|
-
|
(556,120
)
|
Litigation
settlement proceeds
|
-
|
25,000
|
(Loss) from foreign
exchange transactions
|
(1,288
)
|
-
|
Gain on interest
forgiveness
|
-
|
381
|
Debt
release
|
-
|
7,790
|
|
|
|
Total Other
(Expense)
|
(183,046
)
|
(2,503,579
)
|
|
|
|
Net
(loss)
|
$
(1,040,236
)
|
$
(3,496,687
)
|
|
|
|
Basic (Loss) per
common share
|
$
0.00
|
$
(0.01
)
|
|
|
|
Weighted Average
Common Shares Outstanding
|
872,685,608
|
424,874,458
|
|
|
|
Net Income
(Loss)
|
$
(1,040,236
)
|
$
(3,496,687
)
|
Other comprehensive
income:
|
|
|
Unrealized foreign
currency Gain (Loss)
|
110
|
(346
)
|
Comprehensive
(Loss)
|
(1,040,126
)
|
(3,497,033
)
|
|
|
|
Basic (Loss) per
common share
|
(0.00
)
|
(0.01
)
|
|
|
|
Weighted Average
Common Shares Outstanding
|
872,685,608
|
424,874,458
|
See Accompanying Notes To These
Financial Statements.
Sunshine
Biopharma, Inc.
|
|
|
Consolidated
Statement Of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
Cash Flows From Operating Activities:
|
|
|
|
|
|
Net
(Loss)
|
$
(1,040,236
)
|
$
(3,496,687
)
|
Amortization
and Depreciation
|
6,629
|
60,731
|
Stock
issued for services
|
427,400
|
702,300
|
Loss
on impairment of patents
|
-
|
556,120
|
Loss
on conversion of notes payable
|
76,929
|
1,945,898
|
Stock
issued for payment of interest
|
3,022
|
9,270
|
Debt
forgiveness
|
-
|
(1,313
)
|
(Increase)
decrease in prepaid expenses
|
(8,660
)
|
2,104
|
Increase
(decrease) in Accounts Payable
|
(8,808
)
|
(18,960
)
|
Increase
in Accounts Payable - related entity
|
-
|
(80,000
)
|
Increase(decrease)
in interest payable
|
204
|
6,355
|
|
|
|
Net Cash Flows (used) in Operations
|
(543,520
)
|
(314,182
)
|
|
|
|
Cash Flows From Investing Activities:
|
|
|
|
|
Purchase
equipment
|
(3,718
)
|
(3,439
)
|
Deposits
on business acquisition
|
(80,290
)
|
-
|
|
|
|
Net Cash Flows (used) in Investing Activities
|
(84,008
)
|
(3,439
)
|
|
|
|
Cash Flows From Financing Activities:
|
|
|
|
|
Proceed
from note payable
|
660,565
|
131,150
|
Notes
Payable - Interest expense
|
33,977
|
|
Payment
of notes payable
|
(115,000
)
|
-
|
Origination
fees
|
25,000
|
22,312
|
Notes
payable - related party
|
2,251
|
67,032
|
Note
payable related entity for patent purchase
|
-
|
-
|
Sale
of common stock
|
63,912
|
104,128
|
|
|
|
Net Cash Flows Provided by Financing Activities
|
670,705
|
324,622
|
|
|
|
|
|
|
Net
Increase (Decrease) In Cash and cash equivalents
|
43,177
|
7,001
|
Foreign
currency translation adjustment
|
6,902
|
(346
)
|
Cash
and cash equivalents at beginning of period
|
$
57,453
|
$
50,798
|
|
|
|
|
$
107,532
|
$
57,453
|
Supplementary Disclosure Of Cash Flow Information:
|
Cash
paid for interest
|
$
21,900
|
$
5,264
|
Cash
paid for income taxes
|
$
-
|
$
-
|
|
|
|
Stock
issued for services
|
$
427,400
|
$
702,300
|
Stock
issued for note conversions
|
$
128,451
|
$
3,077,950
|
Stock
issued to buy equipment
|
$
56,700
|
$
-
|
Loan
issued for interest
|
$
58,977
|
$
-
|
Stock
issued for payment of interest
|
$
3,022
|
$
-
|
|
|
|
See Accompanying Notes To These
Financial Statements.
Sunshine
Biopharma, Inc.
|
Statement of
Shareholders' Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at
December 31, 2015
|
198,265,118
|
$
198,265
|
$
8,235,217
|
500,000
|
$
50,000
|
$
740
|
$
(9,081,267
)
|
$
(597,045
)
|
|
|
|
|
|
|
|
|
|
Common stock issued for
cash
|
12,555,556
|
12,556
|
91,572
|
|
|
|
|
104,128
|
|
|
|
|
|
|
|
|
|
Common stock issued for
services
|
146,750,000
|
146,750
|
555,550
|
|
|
|
|
702,300
|
|
|
|
|
|
|
|
|
|
Common stock issued for the
reduction of note payable
|
|
|
|
|
|
|
|
|
and payment of
interest
|
411,829,184
|
411,829
|
2,666,121
|
|
|
|
|
3,077,950
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
(Loss)
|
-
|
-
|
-
|
|
|
(346
)
|
(3,496,687
)
|
(3,497,033
)
|
Balance at
December 31, 2016
|
769,399,858
|
$
769,400
|
$
11,548,460
|
500,000
|
$
50,000
|
$
394
|
$
(12,577,954
)
|
$
(209,700
)
|
|
|
|
|
|
|
|
|
|
Common stock issued for
cash
|
34,000,000
|
34,000
|
29,912
|
|
|
|
|
63,912
|
|
|
|
|
|
|
|
|
|
Common stock issued for
services
|
61,804,348
|
61,804
|
365,596
|
|
|
|
|
427,400
|
|
|
|
|
|
|
|
|
|
Common stock issued for
equipment
|
11,004,167
|
11,004
|
45,696
|
|
|
|
|
56,700
|
|
|
|
|
|
|
|
|
|
Common stock issued for the
reduction of note payable
|
|
|
|
|
|
|
|
|
and payment of
interest
|
42,528,125
|
42,528
|
85,923
|
|
|
|
|
128,451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income
(Loss)
|
-
|
-
|
-
|
|
|
110
|
(1,040,236
)
|
(1,040,126
)
|
Balance at
December 31, 2017
|
918,736,498
|
$
918,736
|
$
12,075,586
|
500,000
|
$
50,000
|
$
504
|
$
(13,618,190
)
|
$
(573,363
)
|
See Accompanying Notes To These Financial
Statements.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Note 1 – Description of Business
The
Company was originally incorporated under the name Mountain West
Business Solutions, Inc. (“MWBS”) on August 31, 2006 in
the State of Colorado. Effective October 15, 2009, MWBS acquired
Sunshine Biopharma, Inc. in a transaction classified as a reverse
acquisition. MWBS concurrently changed its name to Sunshine
Biopharma, Inc. and Sunshine Biopharma, Inc. changed its name to
Sunshine Etopo, Inc. In 2015, Sunshine Etopo, Inc. became inactive
and was recently dissolved.
On
January 1, 2018, the Company acquired Atlas Pharma Inc., a fully
certified Canadian company offering chemical analysis of
pharmaceutical and other industrial samples. As a result of this
and the recent formation of NOX Pharmaceuticals, Inc., Sunshine
Biopharma, Inc. is now operating through three wholly owned
subsidiaries, including:
●
NOX
Pharmaceuticals, Inc., a recently formed Colorado company focused
on the research, development and commercialization of proprietary
drugs for the treatment of cancer including Adva-27a, a
multi-purpose anti-tumor compound targeted for the treatment of
multidrug resistant cancer;
●
Sunshine Biopharma
Canada Inc., a Canadian company formed in July 2014, which offers
generic prescription drugs for the treatment of cancer and other
acute and chronic indications; and
●
Atlas Pharma Inc.,
a Canadian company acquired in January 2018, offering certified
chemical analysis of pharmaceutical and other industrial
samples.
The
financial statements represent the consolidated activity of
Sunshine Biopharma, Inc. and its subsidiaries (hereinafter
collectively referred to as the "Company"). The Company was
originally formed for the purposes of conducting research,
development and commercialization of drugs for the treatment of
various forms of cancer. The Company may also engage in any other
business that is permitted by law, as designated by the Board of
Directors of the Company. NOX Pharmaceuticals, Inc. and Atlas
Pharma Inc. are not included in the Company's 2017
financials.
During
the last year the Company has continued to raise money through
stock sales and borrowings.
The
Company’s activities are subject to significant risks and
uncertainties, including failing to secure additional funding to
operationalize the Company’s generic pharmaceuticals business
and proprietary drug development program.
Note 2 – Summary of Significant Accounting
Policies
This summary of significant accounting policies
is presented to assist the reader in understanding the
Company's financial statements. The consolidated
financial statements and notes are representations of the Company's
management, which is responsible for their integrity and
objectivity. These accounting policies conform to generally
accepted accounting principles and have
been consistently applied in the
preparation of the financial
statements.
PRINCIPLES OF CONSOLIDATION
The
accompanying consolidated financial statements include the accounts
of the Company and its wholly owned subsidiary. All intercompany
accounts and transactions have been eliminated in
consolidation.
USE OF ESTIMATES
The preparation of financial
statements in conformity with U.S. generally
accepted accounting principles requires
management to make estimates and
assumptions that affect the reported amounts of
assets and liabilities and disclosure of
contingent assets and liabilities at the date of
the financial statements and the reported
amounts of revenues and expenses
during the reporting period. The more
significant estimates and assumptions made
by management are valuation of equity
instruments, depreciation of property and
equipment, and deferred tax asset valuation.
Actual results could differ from those estimates as the current
economic environment has increased the degree of uncertainty
inherent in these estimates and assumptions.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
CASH AND CASH EQUIVALENTS
For
the Balance Sheets and Statements of
Cash Flows, all highly liquid investments with
maturity of 90 days or less are considered to be cash
equivalents. The Company had a cash balance of $107,532 and
$57,453 as of December 31, 2017 and December 31, 2016,
respectively. At times such cash balances may be in excess of the
FDIC limit of $250,000 or the equivalent in Canada.
PROPERTY AND EQUIPMENT
Property
and equipment is reviewed for recoverability when events or changes
in circumstances indicate that its carrying value may exceed future
undiscounted cash inflows. As of December 31, 2017 and 2016, the
Company had not identified any such impairment. Repairs and
maintenance are charged to operations when incurred and
improvements and renewals are capitalized.
Property
and equipment are stated at cost. Depreciation is calculated using
the straight-line method for financial reporting purposes and
accelerated methods for tax purposes. Their estimated useful lives
are as follows:
|
Office
Equipment:
|
5-7
Years
|
|
Laboratory
Equipment
|
5
Years
|
|
Vehicles
|
5
Years
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
INTELLECTUAL PROPERTY RIGHTS - PATENTS
The
cost of patents acquired is capitalized and will be amortized over
the shorter of the term of the patent life (20 years) or the
remaining life of the underlying patents.
The
Company evaluates recoverability of identifiable intangible assets
whenever events or changes in circumstances indicate that
intangible assets carrying amount may not be recoverable. Such
circumstances include, but are not limited to: (1) a significant
decrease in the market value of an asset, (2) a significant adverse
change in the extent or manner in which an asset is used, or (3) an
accumulation of cost significantly in excess of the amount
originally expected for the acquisition of an asset. The Company
measures the carrying amount of the assets against the estimated
undiscounted future cash flows associated with it.
There
was an impairment loss of $556,120 for the year ended December 31,
2016.
The
Company’s management determined that the expected cash flows
would be less than the carrying amount of assets being evaluated;
therefore an impairment loss was recognized. The impairment loss
was calculated as the amount by which the carrying amount of the
assets, exceed fair value.
EARNINGS PER SHARE
The
Company has adopted the
Financial
Accounting Standards Board
(FASB) ASC Topic 260 regarding
earnings / loss per share, which provides for calculation of
“basic” and “diluted” earnings / loss per
share. Basic earnings / loss per share includes no dilution and is
computed by dividing net income / loss available to common
shareholders by the weighted average common shares outstanding for
the period. Diluted earnings / loss per share reflect the potential
dilution of securities that could share in the earnings of an
entity similar to fully diluted earnings / loss per
share.
There
were no potentially dilutive instruments outstanding during the
period ended December 31, 2017 or the year ended December 31,
2016.
INCOME TAXES
In accordance with ASC 740 - Income Taxes, the provision for income
taxes is computed using the asset and liability method. The
liability method measures deferred income taxes by
applying enacted statutory rates in effect at the
balance sheet date to the differences between the tax
basis of assets and liabilities and their
reported amounts on the financial
statements. The resulting deferred tax assets or
liabilities have been adjusted to reflect changes in tax laws as
they occur. A valuation allowance is provided when it is
more likely than not that a deferred tax asset will not be
realized.
The Company expects to recognize the financial statement benefit of
an uncertain tax position only after considering the probability
that a tax authority would sustain the position in an examination.
For tax positions meeting a "more-likely-than-not" threshold, the
amount to be recognized in the financial statements will be the
benefit expected to be realized upon settlement with the tax
authority. For tax positions not meeting the threshold, no
financial statement benefit is recognized. As of December 31, 2017,
the Company had no uncertain tax positions. The Company recognizes
interest and penalties, if any, related to uncertain tax positions
as general and administrative expenses. The Company currently has
no federal or state tax examinations nor has it had any federal or
state examinations since its inception. To date, the Company has
not incurred any interest or tax penalties.
For Canadian and US tax purposes, the Company’s 2014 through
2016 tax years remain open for examination by the tax authorities
under the normal three-year statute of limitations.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
FUNCTIONAL CURRENCY
The
U.S. dollar is the functional currency of the Company which is
operating in the United States. The functional currency for the
Company's Canadian subsidiary is the Canadian dollar.
The
Company translates its Canadian subsidiary's financial statements
into U.S. dollars as follows:
●
Assets and
liabilities are translated at the exchange rate in effect as of the
financial statement date.
●
Income statement
accounts are translated using the weighted average exchange rate
for the period.
The
Company includes translation adjustments from currency exchange and
the effect of exchange rate changes on intercompany transactions of
a long-term investment nature as a separate component of
shareholders’ equity. There are currently no transactions of
a long-term
investment
nature, nor any gains or losses from non U.S. currency
transactions.
CONCENTRATION OF CREDIT RISKS
Financial
instruments that potentially subject the Company to concentrations
of credit risk consist principally of cash equivalents, notes
receivables, deposits, and trade receivables. The Company places
its cash equivalents with high credit quality financial
institutions. As of December 31, 2017 and 2016 there were no trade
receivables.
FINANCIAL INSTRUMENTS AND FAIR VALUE OF FINANCIAL
INSTRUMENTS
The
Company applies the provisions of accounting guidance, FASB Topic
ASC 825,
Financial
Instruments
. ASC 825 requires all entities to disclose the
fair value of financial instruments, both assets and liabilities
recognized and not recognized on the balance sheet, for which it is
practicable to estimate fair value, and defines fair value of a
financial instrument as the amount at which the instrument could be
exchanged in a current transaction between willing parties. As of
December 31, 2017 and 2016, the fair value of cash, accounts
receivable and notes receivable, accounts payable, accrued
expenses, and other payables approximated carrying value due to the
short maturity of the instruments, quoted market prices or interest
rates which fluctuate with market rates.
The
Company defines fair value as the price that would be received to
sell an asset or be paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
The Company applies the following fair value hierarchy, which
prioritizes the inputs used to measure fair value into three levels
and bases the categorization within the hierarchy upon the lowest
level of input that is available and significant to the fair value
measurement. The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable
inputs (Level 3 measurements).
Level 1
— Level 1 inputs are quoted prices (unadjusted) in active
markets for identical assets or liabilities that the reporting
entity has the ability to access at the measurement
date.
Level 2
— Level 2 inputs are inputs other than quoted prices included
within Level 1 that are observable for the asset or liability,
either directly or indirectly. If the asset or liability has a
specified (contractual) term, a Level 2 input must be observable
for substantially the full term of the asset or
liability.
Level 3
— Level 3 inputs are unobservable inputs for the asset or
liability in which there is little, if any, market activity for the
asset or liability at the measurement date.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
The
carrying value of financial assets and liabilities recorded at fair
value is measured on a recurring or nonrecurring basis. Financial
assets and liabilities measured on a non-recurring basis are those
that are adjusted to fair value when a significant event occurs.
The Company had no financial assets or liabilities carried and
measured on a nonrecurring basis during the reporting periods.
Financial assets and liabilities measured on a recurring basis are
those that are adjusted to fair value each time a financial
statement is prepared.
NOTES PAYABLE
Borrowings
are recognized initially at fair value, net of transaction costs
incurred. Borrowings are subsequently carried at amortized cost;
any difference between the proceeds (net of transaction costs) and
the redemption value is recognized in the income statement over the
period of the borrowings using the effective interest
method.
ACCOUNTING FOR DERIVATIVES LIABILITIES
The
Company evaluates stock options, stock warrants or other contracts
to determine if those contracts or embedded components of those
contracts qualify as derivatives to be separately accounted for
under the relevant sections of ASC Topic 815-40,
Derivative Instruments and Hedging: Contracts
in Entity’s Own Equity
. The result of this accounting
treatment could be that the fair value of a financial instrument is
classified as a derivative instrument and is marked-to-market at
each balance sheet date and recorded as a liability. In the event
that the fair value is recorded as a liability, the change in fair
value is recorded in the statement of operations as other income or
other expense.
Upon
conversion or exercise of a derivative instrument, the instrument
is marked to fair value at the conversion date and then that fair
value is reclassified to equity. Financial instruments that are
initially classified as equity that become subject to
reclassification under ASC Topic 815-40 are reclassified to a
liability account at the fair value of the instrument on the
reclassification date. The Company determined that none of the
Company’s financial instruments meet the criteria for
derivative accounting as of December 31, 2017 and
2016.
EQUITY INSTRUMENTS ISSUED TO NON-EMPLOYEES FOR AQUIRING GOODS OR
SERVICES
Issuances of the Company’s common stock or warrants for
acquiring goods or services are measured at the fair value of the
consideration received or the fair value of the equity instruments
issued, whichever is more reliably measurable. The measurement date
for the fair value of the equity instruments issued to consultants
or vendors is determined at the earlier of (i) the date at which a
commitment for performance to earn the equity instruments is
reached (a “performance commitment” which would include
a penalty considered to be of a magnitude that is a sufficiently
large disincentive for nonperformance) or (ii) the date at which
performance is complete. When it is appropriate for the Company to
recognize the cost of a transaction during financial reporting
periods prior to the measurement date, for purposes of recognition
of costs during those periods, the equity instrument is measured at
the then-current fair values at each of those interim financial
reporting dates.
NONCASH EQUITY TRANSACTIONS
Shares of equity instruments issued for noncash consideration are
recorded at the estimated fair market value of the consideration
granted based on the estimated market value of the equity
instrument, or at the estimated value of the goods or services
received whichever is more readily determinable.
RELATED PARTIES
A party is considered to be related to the Company if the party
directly or indirectly or through one or more intermediaries,
controls, is controlled by, or is under common control with the
Company. Related parties also include principal owners of the
Company, its management, members of the immediate families of
principal owners of the Company and its management and other
parties with which the Company may deal if one party controls or
can significantly influence the management or operating policies of
the other to an extent that one of the transacting parties might be
prevented from fully pursuing its own separate interests. A party
which can significantly influence the management or operating
policies of the transacting parties or if it has an ownership
interest in one of the transacting parties and can significantly
influence the other to an extent that one or more of the
transacting parties might be prevented from fully pursuing its own
separate interests is also a related party.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
GENERAL AND ADMINISTRATIVE EXPENSES
General
and administrative expenses consisted of professional service fees,
rent and utility expenses, meals, travel and entertainment
expenses, and other general and administrative overhead costs.
Expenses are recognized when incurred.
BASIC AND DILUTED NET GAIN (LOSS) PER SHARE
The Company computes loss per share in accordance with ASC
260,
Earnings per Share.
ASC 260 requires presentation of both
basic and diluted earnings per share (“EPS”) on the
face of the income statement.
Basic
net income (loss) per share is calculated by dividing net (loss) by
the weighted-average common shares outstanding. Diluted net income
per share is calculated by dividing net income by the
weighted-average common shares outstanding during the period using
the treasury stock method or the two-class method, whichever is
more dilutive. As the Company incurred net losses for the year
ended December 31, 2017 no potentially dilutive securities were
included in the calculation of diluted earnings per share as the
impact would have been anti-dilutive.
Therefore,
basic and dilutive net (loss) per share were the same as of
December 31, 2017 and 2016.
REVENUE RECOGNITION
The
Company is focused on the research, development and
commercialization of drugs for the treatment of various forms of
cancer. The Company does not expect to generate revenues until
clinical trials of its proposed products are completed. Once
completed, revenues would be recognized as its technology is
licensed or sold or its products become marketable.
IMPACT OF NEW ACCOUNTING STANDARDS
In
March 2017, the FASB issued ASU No. 2017-08, Receivables —
Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium
Amortization on Purchased Callable Debt Securities, to amend the
amortization period for certain purchased callable debt securities
held at a premium. The ASU shortens the amortization period for the
premium to the earliest call date. Under current Generally Accepted
Accounting Principles (“GAAP”), entities generally
amortize the premium as an adjustment of yield over the contractual
life of the instrument. The amendments should be applied on a
modified retrospective basis, and are effective for fiscal years
beginning after December 15, 2018. Early adoption is permitted,
including adoption in an interim period. The Company is currently
evaluating the impact of this amendment on its financial
statements.
In
February 2017, the FASB issued ASU No. 2017-05, Other
Income—Gains and Losses from the Derecognition of
Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of
Asset Derecognition Guidance and Accounting for Partial Sales of
Nonfinancial Assets, to clarify the scope of Subtopic 610-20, Other
Income—Gains and Losses from the Derecognition of
Nonfinancial Assets, and to add guidance for partial sales of
nonfinancial assets. Subtopic 610-20, which was issued in May 2014
as a part of ASU No. 2014-09, Revenue from Contracts with Customers
(Topic 606), provides guidance for recognizing gains and losses
from the transfer of nonfinancial assets in contracts with
noncustomers. The amendments are effective for fiscal years
beginning after December 15, 2017, including interim periods within
those fiscal years, which is the same time as the amendments in ASU
No. 2014-09, and early adoption is permitted. The Company is
currently evaluating the impact of this amendment on its financial
statements.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
In
January 2017, the FASB issued ASU No. 2017-03, Accounting Changes
and Error Corrections (Topic 250). The ASU adds SEC disclosure
requirements for both the quantitative and qualitative impacts that
certain recently issued accounting standards will have on the
financial statements of a registrant when such standards are
adopted in a future period. Specially, these disclosure
requirements apply to the adoption of ASU No. 2014- 09, Revenue
from Contracts with Customers (Topic 606); ASU No. 2016-02, Leases
(Topic 842); and ASU No. 2016-13, Financial Instruments —
Credit Losses (Topic 326): Measurement of Credit Losses on
Financial Instruments. The Company is currently
evaluating the impact of these amendments on its financial
statements.
Between
May 2014 and December 2016, the FASB issued several ASU’s on
Revenue from Contracts with Customers (Topic 606). These updates
will supersede nearly all existing revenue recognition guidance
under current U.S. generally accepted accounting principles (GAAP).
The core principle is to recognize revenues when promised goods or
services are transferred to customers in an amount that reflects
the consideration to which an entity expects to be entitled for
those goods or services.
A
five-step process has been defined to achieve this core principle,
and, in doing so, more judgment and estimates may be required
within the revenue recognition process than are required under
existing U.S. GAAP. The standards are effective for annual periods
beginning after December 15, 2017, and interim periods therein,
using either of the following transition methods: (i) a full
retrospective approach reflecting the application of the standards
in each prior reporting period with the option to elect certain
practical expedients, or (ii) a retrospective approach with the
cumulative effect of initially adopting the standards recognized at
the date of adoption (which includes additional footnote
disclosures). The Company is currently evaluating the impact of its
pending adoption of these standards on its financial statements and
has not yet determined the method by which it will adopt the
standard in 2018.
In
November 2016, the FASB issued ASU No. 2016-18, Statement of Cash
Flows (Topic 230): Restricted Cash (a consensus of the FASB
Emerging Issues Task Force), to provide guidance on the
presentation of restricted cash or restricted cash equivalents in
the statement of cash flow. The amendments should be applied using
a retrospective transition method, and are effective for fiscal
years beginning after December 15, 2017, including interim periods
within those fiscal years. The Company is currently evaluating the
impact of these amendments on its financial
statements.
DIRECTOR AND OFFICER COMPENSATION
For the
period ended December 31, 2017, the Company issued to the Board of
Directors 42,000,000 shares of par value $0.001 Common Stock valued
at $336,000 or $0.008 per share. During the year ended December 31,
2017, the Directors and Officers were paid $184,271 in cash. Of
this amount, $147,695 was paid to Advanomics Corporation, a company
controlled by the CEO of the Company.
For the
period ended December 31, 2016, the Company issued 78,000,000
shares of par value $0.001 Common Stock to the three Company
officers/directors valued at $241,800 or $0.0031 per share. The
Company also issued to the Board of Directors 36,000,000 shares of
$0.001 Common Stock valued at $252,000 or $0.0078 per share. In
addition, the Company paid its officers $5,597 in
cash.
LEGAL FEES
During
the years ended December 31, 2017 and 2016, legal fees were
incurred largely as a result of services provided to the Company to
assist with its regulatory requirements with the Securities and
Exchange Commission and a litigation in which it was involved and
since been resolved.
DATE OF MANAGEMENT’S REVIEW
Subsequent
events have been evaluated through March 29, 2018, which is the
date the Financial Statements were available to be
issued.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Note 3 – Going Concern
The
accompanying financial statements have been prepared assuming the
Company will continue as a going concern, which contemplates, among
other things, the realization of assets and satisfaction of
liabilities in the normal course of business. The Company had an
accumulated deficit of approximately $13,618,190 and $12,577,954 at
December 31, 2017 and 2016, respectively, had a net loss of
approximately $1,040,236 for the year ended December 31, 2017 and a
net loss of $3,496,687 for the fiscal year ended December 31, 2016,
and Shareholders’ Deficit of approximately $573,363 and
$209,700 at December 31, 2017 and 2016, respectively.
These
matters, among others, raise substantial doubt about the
Company’s ability to continue as a going concern. The Company
believes it can raise capital through equity sales and borrowing to
fund its operations. Management believes this will contribute
toward its subsequent profitability. The accompanying Financial
Statements do not include any adjustments that might be necessary
if the Company is unable to continue as a going
concern.
Note 4 – Patents
The
following is a summary of the Patents held by the Company at
December 31, 2017 and 2016:
On
October 8, 2015, the Company acquired U.S. Patent Number 8,236,935
(the “US Patent”) for the Adva-27a anticancer compound
from Advanomics Corporation (“Advanomics”), a related
party, in exchange for an interest-free note payable for
$4,320,000. Effective December 28, 2015, the parties executed an
amendment pursuant to which this note payable for $4,320,000 was
cancelled and replaced with a new interest-free convertible note
having a face value of $210,519, comprised of $155,940 in principal
amount which is the Advanomics book value of the US Patent, plus
$54,579 as an adjustment for the currency exchange difference. The
new note is automatically convertible into 80,968,965 shares of the
Company’s Common Stock upon the Company increasing its
authorized capital to a level that would permit the issuance of
such shares.
On
December 28, 2015, the Company acquired the remaining worldwide
issued and pending patents under PCT/FR2007/000697 and
PCT/CA2014/000029 (the “Worldwide Patents”) for the
Adva-27a anticancer compound from Advanomics, a related party, in
exchange for a note payable for $12,822,499. Effective December 28,
2015, the parties executed an amendment pursuant to which this note
payable for $12,822,499 was cancelled and replaced with a new
interest-free convertible note having a face value of $624,875,
comprised of $462,870 in principal amount, which is the Advanomics
book value of the Worldwide Patents, plus $162,005 as an adjustment
for the currency exchange difference. The new note is automatically
convertible into 240,336,451 shares of the Company’s Common
Stock upon the Company increasing its authorized capital to a level
that would permit the issuance of such shares. The US Patent and
the Worldwide Patents are herein referred to as the
“Patents.”
The
Patents were therefore acquired from the related party (Advanomics)
for a total of $835,394, including a total of $216,584 in
adjustments for the currency exchange difference ($618,810 net).
Patents expire 20 years from the priority date and are therefore
amortized over 20 years. The oldest of the Patents expires on April
25, 2026 and therefore the Company has deemed that the Patents have
approximately 10 years remaining on their useful life.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
In July
2016, the Company issued 321,305,416 shares of $0.001 par value
Common Stock in exchange for notes payable totaling
$835,394.
|
|
|
|
|
|
Adva-27a US
Patent
|
$
|
$
155,940
|
Adva-27a Worldwide
Patents
|
$
|
$
462,870
|
|
|
|
Total
|
$
|
$
618,810
|
Less: accumulated
amortization
|
|
(62,690
)
|
Loss on
impairment
|
|
(556,120
)
|
Total
|
|
|
|
$
-0-
|
$
-0-
|
Note 5 – Capital Stock
The
Company’s authorized capital is comprised of 3,000,000,000
shares of $0.001 par value Common Stock and 30,000,000 shares of
$0.10 par value Preferred Stock, to have such rights and
preferences as the Directors of the Company have or may assign from
time to time. Out of the authorized Preferred Stock, the Company
has designated 850,000 shares as Series “A” Preferred
Stock (“Series A”). The Series A is convertible at any
time after issuance into 20 shares of the Company's Common Stock
with no further consideration, has full voting rights at 20 votes
per share, and has superior liquidation rights to the Common Stock.
During the year ended December 31, 2015, the Company authorized
500,000 shares of $0.10 par value Series “B” Preferred
Stock (“Series B”). The Series B Preferred Stock is
non-convertible, non-redeemable and non-retractable. It has
superior liquidation rights to the Common Stock at $0.10 per share
and gives the holder the right to 1,000 votes per share. All shares
of the Series B Preferred Stock are held by the CEO of the Company.
Through December 31, 2017 and December 31, 2016, the Company has
issued and outstanding a total of 918,736,498 and 769,399,858
shares of Common Stock, respectively. Through the same periods, the
Company has issued and outstanding a total of -0- and -0- shares of
Series A Preferred Stock and 500,000 and 500,000 shares of Series B
Preferred Stock, respectively.
During
the fiscal year ended December 31, 2017, the Company issued an
aggregate of 149,336,640 shares of its Common Stock as
follows:
●
40,000,000 shares
for cash in the amount of $100,000 Canadian or $78,312
US
●
11,004,167 shares
for the purchase of laboratory and generic drugs warehouse
equipment valued at $56,700
●
42,000,000 shares
valued at $336,000 as compensation to the Company’s Directors
and Officers
●
13,804,348 shares
for services rendered to the Company by third parties valued at
$77,000
●
42,528,125 valued
at $128,451 shares in connection with the conversion of $48,500 in
debt and interest of $3,022 resulting in a $76,929 loss on
conversion
During
the fiscal year ended December 31, 2016, the Company issued
411,829,184 shares of Common Stock for the conversion of $1,122,782
in debt and interest of $9,270 generating a loss of $1,945,898 on
conversion. The Company sold 12,555,556 shares of Common Stock for
cash of $104,128 and issued 146,750,000 shares of Common Stock in
exchange for services valued at $702,300. In 2016, 114,000,000
shares valued at $493,800 were issued to the Directors and Officers
of the Company. The Officers and Directors shares are restricted
and may not be sold without prior written consent of the Board of
Directors of the Company.
The
Company has declared no dividends since inception.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Note 6 – Earnings per Share
The
following table sets forth the computation of basic and diluted net
income per share for the years ended December 31:
|
|
|
Net (loss)
attributable to Common Stock
|
$
(1,040,236
)
|
$
(3,496,687
)
|
Basic weighted
average outstanding shares of Common Stock
|
872,685,608
|
424,874,458
|
Dilutive effects of
common share equivalents
|
-0-
|
-0-
|
Dilutive weighted
average outstanding shares of common stock
|
872,685,608
|
424,874,458
|
Net loss per share
of Common Stock
|
|
|
Basic and
Diluted
|
$
(0.00
)
|
$
(0.01
)
|
Note 7 – Income Taxes
The
Company files a United States federal income tax return and a
Canadian branch return on a calendar year basis. The Company and
its wholly-owned subsidiary, Sunshine Biopharma Canada Inc., have
not generated taxable income since inception.
Deferred
income taxes arise from the temporary differences between financial
statement and income tax recognition of net operating losses. These
loss carryovers are limited under the Internal Revenue Code should
a significant change in ownership occur. The Company accounts for
income taxes pursuant to ASC 740.
Deferred
income taxes arise from the temporary differences between financial
statement and income tax recognition of net operating losses and
other items. Loss carryovers are limited under the Internal Revenue
Code should a significant change in ownership occur.
The
Company follows FASB Statement Accounting Standards Codification
No. 740, “Accounting for Income Taxes”, which requires,
among other things, an asset and liability approach to calculating
deferred income taxes. The components of the deferred income tax
assets and liabilities arising under ASC No. 740 were as
follows:
There
were no deferred income taxes at December 31, 2017 and
2016.
The
types of temporary differences between the tax basis of assets and
their financial reporting amounts that give rise to a significant
portion of the deferred assets and liabilities are as
follows:
|
|
|
|
|
|
|
|
Deferred tax
assets:
|
|
|
|
|
Net operating loss
US
|
$
10,611,921
|
$
3,932,778
|
$
9,609,340
|
$
3,561,221
|
Net operating loss
Canada
|
266,498
|
71,421
|
202,188
|
46,099
|
Total
|
10,878,419
|
4,004,199
|
9,811,528
|
3,607,320
|
|
|
|
|
|
Valuation
allowance
|
(10,878,419
)
|
(4,004,199
)
|
(9,811,528
)
|
(3,607,320
)
|
|
|
|
|
|
Total deferred tax
asset
|
-0-
|
-0-
|
-0-
|
-0-
|
|
|
|
|
|
Net deferred tax
asset
|
$
-0-
|
$
-0-
|
$
-0-
|
$
-0-
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Deferred
income taxes arise from the temporary differences between financial
statement and income tax recognition of net operating losses. These
loss carryovers are limited under the Internal Revenue Code should
a significant change in ownership occur.
At
December 31, 2017 and December 31, 2016, the Company had
approximately $10,611,921 and $9,609,340, respectively in unused
federal net operating loss carryforwards, which begin to expire
principally in the year 2029. A deferred tax asset at each date of
approximately $3,950,013 and $3,607,320 resulting from the loss
carryforwards has been offset by a 100% valuation allowance. The
change in the valuation allowance for the period ended December 31,
2017 and December 31, 2016 was approximately $342,693and $521,180,
respectively.
A
reconciliation of the U.S. statutory federal income tax rate to the
effective tax rate is as follows:
|
|
|
|
|
U.S. Federal
statutory graduated rate
|
34.00
%
|
34.00
%
|
State income tax
rate,
net of federal benefit
|
3.06
%
|
3.06
%
|
Net
rate
|
37.06
%
|
37.06
%
|
|
|
|
Net operating loss
used
|
0.00
%
|
0.00
%
|
Net operating loss
for which no tax
benefit is currently
available
|
-37.06
%
|
-37.06
%
|
|
0.00
%
|
0.00
%
|
The
Company’s income tax filings are subject to audit by various
taxing authorities. The Company’s open audit periods are
2014, 2015, and 2016, although, the statute of limitations for the
2014 tax year will expire effective March 15, 2018. In evaluating
the Company’s provisions and accruals, future taxable income,
and reversal of temporary differences, interpretations and tax
planning strategies are considered.
Note 8 – Notes Payable
Notes payable consist of the
following:
|
|
|
|
|
|
A Note
Payable having a Face Value of $21,439 at December 31, 2016 and
accruing interest at 12% was due December 31, 2017. On December 31,
2017, the Company renewed the note, together with accrued interest
of $2,573, for a 12-month period. The new note has a Face Value of
$24,012 and is due December 31, 2018. The new note accrues interest
at 12% and is convertible anytime from the date of issuance into
$0.001 par value Common Stock at a 35% discount from market price.
The Company estimates that the fair value of this convertible debt
approximates the face value, so no value has been assigned to the
beneficial conversion feature. Any gain or loss will be recognized
at conversion.
|
$
24,012
|
$
21,439
|
|
|
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
On July 1, 2016,
the Company received monies in exchange
for a note payable
having a Face Value of $55,000 with interest
accruing at 10% is
due April 1, 2017. The Note is convertible after
180
days from issuance into $0.001 par value Common Stock at
a
price 40% below market value.
In December
2016, $6,500 of
the principal was
converted
into 5,000,000 shares
of
$0.001 par
value Common Stock
valued at $20,000 and generating a loss of
$13,500 on
conversion. In January 2017, the remaining principal
amount
of $48,500 together with accrued interest of $3,022 was
converted
into 42,528,125 shares of
$0.001 par value Common
Stock valued at
$128,451 and generating a loss of $76,929
on
conversion.
|
$
-0-
|
$
48,500
|
|
|
|
On February 10,
2017, the Company received $48,000 cash in exchange
for a
note payable having a Face Value of $50,000 with interest
accruing at 8%,
which is due November 20, 2017. The Note is
convertible after
180 days from issuance into $0.001 par value
Common Stock at a
price 35% below market value. In August
2017, the note was
paid off with additional $1,863 in accrued interest and
$15,559 as prepayment penalty
.
|
$
-0-
|
$
-0-
|
|
|
|
On April 1, 2017,
the Company received monies in exchange
for a note payable
having a Face Value of $100,000 Canadian
($79,710 US) with
interest payable quarterly at 9%, which is due
April 1, 2019. The
Note is convertible any time after issuance
into $0.001 par
value Common Stock at
a price of
$0.015 Canadian
(approximately $0.012 US) per share.
The
Company
estimates that
the
fair
value of this convertible debt approximates the face value, so
no
value
has been assigned to the beneficial conversion feature.
Any
gain or loss will be recognized at conversion.
|
$
79,710
|
$
-0-
|
|
|
|
On April 26, 2017,
the Company received $63,000 cash in exchange
for a note having a
Face Value of $ 65,000 with interest
accruing at 8%,
which is due April 26, 2018. The Note is convertible
after
180 days from issuance into $0.001 par value Common
Stock
at
a price 35% below market
value.
In August 2017 the
note was paid off
with additional $2,607 in accrued interest and $19,500 as
prepayment penalty
.
|
$
-0-
|
$
-0-
|
|
|
|
On August 3, 2017,
the Company received $76,000 in exchange
for a note payable
having a Face Value of $ 80,000 with interest
accruing at 8%,
which is due August 3, 2018. The Note is convertible
after
180 days from issuance into $0.001 par value Common
Stock
at
a price 35% below market value. The
Company estimates that
the
fair value of this convertible debt approximates the face
value,
so
no value has been assigned to the beneficial conversion
feature.
Any gain or loss will be
recognized at conversion.
|
$
80,000
|
$
-0-
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
On August 21, 2017,
the Company received $80,000 cash in exchange
for a note payable
having a Face Value of $ 83,000 with interest
accruing at 8% ,
which is due May 30, 2018. The Note is convertible
after
180 days from issuance into $0.001 par value Common
Stock
at
a price 35% below market value. The
Company estimates that
the
fair value of this convertible debt approximates the face
value,
so
no value has been assigned to the beneficial conversion
feature.
Any gain or loss
will be recognized at conversion.
|
$
83,000
|
$
-0-
|
|
|
|
On September 22,
2017, the Company received $60,000 cash in
exchange for a note
having a Face Value of $ 62,000 with
interest accruing
at 8%, which is due June 30, 2018. The Note is
convertible after
180 days from issuance into $0.001 par
value Common Stock
at
a price 35% below market
value.
The
Company estimates that the fair value of this convertible
debt
approximates
the face value, so no value has been assigned
to the beneficial conversion feature.
Any
gain or loss will be
recognized at
conversion.
|
$
62,000
|
$
-0-
|
|
|
|
On October 26,
2017, the Company received $110,000 cash in
exchange for a note
payable having a Face Value of $ 115,000
with interest
accruing at 8%, which is due October 26, 2018. The
Note is
convertible after 180 days from issuance into $0.001 par
value
Common Stock at
a price 35% below
market value. The
Company
estimates that the fair value of this convertible debt
approximates
the face value, so no value has been assigned to the
beneficial conversion feature.
Any gain or
loss will be recognized
at
conversion.
|
$
115,000
|
$
-0-
|
|
|
|
On November 14,
2017, the Company received $106,000 cash in
exchange for a note
payable having a Face Value of $ 113,000
with interest
accruing at 8%, which is due November 14, 2018. The
Note is
convertible after 180 days from issuance into $0.001
par
value Common Stock at
a price 35%
below market value.
The
Company estimates that the fair value of this convertible
debt
approximates
the face value, so no value has been assigned to
the beneficial conversion feature.
Any gain or loss will
be
recognized at
conversion.
|
$
113,000
|
$
-0-
|
|
|
|
On December 1, 2017
the Company received monies in
exchange for a note
having a Face Value of $ 50,000 Canadian
($39,855 US) with
interest accruing at 8%, due November 30,
2018. The Note is
convertible after 180 days from issuance
into $0.001 par
value Common Stock at
a price 35%
below
market
value. The Company estimates that the fair value of this
convertible
debt approximates the face value, so no value has been
assigned to the beneficial conversion
feature.
Any gain or loss will be
recognized at
conversion.
|
$
39,855
|
$
-0-
|
|
|
|
Total Current
Debt
|
$
596,577
|
$
69,939
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Interest
expense for the years ended December 31, 2017 and 2016 was $79,833
and $34,732, respectively. The balance of interest payable at
December 31, 2017 and 2016 was $9,215 and $9,011, respectively.
Loss on conversion of notes payable for the years ended December
31, 2017 and 2016 was $76,929 and $1,945,898,
respectively.
Note 9 – Notes Payable Related Party
Notes payable to
related parties consist of the following:
|
|
|
|
|
|
A note payable held
by a private individual who subsequently
became a principal
shareholder of the Company having a face
value of $100,000
at December 31, 2016 and a maturity date
of March 31, 2017,
accrues interest at 12%. The Note is
convertible any
time from the date of issuance into $0.001 par
value Common Stock
at a 35% discount from market price. On
March 31, 2017, the
note’s principal balance of $100,000 plus
accrued interest of
$11,715 was renewed for a period of 90 days
under the same
terms and conditions as the original note. The
new note now having
a face value of $111,715 matures on June
30, 2017. On June
30, 2017, the note’s principal balance of
$111,715 plus
accrued interest of $3,342 was renewed for a
period of 90 days
under the same terms and conditions as the
original note. The
new note now having a face value of $115,057
matures on
September 30, 2017. On September 30, 2017, the
note’s
principal balance of $115.057 plus accrued interest of
$3,480
was renewed for a period of 90 days under the same
terms
and conditions as the original note. The new note now
having
a principal balance of $118,537 matures on December
31,
2017. On December 31, 2017 the note plus accrued interest of $3,556
was renewed for a
12-month period
under the same terms and conditions as before.
The new note has a
face value of $122,093 and matures on
December 31, 2018.
The Company estimates that the fair value
of this convertible
debt approximates the face value, so no value
has been assigned
to the beneficial conversion feature. Any
gain or loss will
be recognized at conversion.
|
$
122,093
|
$
100,000
|
|
|
|
In December 2016,
the Company received monies from its
CEO in exchange for
a note payable having a principal amount
of $90,000 Canadian
($67,032 US) with interest at 12% due
March 31, 2017. The
note was convertible any time after
the date of
issuance into $0.001 par value Common Stock
at a price 35%
below market value. This note was
collateralized by
all of the assets of the Company. In the
event of default,
the interest rate will increased to 18% per
annum and a penalty
of $1,000 Canadian ($752 US) per day
will accrue. On
March 31, 2017, the note, together with
accrued interest of
$3,021 Canadian ($2,271 US) and an
additional
principal amount of $3,000 Canadian ($2,247 US)
paid to the Company
on March 28, 2017, was renewed for a
90-day period under
the same terms and conditions as the
original note. The
new note now having a face value of
$96,021 Canadian
($72,198 US) was due on June 30, 2017.
On June 30, 2017,
the note, together with accrued interest of
$2,873 Canadian
($2,005 US), was renewed for a 90-day
period under the
same terms and conditions as the original
note except that
the new note is non-convertible. The new
note now having a
face value of $98,894 Canadian
($76,072US) is due
on September 30, 2017. On September
30, 2017, the note,
together with accrued interest of $2,991
Canadian ($2,397
US) was renewed for a 90-day period
under the same
terms and conditions as the original note
except that the new
note is nonconvertible. The new note
now having a
principal balance of $101,885 Canadian
($81,640 US)
matures December 31, 2017. On December
31, 2017 the note
was renewed for a 12-month period under
the same terms and
conditions as before except that this new
note is unsecured
and nonconvertible. The new note has a
face value of
$104,942 Canadian ($83,649 US) and matures
on December 31,
2018.
|
$
83,649
|
$
67,032
|
|
|
|
Total Current
Related Party Debt
|
$
205,742
|
$
167,032
|
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Note 10 – Related Party Transactions
In
December 2016, the Company received monies from our CEO in exchange
for a note payable having a principal of $90,000 Canadian ($67,032
US) with interest at 12% due March 31, 2017. The Note is
convertible any time after the date of issuance into shares of our
Common Stock at
a price 35% below
market value. We estimated that the fair value of the convertible
debt approximates the face value, so no value has been assigned to
the beneficial conversion feature.
This Note is
collateralized by all of the assets of the Company. On March 31,
2017, the note, together with accrued interest of $3,021 Canadian
($2,271 US) and an additional principal amount of $3,000 Canadian
($2,247 US) paid to the Company on March 28, 2017, was renewed for
a 90-day period under the same terms and conditions as the original
note. The new note now having a face value of $96,021 Canadian
($72,198 US) was due on June 30, 2017. On June 30, 2017, the note,
together with accrued interest of $2,873 Canadian ($2,005 US), was
renewed for a 90-day period under the same terms and conditions as
the original note except that the new note is nonconvertible. The
new note now having a face value of $98,894 Canadian ($76,072US) is
due on September 30, 2017. On September 30, 2017, the note,
together with accrued interest of $2,991 Canadian ($2,397 US), was
renewed for a 90-day period under the same terms and conditions as
the original note except that the new note is nonconvertible. The
new note now having a principal balance of $101,885 Canadian
($81,640 US) matures December 31, 2017. On December 31, 2017, the
note was renewed for a 12-month period under the same terms and
conditions as the original note except that this note is unsecured
and non-convertible. The new note has a face value of $104,942
Canadian ($84,649 US) and matures on December 31,
2018.
A note
payable held by a private individual who subsequently became a
principal shareholder of the Company having a face value of
$100,000 at December 31, 2016 and a maturity date of March 31,
2017, accrues interest at 12%. The Note is convertible any time
from the date of issuance into $0.001 par value Common Stock at a
35% discount from market price. On March 31, 2017, the note’s
principal balance of $100,000 plus accrued interest of $11,715 was
renewed for a period of 90 days under the same terms and conditions
as the original note. The new note now having a face value of
$111,715 matures on June 30, 2017. On June 30, 2017, the
note’s principal balance of $111,715 plus accrued interest of
$3,342 was renewed for a period of 90 days under the same terms and
conditions as the original note. The new note now having a face
value of $115,057 matures on September 30, 2017. On September 30,
2017, the note’s principal balance of $115.057 plus accrued
interest of $3,480 was renewed for a period of 90 days under the
same terms and conditions as the original note. The new note now
having a principal balance of $118,537 matures on December 31,
2017. On December 31, 2017 the note was renewed for a 12-month
period under the same terms and conditions as before. The new note
has a face value of $122,093 and matures on December 31,
2018.
Until
June 1, 2017, the Company’s principal place of business was
located at 469 Jean-Talon West, 3rd Floor, Montreal, Quebec, Canada
H3N R4. This was also the location of the
Company’s former licensor, Advanomics Corporation
(“Advanomics”), who provided this space to the Company
on a rent free basis in 2015 and 2016. Starting January
1, 2017, the Company took over the lease from Advanomics for this
space until it moved to its current location in June
2017.
In
February and April 2016, the Company paid $30,000 and $50,487 to
Advanomics for the balance of 2015 licensing fees.
In 2016, Advanomics Corporation paid
on behalf of the Company $13,725 Canadian in patenting fees.
Advanomics was fully reimbursed by the Company in January
2017.
Dr.
Steve N. Slilaty, the Company’s Chief Executive Officer and a
Director, is an Officer, Director and principal shareholder of
Advanomics.
During
the period ended December 31, 2017, the Company issued to its
Directors and Officers 42,000,000 shares of $0.001 par value Common
Stock valued at $336,000 or $0.008 per share. In addition, the
Directors and Officers were paid an aggregate of $184,271 for their
services in 2017. Of this amount, $147,695 was paid to Advanomics
Corporation, a company controlled by the CEO of the
Company.
During
the period ended December 31, 2016, the Company issued 78,000,000
shares of $0.001 par value Common Stock to the three Company
officers valued at $241,800 or $0.0031 per share. During the same
period, the Company also issued to the Board of Directors
36,000,000 shares of $0.001 par value Common Stock valued at
$252,000 or $0.0078 per share. In addition, the Company paid its
officers $5,597 in cash.
Sunshine Biopharma, Inc.
Notes
to Consolidated Financial Statements
December
31, 2017 and 2016
Note 11 – Royalties Payable
As part
of a subscription agreement entered into in February 2016, the
Company has an obligation to pay a royalty of 5% of net sales on
one of its generic products (Anastrozole) for a period of three (3)
years from the date of the first sale of that product. As of the
date hereof, the Company has not received revenues from the sale of
this product.
Note 12 – Acquisition of Atlas Pharma Inc.
In
December 2017, the Company issued a payment of $100,500 Canadian
($80,290 US) to Mr. Mohamed Belhai as a deposit towards the
acquisition of Atlas Pharma Inc. On January 1, 2018, the Company
entered into a Share Purchase Agreement with Mr. Mohamed Belhaj and
Atlas Pharma Inc. (the “Atlas Agreement”), wherein the
Company acquired all of the issued and outstanding shares (the
“Shares”) of Atlas Pharma Inc., (“Atlas”)
from Mr. Belhaj. The purchase price for the Shares was $848,000
Canadian (approximately $678,400 US). The purchase price included a
cash payment of $100,500 Canadian ($80,290 US), plus issuance of
20,000,000 shares of the Company’s Common Stock, plus a
promissory note in the principal amount of $450,000 Canadian
(approximately $360,000 US), with interest payable at the rate of
3% per annum. The Company is required to make payments of $10,000
per calendar quarter, due and payable on or before the end of each
such calendar quarter through December 31, 2023.
Note 13 – Subsequent Events
On
January 1, 2018, the Company acquired Atlas Pharma Inc., a
Montreal-based, fully certified analytical chemistry company
dedicated to chemical analysis of pharmaceutical and other
industrial samples. More information about Atlas Pharma is
available at
www.atlaspharmainc.ca
.
On
January 12, 2018, the Company received monies in exchange for a
convertible note payable having a face value of
$102,000.
On
February 6, 2018, the Company issued payment in the amount of
$51,613 to pay off approximately half of a note payable dated
August 3, 2017, and on February 12 and 21 the remainder was
converted into a total of 6,555,761 shares of the Company's Common
Stock.
On
February 7, 2018, the Company received monies in exchange for a
convertible note payable having a face value of
$150,000.
On
February 16, 2018, the Company issued payment in the amount of
$115,370 to pay off a note payable dated August 21,
2017.
On
February 20, 2018, the Company received monies in exchange for a
convertible note payable having a face value of
$85,000.
On
March 27, 2018, the holder of a convertible note having a face
value of $62,000 elected to convert $15,000 of the outstanding
principal amount into 2,727,273 shares of the Company's Common
Stock, leaving a principal balance of $47,000.
PART II - INFORMATION NOT REQUIRED IN PROSPECTUS
OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The
following table presents fees for professional audit services
rendered by B F Borgers CPA PC, our independent auditors, during
our fiscal year ended December 31, 2017 and 2016:
|
|
|
Audit
Fees
|
$
21.600
|
$
21,600
|
|
|
|
Tax
Fees
|
|
|
All Other
Fees
|
|
|
Total
|
$
21,600
|
$
21,600
|
Audit Fees
. Consist of amounts billed for professional
services rendered for the audit of our annual financial statements
included in our Annual Reports on Forms 10-K for our fiscal years
ended December 31, 2017 and 2014 and reviews of our interim
financial statements included in our Quarterly Reports on Form
10-Q.
Tax Fees
. Consists of amounts billed for
professional services rendered for tax return preparation, tax
planning and tax advice.
All Other
Fees
. Consists of
amounts billed for services other than those noted
above.
We
do not have an audit committee and as a result our entire board of
directors performs the duties of an audit committee. Our
board of directors evaluates the scope and cost of the engagement
of an auditor before the auditor renders audit and non-audit
services.
INDEMNIFICATION OF OFFICERS AND DIRECTORS
Section 7-108-402 of the Colorado Business Corporation Act (the
“CBCA”) provides, generally, that the articles of
incorporation may contain a provision eliminating or limiting the
personal liability of a director to the corporation or its
shareholders for monetary damages for breach of fiduciary duty as a
director, except that any such provision shall not eliminate or
limit the liability of a director (i) for any breach of the
director’s duty of loyalty to the corporation or its
shareholders, (ii) acts or omissions not in good faith or which
involve intentional misconduct or a knowing violation of law, (iii)
acts specified in Section 7-108-403 of the CBCA
Section 7-109-102(1) of the CBCA permits indemnification
of a director of a Colorado corporation, in the case of a third
party action, if the director (a) conducted himself or herself
in good faith, (b) reasonably believed that (i) in the
case of conduct in his or her official capacity, his or her conduct
was in the corporation’s best interest, or (ii) in all
other cases, his or her conduct was not opposed to the
corporation’s best interest, and (c) in the case of any
criminal proceeding, had no reasonable cause to believe that his
conduct was unlawful. Section 7-109-103 further provides for
mandatory indemnification of directors and officers who are
successful on the merits or otherwise in litigation.
Section 7-109-102(4) of the CBCA limits the
indemnification that a corporation may provide to its directors in
two key respects. A corporation may not indemnify a director
in a derivative action in which the director is held liable to the
corporation, or in any proceeding in which the director is held
liable on the basis of his improper receipt of a personal
benefit. Sections 7-109-104 of the CBCA permits a corporation
to advance expenses to a director, and
Section 7-109-107(1)(c) of the CBCA permits a corporation
to indemnify and advance litigation expenses to officers, employees
and agents who are not directors to a greater extent than directors
if consistent with law and provided for by the bylaws, a resolution
of directors or shareholders, or a contract between the corporation
and the officer, employee or agent.
Our
bylaws include provisions that require the company to indemnify our
directors or officers against monetary damages for actions taken as
a director or officer of our Company. We are also expressly
authorized to carry directors’ and officers’ insurance
to protect our directors, officers, employees and agents for
certain liabilities. Our articles of incorporation do not contain
any limiting language regarding director immunity from
liability.
The
limitation of liability and indemnification provisions under the
CBCA and our bylaws may discourage stockholders from bringing a
lawsuit against directors for breach of their fiduciary duties.
These provisions may also have the effect of reducing the
likelihood of derivative litigation against directors and officers,
even though such an action, if successful, might otherwise benefit
us and our stockholders. However, these provisions do not limit or
eliminate our rights, or those of any stockholder, to seek
non-monetary relief such as injunction or rescission in the event
of a breach of a director’s fiduciary duties. Moreover, the
provisions do not alter the liability of directors under the
federal securities laws. In addition, your investment may be
adversely affected to the extent that, in a class action or direct
suit, we pay the costs of settlement and damage awards against
directors and officers pursuant to these indemnification
provisions.
RECENT SALES OF UNREGISTERED SECURITIES
The
following sets forth information regarding all unregistered
securities sold by us in transactions that were exempt from the
requirements of the Securities Act in the last three years. Except
where noted, all of the securities discussed in this Item 15 were
all issued in reliance on the exemption under Section 4(a)(2) of
the Securities Act. Unless otherwise indicated, all of the share
issuances described below were made in reliance on the exemption
from registration provided by Section 4(a)(2) of the Securities
Act.
During
the six months ended June 30, 2018, we issued a total of
185,369,308 shares of our Common Stock. Of these, 42,584,566 shares
valued at $290,286 were issued upon conversion of outstanding notes
payable, reducing outstanding debt by $188,568 and interest payable
by $8,133 and generating a loss on conversion of $93,585. We also
issued 93,650,000 shares valued at $558,200 for services, and
29,134,742 shares valued at $174,808 in exchange for
equipment.
During
the fiscal year ended December 31, 2017, we issued an aggregate of
149,336,640 shares of our Common Stock as follows:
●
40,000,000 shares
for cash in the amount of $100,000 Canadian or $78,312
US
●
11,004,167 shares
for the purchase of laboratory and generic drugs warehouse
equipment valued at $56,700
●
42,000,000 shares
valued at $336,000 as compensation to the Company’s Directors
and Officers
●
13,804,348 shares
for services rendered to the Company by third parties valued at
$77,000
●
42,528,125 shares
valued at $128,451 in connection with the conversion of $48,500 in
debt and interest of $3,022 resulting in a $76,929 loss on
conversion.
During
the fiscal year ended December 31, 2016, the Company issued
411,829,184 shares of Common Stock for the conversion of $1,122,782
in debt and interest of $9,270 generating a loss of $1,945,898 on
conversion. The Company sold 12,555,556 shares of Common Stock for
cash of $104,128 and issued 146,750,000 shares of Common Stock in
exchange for services valued at $702,300. In 2016, 114,000,000
shares valued at $493,800 were issued to the Directors and Officers
of the Company. The Officers and Directors shares are restricted
and may not be sold without prior written consent of the Board of
Directors of the Company.
During
the fiscal year ended December 31, 2015, the Company issued
124,714,077 shares of Common Stock. Of these, 102,914,077 were
issued for the conversion of $501,624 in debt and $12,886 in
interest, generating a loss of $575,144 on conversion. In addition,
the Company sold 20,000,000 shares of Common Stock for cash of
$236,550 and issued 1,800,000 shares of Common Stock in exchange
for services valued at $66,500. In 2015, the Company also issued
500,000 shares of Series “B” Preferred Stock to the CEO
of the Company in exchange for services valued at
$50,000.
The
preceding securities were not registered under the Securities Act
of 1933, as amended (the “Securities Act”), but
qualified for exemption under Section 4(a)(2) of the Securities
Act. The securities were exempt from registration under Section
4(a)(2) of the Securities Act because the issuance of such
securities by the Company did not involve a “public
offering,” as defined in Section 4(a)(2) of the Securities
Act, due to the insubstantial number of persons involved in the
transaction, size of the offering, and manner of the offering and
number of securities offered. The Company did not undertake an
offering in which it sold a high number of securities to a high
number of investors. In addition, the Investor had the necessary
investment intent as required by Section 4(a)(2) of the Securities
Act since they agreed to, and received, the securities bearing a
legend stating that such securities are restricted pursuant to Rule
144 of the Securities Act. This restriction ensures that these
securities would not be immediately redistributed into the market
and therefore not be part of a “public offering.” Based
on an analysis of the above factors, the Company has met the
requirements to qualify for exemption under Section 4(a)(2) of the
Securities Act.
EXHIBITS
The following exhibits are included herewith:
Exhibit No.
|
|
Description
|
|
|
Opinion
of Lucosky Brookman LLP
|
|
|
Consent
of BF Borgers CPA PC
|
23.2
|
|
Opinion
of Lucosky Brookman LLP (see Exhibit 5.1 herein)
|
Following are a list of exhibits which we previously filed in other
reports which we filed with the SEC, including the Exhibit No.,
description of the exhibit and the identity of the filing where the
exhibit was filed.
No.
|
|
Description
|
|
Filed With
|
|
Date
|
|
|
Articles
of Incorporation
|
|
Form
SB-2 Registration Statement
|
|
October
19, 2007
|
|
|
Bylaws
|
|
Form
SB-2 Registration Statement
|
|
October
19, 2007
|
|
|
Articles
of Amendment (Name Change)
|
|
Form
8-K Dated November 2, 2009
|
|
November
6, 2009
|
|
|
Statement
of Share and Equity Capital Exchange
|
|
Form
10-Q For Quarter Ended June 30, 2010
|
|
August
4, 2010
|
|
|
Articles
of Amendment (Add Preferred and Series A Preferred to
Authorized)
|
|
Form
10-Q For Quarter Ended June 30, 2010
|
|
August
4, 2010
|
4.1
|
|
Promissory
Note
|
|
Form
8-K dated September 14, 2018
|
|
September
14, 2018
|
|
|
Share
Exchange Agreement with Sunshine Biopharma, Inc.
|
|
Form
8-K dated October 15, 2009
|
|
October
20, 2009
|
|
|
License
Agreement with Advanomics, Inc.
|
|
Form
8-K/A dated October 15, 2009
|
|
January
19, 2010
|
|
|
Amendment
No. 1 to License Agreement with Advanomics, Inc.
|
|
Form
8-K/A dated October 15, 2009
|
|
January
19, 2010
|
|
|
Research
Agreement with The Research Foundation of the State University of
New York
|
|
Form
8-K dated January 17, 2011
|
|
January
19, 2011
|
|
|
Research
Agreement with Jewish General Hospital
|
|
Form
8-K dated June 14, 2011
|
|
June
17, 2011
|
|
|
Amendment
No. 2 to License Agreement with Advanomics
|
|
Form
8-K dated December 21, 2011
|
|
December
27, 2011
|
|
|
Investment
Agreement with Dutchess Investment Group II
|
|
Form
8-K dated April 28, 2014
|
|
April
28, 2014
|
|
|
Registration
Rights Agreement with Dutchess Investment Group II
|
|
Form
8-K dated April 28, 2014
|
|
April
28, 2014
|
|
|
Patent
Purchase Agreement with Advanomics Corporation
|
|
Form
8-K dated October 8, 2016
|
|
October
9, 2016
|
|
|
Second
Patent Purchase Agreement with Advanomics Corporation
|
|
Form
8-K dated December 28, 2015
|
|
December
28, 2015
|
|
|
Amendment
No. 1 to Patent Purchase Agreement with Advanomics Corporation
dated October 8, 2016, including Secured Convertible Promissory
Note.
|
|
Form
8-K dated March 14, 2016
|
|
March
14, 2016
|
|
|
Amendment
No. 1 to Patent Purchase Agreement with Advanomics Corporation
dated December 28, 2016, including Secured Convertible Promissory
Note
|
|
Form
8-K dated March 14, 2016
|
|
March
14, 2016
|
10.13
|
|
Share
Purchase Agreement with Mohamed Belhaj and Atlas Pharma,
Inc.
|
|
Form
8-K dated January 4, 2018
|
|
January
4, 2018
|
10.14
|
|
Equity
Financing Agreement
|
|
Form
8-K dated September 14, 2018
|
|
September
14, 2018
|
10.15
|
|
Registration
Rights Agreement
|
|
Form
8-K dated September 14, 2018
|
|
September
14, 2018
|
21.1
|
|
List of
Subsidiaries
|
|
Form
10-K dated April 2, 2018
|
|
April
2, 2018
|
*Filed
herewith
ITEM 17. UNDERTAKINGS.
The
undersigned registrant hereby undertakes
1.
To
file, during any period in which offers or sales are being made, a
post-effective amendment to this Registration
Statement:
i.
To
include any Prospectus required by section 10(a)(3) of the
Securities Act of 1933;
ii.
To
reflect in the Prospectus any facts or events arising after the
effective date of the Registration Statement (or the most recent
post-effective amendment thereof) which, individually or in the
aggregate, represent a fundamental change in the information set
forth in the Registration Statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the
total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of
the estimated maximum offering range may be reflected in the form
of Prospectus filed with the Commission pursuant to Rule 424(b) if,
in the aggregate, the changes in volume and price represent no more
than 20% change in the maximum aggregate offering price set forth
in the “Calculation of Registration Fee” table in the
effective Registration Statement.
iii.
To
include any material information with respect to the plan of
distribution not previously disclosed in the Registration Statement
or any material change to such information in the Registration
Statement;
2.
That,
for the purpose of determining any liability under the Securities
Act of 1933, each such post-effective amendment shall be deemed to
be a new Registration Statement relating to the securities offered
therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
3.
To
remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
4.
That,
for the purpose of determining liability of the registrant under
the Securities Act of 1933 to any purchaser in the initial
distribution of the securities: The undersigned registrant
undertakes that in a primary offering of securities of the
undersigned registrant pursuant to this Registration Statement,
regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such
purchaser by means of any of the following communications, the
undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such
purchaser:
i.
Any
Preliminary Prospectus or Prospectus of the undersigned registrant
relating to the offering required to be filed pursuant to Rule
424;
ii.
Any
free writing Prospectus relating to the offering prepared by or on
behalf of the undersigned registrant or used or referred to by the
undersigned registrant;
iii.
The
portion of any other free writing Prospectus relating to the
offering containing material information about the undersigned
registrant or its securities provided by or on behalf of the
undersigned registrant; and
iv.
Any
other communication that is an offer in the offering made by the
undersigned registrant to the purchaser.
5.
That,
for the purpose of determining liability under the Securities Act
of 1933 to any purchaser: Each Prospectus filed pursuant to Rule
424(b) as part of a Registration Statement relating to an offering,
other than Registration Statements relying on Rule 430B or other
than Prospectuses filed in reliance on Rule 430A, shall be deemed
to be part of and included in the Registration Statement as of the
date it is first used after effectiveness. Provided, however, that
no statement made in a Registration Statement or Prospectus that is
part of the Registration Statement or made in a document
incorporated or deemed incorporated by reference into the
Registration Statement or Prospectus that is part of the
Registration Statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify any
statement that was made in the Registration Statement or Prospectus
that was part of the Registration Statement or made in any such
document immediately prior to such date of first use.
Insofar
as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to our directors, officers and controlling
persons, we have been advised that in the opinion of the Securities
and Exchange Commission, such indemnification is against public
policy as expressed in the Securities Act of 1933 and is,
therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by
us of expenses incurred or paid by a director, officer or
controlling person of the corporation in the successful defense of
any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities
being registered, we will, unless in the opinion of our counsel the
matter has been settled by a controlling precedent, submit to a
court of appropriate jurisdiction the question of whether such
indemnification by us is against public policy as expressed in the
Securities Act of 1933, as amended, and will be governed by the
final adjudication of such case.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, the registrant
has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized on October 8,
2018.
DATE
|
|
SIGNATURE
|
|
TITLE
|
|
|
|
|
|
October
8, 2018
|
|
/s/Dr. Steve N. Slilaty
|
|
President,
Chief Executive Officer
|
|
|
Dr.
Steve N. Slilaty
|
|
and
Chairman
|
|
|
|
|
(Principal
Executive Officer)
|
In
accordance with the requirements of the Securities Act of 1933,
this Registration Statement was signed by the following persons in
the capacities and on the dates stated:
DATE
|
|
SIGNATURE
|
|
TITLE
|
|
|
|
|
|
October
8, 2018
|
|
/s/
Dr.
Steve N. Slilaty
|
|
President,
Chief Executive Officer and Chairman
|
|
|
Dr.
Steve N. Slilaty
|
|
Officer
(Principal Executive Officer)
|
|
|
|
|
|
October
8, 2018
|
|
/s/ Camille Sebaaly
|
|
Chief
Financial Officer , Secretary and Director
|
|
|
Camille
Sebaaly
|
|
(Principal
Financial Officer) (Principal Accounting Officer)
|
|
|
|
|
|
October
8, 2018
|
|
/s/ Dr. Abderrazzak Merzouki
|
|
Chief
Operating Officer and Director
|
|
|
Dr.
Abderrazzak Merzouki
|
|
|